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DEVELOPMENT OF IMPROVED ACELLULAR PERTUSSIS VACCINES THROUGH 
INCLUSION OF THE RTX ANTIGEN OR INDUCTION OF MUCOSAL IMMUNITY 
Dylan T. Boehm 
Pertussis is a human respiratory disease, primarily caused by the Gram-negative 
pathogen Bordetella pertussis. The infection is most severe and can be life-threatening 
in young children and infants where it manifests as a series of paroxysmal coughs. The 
disease is more commonly known as whooping cough, due to the whoop omitted during 
a massive inspiratory effort to bring air back into the lungs. Pertussis is a toxin-mediated 
disease that persists due to an early release of toxins that allow that bacteria to evade 
the cells of the innate immune response. The inhibition of the host response continues 
as toxin activity disrupts the signaling generating an adaptive immune response. 
Fortunately, two generations of vaccines have been developed to combat the spread of 
the highly contagious disease. The whole-cell pertussis (wP) vaccine was implemented 
in the 1950s and was successful in controlling cases. However, due to adverse side 
effects associated with the immunization, wP vaccines were replaced with acellular 
protein (aP) vaccines absorbed to an alum adjuvant. The second generation aP 
vaccines induced an immune response capable of neutralizing key virulence factors 
contained in the vaccine, thereby controlling the symptoms of the disease. 
Unfortunately, there has been a re-emergence of pertussis incidence in countries using 
the aP vaccines. Included in this resurgence is an increased number of adolescents and 
adults with unrecognized pertussis, leading to the potential of adult and adolescent 
reservoirs of the infection. We reasoned that a pertussis vaccine capable of inducing 
sterilizing immunity, rather than controlling the symptoms, would decrease the spread of 
pertussis. In this work, we propose two directions towards this goal. The first was 
through the neutralization of a key virulence factor not included in any current vaccine 
formulations, adenylate cyclase toxin (ACT). This was accomplished through the 
optimization of a mouse immunization and challenge model. In initial experiments using 
a neutrophil reporter mouse, NeCre luc, we visualized the spatiotemporal localization of 
neutrophils after B. pertussis challenge in wP or aP immunized mice with a vaccine 
dose known to be protective. In these experiments wP immunized mice elicited an 
exaggerated immune response, that persisted after clearance of the pathogen, raising 
concerns to the relevance of the high vaccine dose in characterizing the immune 
response. In subsequent experiments, we addressed these concerns, by titrating the 
concentration of a Diphtheria-Tetanus-acellular Pertussis (DTaP) subunit vaccine to a 
dose that did not induce a protective response in a murine model. In defining a sub-
optimal protective dose for mice, the additive effects of potential antigens could be 
evaluated, that were previously masked by the higher concentrations of vaccine. This 
model was confirmed through the addition of an ACT toxoid, RTX. The inclusion of RTX 
into a DTaP vaccine produced an antibody response that neutralized the toxin in vitro, 
and upon challenge with B. pertussis reduced the bacterial burden compared to mice 
only receiving the DTaP vaccine. We continued in the direction of promoting a vaccine-
induced immune response capable of clearing B. pertussis from the respiratory tract in 
future experiments. We hypothesized that early neutralization of the bacterial toxins 
through the generation of a mucosal immune response in the respiratory tract would 
increase the clearance of the pathogen. This was tested using a mucosal, intranasally 
(IN) administered DTaP vaccine. Administration of DTaP through the IN route induced a 
B. pertussis-specific systemic IgG response, and mucosal IgA response, capable of 
neutralizing the toxins at the site of infection. Furthermore, IN vaccinated mice reduced 
the bacterial burden to the same levels of intraperitoneal immunized mice. The work 
completed in this dissertation demonstrates the protective effects of the antigen RTX 
when incorporated into a current DTaP vaccine. We then altered the route of 
administration to an intranasal delivered vaccine, demonstrating the effectiveness of 
inducing a local mucosal response against B. pertussis infection. Together these 
findings establish a foundation for potential vaccine strategies to suppress the toxin-
mediated dysregulation of the host response and lead to the more efficient clearance of 
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Chapter 1 - Introduction  
Disease Overview 
Pertussis is an exclusively human pathogen that exists in all populations worldwide. In 
the pre-vaccine era, the number of cases often exceeded 200,000 annually in the 
United States, peaking at more than 250,000 in 1934 1. The infection occurs in three 
stages: catarrhal, paroxysmal, and convalescent. In the catarrhal stage, symptoms can 
include a mild cough, rhinorrhea and lacrimation; similar to other upper respiratory 
infections 2,3. Over time the cough worsens in frequency and intensity as the disease 
reaches the paroxysmal phase, normally ranging from 2-8 weeks 3. The paroxysmal 
phase is defined by repeated coughing fits lasting 5-10 coughs per minute, known as a 
paroxysm. Following a paroxysm, an individual performs a massive inspiratory effort to 
refill the lungs with air resulting in the classic whoop 4. The coughing fits are associated 
with production of high amounts of mucus and are commonly followed by post-tussive 
emesis5. Additional symptoms can include elevated white blood cells counts 
(lymphocytosis or leukocytosis), bronchopneumonia, and hypoxia. In the most severe 
cases these symptoms can be fatal and from 2000 - 2016 0.1% of cases resulted in 
fatalities, 88.8% of which occurred in infants 6. The transition to the convalescent phase 
occurs over several weeks or months and is associated with a reduction in severity of 
paroxysms and other symptoms 7.  
Pertussis is a highly contagious respiratory disease that is spread through aerosolized 
B. pertussis, a dispersal method capable of infecting surrounding individuals8. 
Household contact studies have shown that transmission between family members is 
common and capable of causing mild or asymptomatic infections in adults. One study 
found that 46% of asymptomatic household contacts had antibody titers to B. pertussis 
9. An aerosolized dispersal coupled with an incubation period between 7-10 days leads 
to a contagious disease capable of infecting multiple individuals 10. So much so, that 
pertussis still occurs in cyclical epidemics every 2-5 years; as it did in the pre-vaccine 
era 6. Pertussis surveillance data shows that in United States cases rose from 1,010 in 
1976, to a peak of 48,000 cases in 2012 (Figure 1) 1. The increase of pertussis cases is 
also occurring in other countries that have adopted acellular vaccines such as the 
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United Kingdom and Australia 11, suggesting the cyclical pattern of pertussis epidemics 
is unchanged by modern vaccines.  
 
Figure 1: Incidence of clinical B. pertussis cases in the United States from 1922-
2017. Data reported from CDC.  
 
History of B. pertussis vaccination and the increase in B. pertussis incidence 
In 1906, Jules Bordet and Octave Gengou were the first scientists to isolate the bacteria 
B. pertussis from an individual. Prior to the isolation of the bacteria, a disease with the 
same characteristics of Pertussis had been described since the middle ages 12. The first 
documented outbreak occurred in Paris during 1578 12. Until the 1930s there was still a 
debate as to whether B. pertussis was the causative agent of Pertussis, due to repeated 
failed attempts to culture the bacteria from a coughing patient 13. Before the 1950s, the 
World Health Organization (WHO) estimates that nearly half of all children that came 
into contact with B. pertussis would develop symptomatic pertussis 14. The widespread 
implementation of a killed whole-cell pertussis (wP) vaccine drastically reduced the 
incidence and mortality of pertussis, to the point that in 1975, it was proposed as a 
candidate for eradication 15. However, beginning in the 1980s, the number of cases 
began to increase in countries with high vaccine coverage 14. Around this time concerns 
arose regarding the reactogenicity of wP vaccines. In the late 1970s a landmark study 
examined the reactogenicity of whole-cell pertussis vaccine combined with diphtheria 
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and tetanus toxoids (DTP) compared to diphtheria and tetanus toxoids alone (DT) 16. 
The authors determined a correlation with redness, pain, and swelling at the injection 
site; as well as fever, and persistent crying when compared to DT immunization alone. 
In the early years of DTP vaccination there were reports of serious neurologic events 
and in some cases death 17. Understandably, this condition of “vaccine encephalopathy” 
arose as a major concern against pertussis immunization. As a result of these concerns, 
neurologic symptoms following pertussis immunization were extensively studied. Initial 
findings suggested that a correlation existed; however, these experiments lacked proper 
control groups, and multiple conditions could explain the neurological symptoms. A well-
designed study, the National Childhood Encephalopathy Study, concluded there was no 
correlation between encephalopathy and pertussis immunization, and that cases of 
vaccine encephalopathy were the first seizures of infantile epilepsy 18. In the following 
years DTP formulations were altered to be safer; however, in some cases, immunization 
was not as effective and resulted in some countries stopping DTP immunizations all 
together 19. These inconsistencies in wP formulations and public concern pushed for the 
development of safer pertussis vaccines composed of acellular proteins with DT toxoids 
(DTaP) 5. It is important to note that, wP pertussis vaccines are still widely used today, 
especially in low- to middle-income countries; where they are effective at controlling the 
number of cases.  
The first DTaP vaccines were developed in Japan by Sato and colleagues; which 
consisted mainly of filamentous hemagglutinin (FHA), a membrane-bound adhesin of B. 
pertussis, with lower amounts of chemically detoxified pertussis toxin (PT), over time 
other adhesins were included, fimbriae (Fim) proteins and pertactin (PRN) 20. As 
development of DTaP vaccines continued the amount of PT was increased equal to the 
concentration of FHA 21. This generated a more specific immune response capable of 
neutralizing key virulence factors of B. pertussis while reducing fever, and local 
inflammatory reactions seen with wP immunizations. At the time, the Sato vaccines 
were the needed solution because they demonstrated low toxicity in mice, but were 
protective, generating high serum titers to antigens. When DTaP vaccines were moved 
to humans they were less reactogenic than wP immunizations, but still induced a robust 
antibody response 22. Evidence from household-contact studies and a decrease in 
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pertussis surveillance further supported the success of these DTaP vaccines, leading 
other countries, including the US to pursue DTaP vaccines 23. 
A key difference between the development of wP vaccines and DTaP vaccines was the 
method used for testing vaccine efficacy. After early inconsistencies in wP preparation, 
which resulted in ineffective vaccines, a validation method was developed to confirm lot 
validation 5. Pearl Kendrick and others developed the mouse potency test in the mid-
1940s that enabled the prediction of wP vaccine efficacy 24. Briefly, this used an 
intraperitoneal injection of a test vaccine and a standard vaccine into young mice; then 
mice were challenged with 105 of live B. pertussis through intracerebral inoculation 14 to 
17 days after the immunization. Vaccine-induced protection was determined by survival 
of the mouse. Vaccine potency was assessed as international units, determined by 
comparing mouse survival following different lots of wPs compared to survival following 
a standard vaccine. The problem was that DTaP vaccine-induced protection could not 
be fully validated using Kendrick’s mouse potency test, as DTaP immunizations did not 
protect against lethality in the intracerebral challenge 25. To address this, a modified 
Kendrick test was developed to assess vaccine potency of DTaP immunizations 26. This 
protocol extended the time between immunization and challenge allowing for the 
generation of an antibody response 26,27. This led to the validity of DTaP vaccines to be 
determined from antibody titers against the individual antigens composed in a particular 
vaccine. As opposed, to the survival of mice following intracerebral challenge in wP 
validation tests. However, evidence now suggests that IgG antibody titers are not a true 
correlate of protection against pertussis 28. As a result, Guiso et al. developed an 
intranasal mouse challenge model, where B. pertussis was capable of colonizing the 
lung. This protocol led to the validity of DTaP vaccines based on serological titers and 
clearance of the pathogen from the lower-respiratory system of mice 25.  
In the United States vaccine coverage of DTaP has remained high and as of 2016 
93.7% of children aged 19 – 35 months have received ≥3 doses 29. Nevertheless, a 
WHO review concluded that the United States, along with Australia, England, Wales 
and Portugal are experiencing a pertussis resurgence based on increased morbidity 
and hospitalizations 14. The increase in incidence of pertussis cases suggests that 
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current DTaP vaccines do not offer complete protection against B. pertussis. Multiple 
hypotheses have been proposed explaining the resurgence of incidence of pertussis 
including shortcomings of DTaP vaccines, vaccine-driven evolution, and increased 
surveillance of pertussis cases.  
Waning DTaP Vaccine 
Evidence that DTaP vaccine efficacy waned earlier than wP first arose in the early 
2000s 30. The mechanisms of protection between DTaP and wP vaccines will be 
explored at length later in this chapter. Presently, human data exists suggesting 
differences in the long-term protection from individuals immunized with either wP or 
DTaP vaccines, suggesting that wP vaccines offer longer protection 31. Studies in the 
US and Australia examining cohorts of children receiving either wP or DTaP priming 
immunizations, followed by DTaP booster immunizations have allowed for the study of 
the different responses 31. A study comparing protection up to 2 years post–booster 
immunization found higher IgG titers, memory B-cell numbers, and T-cell cytokine 
responses in DTaP primed individuals compared to wP primed children shortly after 
booster immunization 32. At 2 years post-boost DTaP primed children IgG titers 
remained higher, but only a Th1 cellular response was observed in wP primed children 
32. Another study used a similar experimental design; however, they examined 
protection in wP primed children two years later than they did in DTaP primed children 
33. Their findings suggested that even with an additional 2 years post-boost wP primed 
children exhibited a higher cytokine response, and more CD4 and CD8 T cell 
proliferation to B. pertussis antigens 33. A large case-control study in northern California 
found that DTaP protection waned unexpectedly fast following the fifth dose of DTaP 34. 
A parallel study also, found that after the fifth dose of DTaP the odds of acquiring 
pertussis increased on average 42% each year 35. This trend continued as the same 
group compared pertussis rates among adolescents who received the Tdap booster, 
which consists of a lower concentration of vaccine antigens with the addition of Fim 
antigen. These studies found that Tdap effectiveness dropped from 69% the first year 
after vaccination to an alarming 9% after 4 years 36. Predictably, a study found that 
individuals who only received DTaP immunizations compared to those who received the 
wP vaccine schedule were at greater risk of contracting pertussis 37. Together these 
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data clearly demonstrate the waning of protection provided by DTaP vaccines following 
a completed vaccine schedule.  
Asymptomatic Transmission  
Recently, data has emerged suggesting asymptomatic transmission in humans based 
on five areas of research 38. First, it is known that subclinical levels of pertussis exist in 
countries such as the United States and the United Kingdom1,14. Secondly, household 
contact is a well-documented mode of transmission of pertussis 5,9,23. However, based 
on compiled data from household contact studies a symptomatic individual was only 
identified as the source of infection in 42% of cases 11. Third, the process termed 
“cocooning” an infant (vaccinating those that will have early contact with the infant), has 
not been found to increase protection among infants 39,40. Fourth, is the unexpected 
high number of cases in infants, given the high vaccination rate in countries such as the 
United States 41. Lastly, is the persistence of the cyclical epidemics of pertussis similar 
to the pre-vaccine era 14.  
Up to this point, human data suggesting asymptomatic infection is only correlative; 
however, in the non-human primate model it has been shown that asymptomatic 
transmission following DTaP immunization can occur 42. Warfel et al., demonstrate that 
while convalescent or wP vaccine-induced protection inhibited colonization by B. 
pertussis and blocked transmission to an unprotected animal, DTaP immunized 
baboons were colonized and transmitted the infection 42. It is then conceivable to think 
that the correlations stated above by Althouse and Scarpino 38 may be occurring in 
humans, and asymptomatic infection could be accounting for the resurgence of 
pertussis in countries with strictly DTaP immunization schedules.  
Vaccine-driven evolution of B. pertussis 
B. pertussis is often described as an organism with limited genetic variability, although 
recent data has revealed substantial variation in circulating strains across different 
countries 43,44. Weigand et al. find that this variation occurs mostly in genes that encode 
for immunogenic proteins, such as ptxA, fimH, genes encoding for PT and FHA, 
respectively 45. Furthermore, these strains quickly spread through the population, 
leading researchers to conclude that these mutations may be a result of vaccine-driven 
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selection 44,46. Sealey et al., note the increased mutation rate in antigen-encoding genes 
found in various DTaP vaccines, and further mention that the frequency of the mutations 
has increased since the widespread incorporation of DTaP vaccines 47. Perhaps the 
most recognized mutation is the rise of PRN deficient stains, which have spread at 
alarming rates across the United States and Europe 48,49. In the United States a 2015 
study, found that of 753 clinical isolates, 85% were PRN-deficient, a staggering statistic 
when PRN is considered a major immunogen in current vaccine formulations 50.  
Increased Surveillance and Diagnosis  
As mentioned earlier, cyclical outbreaks of pertussis continue to occur. In the pre-
vaccine era, these outbreaks were associated with high fatalities, and this was common 
in low and high-income countries 11,14. Today, these high fatality outbreaks continue to 
occur mainly in low-income countries without established infant immunization programs. 
In these countries, positive diagnosis occur from observation of classical pertussis 
clinical symptoms 51. However, the resurgence of pertussis cases has been observed in 
high-income countries with well-established vaccine programs. In these countries, 
cases of pertussis are now diagnosed using quantitative real-time (RT)-PCR using 
insertion sequences allowing for the identification of Bordetella species, such as IS481, 
IS1001 and IS1002 52. PCR diagnosis was first implemented for pertussis testing in the 
late 1980s and early 1990s and has since become the standard in developed countries 
52,53. It must be considered that the increased sensitivity of pertussis diagnosis is playing 
a role in increased pertussis case incidence. When the WHO assessed the re-
emergence of pertussis they did not support a global increase in pertussis cases due to 
the increasing global population and increased diagnosis sensitivity 14. However, taking 
these factors into consideration they did determine a pertussis resurgence in the United 
States and other developed countries 14.  
Together these proposed hypotheses are supported by evidence that suggests that the 
switch to DTaP immunizations is playing a role in the resurgence of pertussis. A 
proposed strategy to circumvent for this resurgence of cases is a vaccine capable of 
inducing a Th1/Th17 mediated immune response more similar to wP vaccines. The 
rationale behind this strategy is that priming with a more pro-inflammatory vaccine will 
8 
 
lead to the generation of an immune response more similar to the natural infection of B. 
pertussis. The hope being, that this response extends the duration of protection and 
leads to clearance of the pathogen from the respiratory tract.  
Pathogenesis of B. pertussis  
Much of the work performed in understanding the pathogenesis has been performed 
using animal models of B. pertussis infection. B. pertussis colonizes the respiratory tract 
and much of the work has focused on the establishment of colonization following 
inhalation of the bacteria. Aerosolized B. pertussis is transmitted through respiratory 
droplets 54. The bacteria attach to cilia, expressed on respiratory airway epithelial cells, 
through bacterial adhesins, such as Fim and FHA 55. 
Once in the in the host, a currently unknown natural signal activates the sensor kinase 
(BvgS), of the bvgAS locus, a two-component regulatory system responsible for many 
of the virulence factors of B. pertussis. The activation of the histidine kinase BvgS and 
the phosphorylation of the response regulator BvgA results in the transcriptional 
regulation of BvgAS regulated genes, known as the Bvg+ phase 55. Virulence factors 
activated in the Bvg+ phase are known as vags (virulence-activated genes) and include 
ptx (PT), cya (adenylate cyclase toxin), bteA, (type III secretion system), fha (FHA), fim2 
and fim3 (Fim); and have been classically considered essential for infection 56–59. After 
the establishment of infection B. pertussis produces bacterial toxins that either enter the 
bloodstream or effect surrounding cells.  
Pertussis toxin 
Pertussis toxin (PT) is an AB5 toxin, that is exclusively expressed by B. pertussis. In 
earlier stages of the infection, PT plays a role in adherence to ciliated respiratory cells 
60. In later stages, PT inhibits chemotaxis of phagocytic cells to the site of inflammation, 
where it is believed to play a critical role in the clinical symptoms of pertussis 61. PT 
binds to glycoproteins on the cell surface of a wide variety of host cells, and the entire 
holotoxin is phagocytosed. In the endoplasmic reticulum, the S1 subunit is released into 
the cytoplasm, where it catalyzes ADP-ribosylation of Gi proteins, holding them in their 
inactive state 62–64. This results in 1) cytoplasmic increases of cyclic adenosine 
monophoshate (cAMP), and 2) a dysregulation of Gi protein-coupled signaling 
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pathways; PT is specifically known to inhibit macrophage and neutrophil recruitment to 
the site of infection 65,66. In early studies by Morse and associates, PT was termed, 
leukocytosis-inducing factor (LPF), where they determined LPF was responsible for the 
increase in leukocytosis and lymphocytosis following intravenous administration of the 
toxin 67. It was not until the work of Margaret Pittman demonstrated that LPF was an 
essential toxin for the pathogenesis of B. pertussis was the toxin referred to as PT 5,68. It 
has been shown in numerous studies that neutralization of PT alone results in vaccine-
induced protection. Therefore, detoxified toxin is included in all acellular vaccines 60,69–
72. 
 
Figure 2: Pathogenesis of B. pertussis. 
 1) Aerosolized B. pertussis contained in expelled droplets is inhaled by individual. 2) Infection is initiated 
by adherence of bacteria to cilia, present on airway epithelial cells by bacteria adhesins; FHA, PRN, and 
Fim. 3) Activation of BvgAS phosphorelay, leads to expression of vags critical for infection, such as PT 
and ACT. 4) Secretion of PT and ACT dysregulate the innate immune response. PT suppresses systemic 
signaling of Gi protein-coupled signaling pathways utilized by chemokine receptors, resulting in 
leukocytosis. ACT acts locally at the site of infection, through catalytic activity of adenylate cyclase 
domain and hemolysin activity of RTX domain on APCs. The immunomodulatory activity of PT, ACT along 





Adenylate cyclase toxin 
Adenylate cyclase toxin (ACT, CyaA) is a large 177kDa monomeric protein, that 
consists of five regions: 1) N-terminal adenylate cyclase domain (AC), 2) a central 
hydrophobic domain, 3) a modification region responsible for acylation of the protein, 4), 
a repeat in toxin (RTX) hemolysin binding domain, and 5) a C-terminal secretion signal 
61,73–76 . ACT is secreted through a type I secretion system, through a channel formed 
by the CyaBDE proteins 77. Following secretion, ACT is modified by acylation at sites 
K860 and K983.  
This process is essential for toxin activity and it has been shown that acylation 
enhances binding to complement receptor 3 (CR3, αMβ integrin, CD11b/CD18)78. A 
recent hypothesis proposes that FHA may play a role in the delivery of ACT by binding 
to newly secreted ACT; thereby, retaining the toxin on the surface of bacteria 79. This 
hypothesis is supported by findings that suggest delivery of ACT requires a close 
association of live bacteria with target host cells 80. Additionally, activation of the toxin 
also requires calcium, which binds in the RTX motifs of the binding domain, forming 
beta rolls 81. Upon, this activation the RTX region can then bind CR3, leading to the 
penetration of host cell membrane by the hydrophobic region of ACT 82. This allows for 
the translocation of the AC domain into the cytoplasm of the host cell 83. Calmodulin 
present in the cytoplasm of the host cell increases the catalytic activity of ACT, which 
drastically increases cellular cAMP to supraphysiological levels 84. The increases in 
cAMP caused by AC activity of ACT has been shown to inhibit activation of antigen-
presenting cells (APCs), as well as induce apoptosis 84–86. Thus, ACT, along with PT 
has significant immunomodulatory properties, leading to the classification of these two 
toxins as the two most important virulence factors of B. pertussis pathogenesis 61. 
Despite the immunomodulatory properties of ACT, it has yet to be included in newer 
generation pertussis vaccines. Limited studies have evaluated ACT as a potential 
antigen. Guiso et al. demonstrated purified ACT was protective in a murine intranasal 
challenge against B. pertussis 87. Furthermore, the same group demonstrated anti-ACT 
antibodies were capable of neutralizing ACT and inhibiting ACT activity on neutrophils 
88. These studies yielded encouraging results; however, after the widespread 
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incorporation of DTaP into vaccine schedules progress on Pertussis vaccine research 
had slowed. Yet, ACT remains a strong antigen candidate for future pertussis vaccine 
development.  
Adhesin factors of B. pertussis  
FHA is a large, 232-kDa adhesin produced by all Bordetella spp. Studies suggest that 
the protein has multiple binding sites, which facilitate binding of B. pertussis to 
monocytes, macrophages, ciliated respiratory cells, and nonciliated epithelial cells 89–91. 
FHA has been shown to be a strong immunogen and serum antibodies to FHA have 
been found in patients following natural infection and after immunization 92. Due to the 
protein’s immunogenicity and role in attachment, it is considered a major virulence 
factor and included in most DTaP vaccines.  
Another group of antigens included in current 5-component DTaP formulations is the 
Fim proteins. Fim proteins are filamentous, polymeric cell surface proteins, that bind 
host cells. They are also expressed during the Bvg+ growth phase, and like other vags 
have been shown to play a critical role in B. pertussis pathogenesis and adhesion to 
host cells 93. In vivo studies using Fim-negative strains have demonstrated reduced 
growth in the trachea and nasopharynx of mice 94, and reduced bacterial adherence in 
vitro 95. Two serotypes of fimbriae are most commonly observed in clinical isolates, 
Fim2 and Fim3, and are expressed in a serotype-specific manner 96. It has been 
demonstrated that Fim proteins are involved in bacterial agglutination, and included in 
current DTaP formulations as agglutinogens 97.  
The continued research of B. pertussis pathogenesis has driven antigen selection for 
current acellular vaccines. As the field pushes for the development of the next 
generation of pertussis vaccines there is evidence that other virulence factors of B. 
pertussis have the potential for inclusion into new vaccines.  
Immunity to B. pertussis 
Pertussis cases are most severe in infants and can even be fatal. However, the majority 
of individuals are able to clear the infection. Studies using animal models have 
suggested that cells of the innate immune response are able to control the early 
infection in naïve animals 98. The innate immune response generated following 
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challenge with B. pertussis has been shown to consists of antimicrobial peptides, 
components of the complement system, and effector cells such as macrophages, 
neutrophils, natural killer cells, and dendritic cells 99. However, complete clearance 
requires the development of an adaptive, B. pertussis-specific response. Immune 
subversion of the innate immune response and persistence of B. pertussis infection are 
capable of delaying the generation of an adaptive immune response, suggesting that 
the interface between the innate and adaptive immune responses is crucial to 
controlling infection.  
In the natural immune response, adherent bacteria colonize the respiratory epithelium. 
B. pertussis virulence factors act as pathogen-associated molecular patterns (PAMPS) 
such as: lipooligosacharide (LOS), ACT, FHA, PT. These PAMPS bind pattern 
recognition receptors present on mucosal epithelial cells, macrophages and dendritic 
cells (DCs) leading to a cascade of pro-inflammatory responses 100,101. Cytokines such 
as: interleukin-6 (IL-6), interleukin-1 β (IL-1β), interleukin-12 (IL-12), tumor necrosis 
factor alpha (TNF-α) and interleukin-17 (IL-17) have been shown to be produced early 
in B. pertussis infection and lead to recruitment of macrophages, neutrophils, DCs, and 
natural killer T cells to the respiratory tract 69,98,102–104.  
Macrophages are long-lived phagocytic cells capable of residing in the tissue. Thus, 
they are one of the first cell types that play a role in recognition of B. pertussis. In animal 
studies it has been shown that upon challenge with B. pertussis a large percentage of 
the bacteria are cleared early in infection, suggesting that macrophages have a role in 
clearance of the pathogen 65,105. Studies in the mouse model have highlighted the role 
of macrophages in early B. pertussis infection, by showing that depletion of airway 
macrophages enhanced the infection 65. It was previously mentioned that macrophages 
are susceptible to toxins, PT and ACT. There is evidence that some B. pertussis 
survives phagocytosis and can persist in macrophages. This suggests that 
dysregulation caused by bacterial toxins could lead to an intracellular niche and 
persistent infection 106–108. Thus, there is potential that neutralization of both toxins 
would be a beneficial property of future pertussis vaccines.  
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Neutrophils have been shown to have an interesting role in the clearance of B. 
pertussis. In the mouse model following natural infection by the bacteria, neutrophils 
were shown to not play an essential role in bacterial clearance 109. However, when 
bacteria are opsonized, neutrophils do play a significant role in bacterial clearance 109. 
Furthermore, the formation of neutrophil extracellular traps (NETs) has been observed 
following infection with B. pertussis 110. Like macrophages, neutrophils as well are 
affected by B. pertussis toxins through inhibition of chemotaxis, phagocytosis, NET 
formation from ADP-ribosylation and cAMP accumulation 111. The role of neutrophils in 
pertussis has not been fully explored and provides an interesting avenue for future 
research.  
Adaptive immune response  
The generation of an adaptive immune response is necessary for complete protection 
against B. pertussis. DCs from the infected respiratory tract migrate to lymph nodes to 
present antigen to naïve T cells. The lungs of naïve adult mice do not contain high 
numbers of T cells; however, following infection of B. pertussis T cells are recruited to 
the lung which correlates with bacterial clearance from the tissue 101. A critical role of 
CD4+ T cells in pertussis immunity was shown using athymic nu/nu mice, as challenge 
resulted in persistent infection or death 112. Adoptive transfer of convalescent splenic T 
cells into these athymic mice cleared the infection. Conversely, similar experiments 
using transfer of B. pertussis-specific CD8+ T cells to sublethally irradiated BALB/c mice 
did not result in clearance of infection, suggesting cellular responses mediated by CD4+ 
T cells play an important role in immunity to B. pertussis 112. In particular, CD4+ T cells 
from infected mice produce IFN-γ and IL-17, and not Th2 associated cytokines 113. 
Furthermore, IFN-γ -/- mice have a significantly reduced ability to clear the pathogen, and 
lethal disseminating B. pertussis infections have also been observed 113,114. Studies 
using IL-17A -/- mice, also reached similar findings, determining greater bacterial burden, 
and decreased neutrophil concentrations in the lungs of infected knockout mice 
compared to WT mice 115. Data from baboons infected with B. pertussis correlate with 
data from mouse model as both models generate Th1 and Th17 immune responses 
following infection and colonization of B. pertussis 116. Taken together, data from mouse 
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and baboon models demonstrate that the natural infection of B. pertussis is cleared 
through the induction of a mixed Th1 and Th17 immune response116.  
Mucosal immune response  
B. pertussis is strictly a pathogen of the respiratory system. In humans all but the most 
severe cases occur in the upper respiratory tract 5. In the mouse model, B. pertussis 
infection also remains in the respiratory tract and only in immunocompromised models 
or neonatal mice has dissemination into other organs been documented 114,117. Yet 
today, all commercially available pertussis vaccines are given parenterally and have not 
been observed to induce local immune responses in the respiratory system. Therefore, 
it seems that this under-explored avenue of immunity could play an important role 
against B. pertussis. Findings from the non-human primate pertussis model have 
strengthened this possibility. As mentioned early, Warfel et al., demonstrate DTaP 
immunization in baboons did not inhibit transmission of B. pertussis to another animal 
118. While wP immunization inhibited transmission, B. pertussis colonization persisted 
for more than 19 days. Only in baboons that had been previously challenged with B. 
pertussis and convalescent at the time of challenge, was colonization inhibited. In 
another study by the same group, a strong IL-17 response was measured in 
nasopharyngeal wash fluid following B. pertussis infection 116. Upon, re-challenge of 
convalescent baboons Th-17 associated cytokines were increased early in infection. 
The strength of the baboon work comes from relevance to B. pertussis pathogenesis in 
humans. However, non-human primate models are unobtainable for most researchers. 
Mice share similar T cell responses to humans and through the mouse model protection 
from the mucosal immune response can be currently addressed.  
Immunoglobulin A in the respiratory tract 
The induction of a mucosal immune response is associated with production of IgA 
antibody. In the mucosal surfaces IgA is the predominate isotype, where it exists in the 
dimeric form as secretory IgA (SIgA). Mucosal IgAs are known to block adhesion of 
bacteria and neutralize toxins, and serum IgA can facilitate receptor-mediated 
phagocytosis in other bacterial respiratory infections 119. In a study using IgA-/- mice, it 
was shown that upon challenge with B. pertussis infected mice did not exhibit a 
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statistically different bacterial burden compared to WT 120. More so, upon secondary 
challenge there was still no difference, suggesting that IgA did not play a critical role in 
protection in a natural infection or a primed response. Interestingly, IgA antibodies did 
appear to play a significant role in protection against, the closely related, Bordetella 
bronchiseptica clearance in the upper-respiratory tract; however, not in the lower-
respiratory tract 120. The authors do state that this finding may be due to B. pertussis 
infecting human hosts, while B. bronchiseptica effects mainly other mammals. However, 
recent data has determined contradicting findings 121. SIgA antibodies are transported 
across the mucosa through the polymeric Ig receptor. Using a mouse model deficient in 
this receptor, the specific role of SIgA in the respiratory tract was determined in the 
aforementioned study. Solans et. al. found that following intranasal administration of a 
live-attenuated B. pertussis vaccine, BPZE1, that in SIgA-deficient mice protection was 
strongly diminished compared to WT mice 121. Additionally, the authors demonstrate 
that IL-17 plays a critical role in the production of nasal SIgA following BPZE1 
immunization, as IL17-/- mice produced only background levels of the antibody. 
Furthermore, in these mice the vaccine did not inhibit colonization. In human data, 
infection has been shown to be correlated with B. pertussis-specific IgA in the nasal 
secretions of infected patients 122. It was found that these antibodies were detected at 2-
3 weeks after infection, but the response is reduced to low levels around 6 months. A 
possible protective role of human IgA was shown in vitro where anti-B. pertussis IgA 
antibodies from serum and nasal washes of convalescent individuals were shown to 
inhibit adherence of B. pertussis to human respiratory cells 123.  
Local cellular mucosal immune response  
In the pathogenesis of B. pertussis, the first cells to encounter the pathogen are those of 
the lung-resident innate immune cells. The process of antigen-presentation via 
macrophages and DCs to naïve T cells in the draining lymph nodes is well understood, 
as described earlier. The role of Th1 and Th17 immune responses to B. pertussis are 
also well described though, most of this data comes from peripheral T cells 114,115,124. It 
has been shown that T cells from the lung and those from the spleen respond differently 
to bacterial antigens, and suggests a compartmentalization between T cells of periphery 
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and those of the lung 125. More recently, it has been shown that lung CD4+ specific to B. 
pertussis do still secrete IFN-γ and/or IL-17 112,126.  
The group of Kingston Mills has identified a portion of the CD4+ T cells secreting IFN-γ 
and IL-17 are from a population known as tissue-resident memory T cells (TRM) 127. 
These cells exhibit classical memory T cell effector markers, CD44+ and CD62L-, along 
with expression of surface markers associated with tissue retention CD69+ and/or 
CD103+ 127,128. An innovative method was used to confirm that these TRM cells are 
indeed not circulating and retained in tissue. An anti-CD45 labeled-antibody was 
administered intravenously prior to euthanasia, thus labeling cells that were circulating 
as CD45+, while cells retained in the tissue would not be labeled. Then using another 
anti-CD45 labeled-antibody with a different fluorophore, cells were labeled in single-cell 
suspension along with other markers, TRM cells that were negative for the first anti-CD45 
antibody, and positive for the second were classified as cells that were resident in the 
tissue 127. In the study described above, these TRM cells provide a protective role 
following the secondary infection of a mouse previously infected with B. pertussis. 
Additionally, these studies were repeated and found that these cells persisted in the 
lung tissue for several months following the initial infection, and then expanded after re-
challenge. The finding that these mucosal resident TRM are capable of secreting IL-17 
and IFN-γ, suggest that this population may play a critical role in recruitment of 
phagocytes during the secondary immune response. More evidence suggesting a 
critical role was shown when migration of CD4+ T cells was chemically inhibited during 
secondary challenge with B. pertussis, and the infection was still cleared due to the 
presence of TRMs in the lung, this was also shown using adoptive transfer with similar 
findings 127. The findings described in this section provide strong evidence that the 
generation of a local mucosal immune response plays a role in the clearance of B. 
pertussis following previous challenge. However, the generation of a mucosal immune 




Pertussis vaccine-mediated immunity 
It is clear that widespread use of wP vaccines was effective. By the 1970s the average 
yearly rate of pertussis cases in the United States dropped to <1 per 100,000 
population, compared to 157 cases per 100,000 population in the 1950s130. These 
vaccines, still used today, are composed of killed whole B. pertussis organisms. As, a 
result the vaccines consist of numerous potential antigens and adjuvants, creating a 
highly immunogenic vaccine. However, this creates a degree of reactogenicity, mostly 
attributed to the presence of LOS 131. It has been discussed that the adverse effects of 
wPs caused the switch in vaccine schedules to DTaP vaccines, and that following the 
change pertussis cases are re-emerging. Following the resurgence of pertussis, work 
has focused on understanding the differences in the vaccine-induced immune response 
following DTaP or wP immunization. While, it is known that DTaP-induced protection 
wanes significantly each year, initially strong IgG serum titers are observed 132. A recent 
study demonstrated DTaP-induced IgG levels remain higher than individuals immunized 
by wP until 6 years of age; however, wP protection persists longer 133. Data 
characterizing the T cell responses in children following DTaP or wP priming suggests 
greater differences between the immunizations. Children receiving DTaP demonstrated 
Th2 responses, while children receiving wP preferentially induce Th1 cells 134,135. 
Interestingly, current data suggests that the T cell responses induced by initial vaccine 
priming are imprinted. Data from human patients suggests that Tdap booster 
immunizations do not alter the T cell responses or IgG antibody subtypes induced by 
wP, as these patients still produce the response elicited by the wP vaccine 133,136. 
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Table 1: Immune response to B. pertussis following previous infection or vaccination.  
Summary of current literature in mice, baboons, and humans. Figure adapted from Wilk et al.11, Kapil 
and Merkel 102, and Brummelman et al. 101.  
 
 
The vaccine-induced responses following challenge with B. pertussis have been well 
characterized in mouse models. The response to B. pertussis in a wP immunized 
mouse mirrors the response to natural infection. A strong pro-inflammatory response is 
elicited in response to infection, resulting in enhanced bactericidal activity of 
macrophages and neutrophils 102,124,137. In mice, the IgG profile following wP 
immunization is made up primarily of IgG2a/c, as well as IgA, and IgG1 antibodies, 
suggesting a Th1 response, whereas the IgG antibody isotype IgG2a/c (depending on 
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mouse strain) 105,115. This pro-inflammatory response has been shown to be dependent 
upon IFN-γ, as is natural infection, wP-primed IFN-γ-/- mice could not clear a challenge 
with B. pertussis 115,138. Similarly, IL-17 has been shown to be induced following wP-
induced protection, and clearance of B. pertussis was delayed in IL-17-/- compared to 
WT mice, although mice did clear the infection eventually 115. Recent work by Wilk et al. 
has demonstrated a novel finding suggesting that clearance of B. pertussis from the 
nasal cavity is dependent upon IL-17, as the TRM population was not detected in IL-17-/- 
mice, nor could they clear the infection in the nasal cavity 129. Interestingly, the TRM 
population and more so bacterial clearance in the nasal cavity only occurred following 
natural infection with B. pertussis or with intraperitoneal wP immunized mice. Clearance 
from the nasal cavity and the TRM population were not found following challenge of 
DTaP or Tdap primed mice. 
DTaP on the other hand consists of high doses of 3-5 B. pertussis antigens mainly: PT, 
PRN, FHA, Fim2 and Fim3. Thus, DTaP immunizations induce a more specific 
response that is capable of neutralizing the symptoms of the disease; however, it does 
not inhibit colonization or transmission 118. In mice, DTaP induces a predominantly IgG1 
driven humoral immune response. It is known that in mice DTaP induces a Th2 
response, but also a Th17 mediated response. This was further shown through the 
finding that DTaP immunized IL-4-/- mice were fully protected from infection, and the 
protection was mediated through IL-17. The Th17 response is known to be induced by 
aluminum used as an adjuvant. The induction of a Th17 response has not been shown 
to occur in humans or non-human primates and is specific to mice 101,115,118. Although a 
Th17 immune response is observed in DTaP immunized mice, it is not sufficient to 
induce the TRM population that was induced with wP immunization, which may play a 
role in the duration of memory between the vaccine-induced responses. It is clear that 
DTaP-vaccine induced immunity has various shortcomings including narrow specificity, 
different Th-cell subtype response, and different memory T cell populations.  
The goal of this body of work was to better understand and improve upon the current 
DTaP vaccine-induced immune response. The development of DTaP vaccines occurred 
at a time when an answer to the reactogenic wP vaccines was desperately needed. 
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Thus, the development process occurred quickly, the duration and type of immune 
response elicited were not designed to be tested in the safety and efficacy trials. We 
aimed to characterize the DTaP vaccine-induced response through a mouse model 
capable of addressing vaccine efficacy beyond production of B. pertussis-specific IgG 
antibodies. In chapter 2, we characterize the neutrophil response to B. pertussis 
following immunization and challenge. Using, a neutrophil reporter mouse line, NeCre 
luc we observed the drastic neutrophil response following challenge of a wP-primed 
mouse, compared to DTaP protection and even natural infection. We used RNAseq 
analysis to observe transcriptional changes between the vaccinated groups to further 
characterize pro-inflammatory response. The work in chapter 3, discusses the titration 
of DTaP immunization dose to a relevant immunization dose for murine studies. In this 
chapter, we aimed to determine a sub-optimal vaccine dose. Defining this dose would 
enable us to determine effects of potential antigens. Furthermore, we implemented an 
antigen of a key virulence factor of B. pertussis, ACT. The antigen (RTX) induced a 
strong serum IgG response that was capable of neutralizing the toxin in vitro. Inclusion 
of the antigen resulted in increased bacterial clearance and a reduction in the pro-
inflammatory response following B. pertussis infection. Data from non-human primates 
and mice studies suggest that the lack of clearance of B. pertussis from the upper-
respiratory in DTaP protected mice was a shortcoming of the vaccine. In chapter 4, we 
address the mucosal immune response by characterizing DTaP vaccine-induced 
immunity when the vaccine was administered intranasally. In this work we determined 
that intranasal immunization with DTaP can generate a local mucosal immune 
response. When the vaccine was administered with a Th17 promoting adjuvant we 
detected a local IL-17 response at the site of infection and production of IgA in the 
respiratory tract. In chapter 5, the implications of these works in the generation of future 
pertussis vaccines are discussed. The current state of pertussis vaccine research is at a 
crossroads due to the uncertainty of which vaccine avenue to pursue, this work 
establishes a safe, intranasal vaccine with parameters that could be used to establish 
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Bordetella pertussis  (B. pertussis) is the causative agent of pertussis (whooping 
cough). Since the 1990s, pertussis has re-emerged in the United States despite an 
estimated 95% vaccine coverage. Our goal was to characterize neutrophil responses 
and gene expression profiles of murine lungs in the context of vaccination and B. 
pertussis challenge. We utilized a bioluminescent neutrophil mouse model (NECre luc) 
to track neutrophil recruitment. NECre luc mice were immunized with whole cell vaccine 
(WCV), acellular vaccine (ACV), or a truncated adenylate cyclase toxoid (RTX) vaccine. 
Neutrophil recruitment was measured in live mice across time and corroborated by flow 
cytometry and other data. WCV immunized mice showed signs of neutrophilia in 
response to B. pertussis challenge. Mice immunized with either ACV or WCV cleared 
the challenge infection; however immunization with RTX alone was not protective. RNA 
sequencing revealed distinctive gene expression profiles for each immunization group. 
We observed an increase in expression of genes associated with responses to 
infection, and changes in expression of distinct genes in each vaccine group, providing 
a complex view of the immune response to B. pertussis infection in mice. This study 
suggests that combination of immunological analysis with transcriptomic profiling can 














Pertussis is a human disease primarily caused by a respiratory infection of the Gram-
negative pathogen Bordetella pertussis (B. pertussis). The hallmark of pertussis is a 
distinctive whooping cough. What is surprising about pertussis is that the cause of the 
cough has never been elucidated, which highlights the fact that there are many under-
researched aspects of this disease. Aerosolized B. pertussis bacterium are inhaled and 
adhere to airway respiratory epithelial cells through bacterial adhesins such as 
filamentous hemagglutinin (FHA), fimbriae and pertactin1. After colonization B. pertussis 
express multiple toxins including pertussis toxin (PT) and adenylate cyclase toxin 
(ACT). B. pertussis releases PT, which dysregulates the immune response through 
ADP-ribosylation of the G-protein α-subunit of cytokine receptors present on a range of 
leukocytes2–5 . The secretion of PT has long range effects, ACT is thought to act locally 
on host cells by converting ATP into supraphysiological levels of cAMP, further 
dysregulating the host immune response6.  
In the 1940s, an effective whole cell vaccine (WCV) was developed and as a result, 
basic research efforts on B. pertussis decreased. The WCVs were highly reactogenic 
and caused prolonged and unusual crying after administration, hyporesponsivness, and 
febrile convulsions 7–9. These issues led to the development of acellular vaccines 
(ACV), known today as DTaP/Tdap (hereafter referred to as ACV). The ACVs utilize an 
alum adjuvant and induce a Th2 response to several key virulence factors such as PT, 
FHA, fimbriae, and pertactin depending on vaccine formulations. Whereas the ACV 
induces a Th2 response in human and mice, WCV immunization and B. pertussis 
infection promote a Th1/Th17-type response10–14. Since the replacement of the WCV 
with the ACVs there has been a remarkable increase in the number of cases in the US, 
with the number of reported cases in 2012 equaling that of 1954. Multiple factors 
potentially played a role in the return of pertussis in the US. It has been documented 
that the Th2 response induced by ACV immunization may be inferior to the Th1/Th17 
response directed by the WCV15. Additionally, ACV protection wanes significantly as 
early as one year after vaccination, and by 4 years after vaccination vaccine 
effectiveness is only 9%16. Furthermore, in a non-human primate model it has been 
shown that ACV immunized baboons challenged with B. pertussis are capable of 
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carrying the infection and transmitting aerosolized B. pertussis to naïve baboons17. 
Additionally, the findings of an epidemiological study suggest that asymptomatic 
transmission of pertussis is indeed occurring in the human population, and has a role in 
the increase of pertussis incidents18. These recent findings demonstrate the 
shortcomings of the ACV. Utilizing new technologies that were not available during the 
developments of the WCV or ACVs we can further investigate differences between 
WCV and ACV protection. Adenylate cyclase toxin (ACT) is an essential virulence factor 
of B. pertussis and a known protective antigen19–21. ACT contains two main domains: 
adenylate cyclase and the Repeats-in-Toxin (RTX). In the absence of the AC domain, 
the protein is non-toxic and referred to simply as RTX22. In a previous study, sera from 
mice immunized with RTX contained antibodies capable of neutralizing ACT. ACT 
antigens are not included in any commercial formulations of ACVs and many have 
proposed that its inclusion could improve protection6.  
Neutrophils play a role in both the innate and adaptive arms of the immune 
system. Following B. pertussis infection of a naïve mouse, neutrophils reach peak 
recruitment between 5 and 7 days after challenge23,24. This occurs after the bacterial 
burden has begun to decrease. Subsequent studies have determined that neutrophil 
depletion prior to B. pertussis infection in naïve mice does not increase bacterial 
burden. However, when immunized mice are challenged with B. pertussis following 
depletion of neutrophils the B. pertussis bacterial burden increase, demonstrating a 
protective role of neutrophils in immunized mice25. As previously mentioned, B. 
pertussis toxins PT and ACT both affect neutrophils and their recruitment6,26–28. These 
toxins contribute to a significant rise in the number of circulating white blood cells and in 
severe cases leukocytosis is linked to fatality1. Leukocytosis was first described in 
pertussis patients as early as the 1890s29,30. In the 1960’s, Stephen Morse observed 
leukocytosis following WCV immunization31, which he hypothesized was caused by PT, 
then known as leukocytosis-inducing factor32. Therefore, it can be conceived that the 
toxin associated effects on neutrophils would be neutralized following ideal B. pertussis 
immunization, and this raises the question of where and when neutrophils are recruited 
in an ACV or WCV protected mouse?  
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In this study, we utilized in vivo imaging systems (IVIS) to characterize the 
neutrophil responses to B. pertussis challenge in mice vaccinated with ACV or WCV. 
We implemented NECre luc mice, a luminescent neutrophil reporter mouse strain, 
previously used in a Bacillus anthracis infection model to track neutrophil recruitment 
following B. pertussis challenge33. To do so, we: 1) validated the NECre luc mouse as a 
model for tracking neutrophil recruitment in response to B. pertussis infection, 2) tracked 
the spatiotemporal localization of neutrophils in response to B. pertussis challenge in 
ACV and WCV vaccinated mice, and 3) and characterized vaccine-associated gene 
expression profiles of the infected lungs from each group using RNA sequencing. The 
NeCRE luc mouse33 was used to measure the presence and relative quantities of 
neutrophils in live mice during B. pertussis challenge. We then corroborated our findings 
with flow cytometry analysis to quantify neutrophils in the blood and airway of naïve and 
immunized mice. WCV immunization resulted in robust neutrophil recruitment and 
clearance of B. pertussis, but also resulted in morbidity of the NeCre luc mice. RNAseq 
analysis was performed on the lungs of naïve or immunized mice at both early and late 
time-points after challenge with B. pertussis. We observed specific gene signatures for 
each vaccine, and we also identified gene expression profiles that had not been 
associated with B. pertussis or immunization. Neutrophil specific gene expression 
corroborated our cellular analysis of the respiratory tract demonstrating increased 
expression of neutrophil specific genes in WCV immunized mice. Furthermore, we 
determined the T-helper cell gene expression profiles of lung transcriptomes and 
corroborated the activation of Th1 specific gene expression to increased levels of Th1-
associated cytokine production in the lungs of WCV immunized mice. Utilizing the depth 
of data generated through RNAseq, we could classify specific B cell clonotypes present 
in the lung of each immunization group. This technique allowed for analysis of the 
diversity and frequency of the immunoglobulin repertoire of immunized groups. We 
hypothesize that these approaches can continue to be applied to other pathogen to host 
interactions to characterize the underpinnings to disease progression and 




ACV and WCV immunization of NECre luc mice results in clearance of B. 
pertussis, however WCV immunized mice experience increased morbidity and 
mortality.  
To characterize the effects of vaccination on neutrophil recruitment, NECre luc mice 
were immunized with the vaccines as indicated in Supplementary Table S1, and then 
boosted with the same vaccine 21 days later by intraperitoneal injection. We then 
compared the neutrophil recruitment in naïve, ACV, WCV, and RTX-only vaccinated 
NECre luc mice during B. pertussis challenge. At day 35 post initial immunization, 
NECre luc mic were challenged with virulent B. pertussis strain UT25 (Fig. 1) by 
intranasal instillation. A challenge dose of 2 x 107 CFUs B. pertussis does not typically 
cause morbidity in immunocompetent mice such as CD-1 or C57B6/J (data not shown). 
We originally planned to euthanize 4 mice per group on each experimental day (1, 2, 4, 
and 9). However, 2 of 13 naïve challenged NECre luc mice were euthanized at day 2 
due to morbidity (Fig. 2). At day 6, we observed additional unexpectedly morbidity in the 
WCV group, which required euthanasia of all remaining WCV immunized NECre luc 
mice (Fig. 2). Conversely, no morbidity was observed in the ACV and RTX immunized 
mice 9 days post B. pertussis challenge (Fig. 2). We were surprised to observe 
morbidity in the WCV immunized mice. Upon determining viable bacterial burden from 
lung, trachea, and nasal lavage, we observed clearance of B. pertussis to our limits of 
detection in both ACV and WCV immunized mice compared to naïve infection (Fig. 
3abc). Taken together, these data suggested that morbidity of the WCV immunized 
mice was not fully attributed to bacterial burden. Additionally, we determined that 
vaccination with RTX resulted in 100 percent survival out to 9 days post-challenge (pc), 
while bacterial burden were similar to naïve infected mice, suggesting that RTX 
immunization did not improve bacterial clearance (Fig. 3abc).  
Analysis of serological responses of immunized mice.  
As expected, the ACV immunized mice were protected against challenge as they rapidly 
cleared the B. pertussis challenge dose (Fig. 3abc). WCV immunized mice cleared B. 
pertussis, but this response was delayed compared to the ACV mice. To determine the 
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efficacy of immunization on antibody production, we performed serology analysis. PT is 
a common antigen of both the ACV and WCV and we observed a significantly higher 
concentration of anti-PT in the ACV mice compared to the WCV (Fig. 3d). Immunization 
of NECre mice with RTX with alum adjuvant resulted in high anti-RTX antibody titers 
(Fig. 3e) despite the fact that we did not see increased clearance due to RTX 
immunization. In another study, we immunized CD1 mice with RTX and alum adjuvant 
and we also saw no clearance of B. pertussis compared to non-vaccinated mice (data 
not shown). Our data suggest that, while immunization with RTX induces antibody 
production, it is not sufficient to protect mice from B. pertussis infection as a single, 
antigen vaccine.     
Spatiotemporal IVIS imaging of neutrophils in naïve and vaccinated NECre luc 
mice. 
Neutrophil accumulation in NECre luc mice were visualized on days 1, 2, 4, 6 
and 9 post-challenge. Mice were IP injected with the high sensitivity luciferin CycLuc133 
before imaging. A Lumina II IVIS (Xenogen) was used to capture luciferase-driven 
neutrophil luminescence at indicated time-points (Fig. 4 and Supplementary Fig. 1). 
Luminescent signal of the whole body (Fig. 4d) or nasal cavity (Fig. 4e) of vaccinated 
mice was then compared to signal from naïve, non-infected mice and calculated as fold 
change. At day 1 post-challenge, we detected significantly higher luminescence in naïve 
challenged mice compared to naïve non-challenged mice, suggesting that there is a 
higher neutrophil accumulation in challenged mice. Furthermore, whole body 
luminescence in WCV immunized and challenged mice was significantly higher than the 
whole body luminescence of naïve, ACV and RTX B. pertussis challenged mice at day 1 
(Fig. 4d). In general, luminescence signals of all groups decreased across days 2 and 4. 
However, in the WCV group at day 6, we detected an increase in signal in the nasal 
cavity (71-fold) and the whole body (47-fold) compared to naïve not challenged mice 
(Fig. 4de). Due to variability between animals, this increase was not significant 
compared to other groups. At this point WCV immunized mice were morbid and 
required euthanasia. Taken together this data suggests that WCV immunization prior to 
challenge resulted in increased neutrophil accumulation compared to other vaccination 
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groups. We next aimed to corroborate our IVIS luminescence data with flow cytometry 
analysis of respiratory tissues.  
Validation of neutrophil infiltration in respiratory tissue by flow cytometry 
Luminescent signal of luciferase-expressing cells correlates with the localization of 
neutrophils in NECre luc mice33. To confirm this, we measured the relative number of 
neutrophils by performing flow cytometry analysis on respiratory tissue following IVIS 
imaging. Single cell suspensions from lung tissue or nasal lavage were labelled with 
antibodies recognizing cell surface markers. We defined neutrophils as CD11b+GR-1+ 
live cells (Supplementary Fig. 2). Similar to the IVIS data, all B. pertussis challenged 
groups had significantly higher neutrophil percentages in nasal lavage compared to 
naïve non-challenged mice (Fig. 4f). At day 1 post B. pertussis challenge, WCV 
immunized mice had a significantly higher percentage of neutrophils than ACV 
immunized mice in nasal lavage. The percentages of neutrophils decreased from day 1 
to day 2 in all vaccinated groups, as well as the naïve group. At day 4, WCV immunized 
mice exhibited higher levels of neutrophils than those observed at day 2 (Fig. 4g). 
Correlating with the nasal lavage, WCV mice exhibited significantly higher percentages 
of neutrophils in the lungs than ACV mice. Lung neutrophils at day 4 were not 
statistically significant between any of the groups. However, by day 6 there was a 53% 
increase in lung neutrophils compared to day 4 in the WCV group, which directly 
correlates with the increased luminescence signals measured by IVIS imaging (Fig. 4g).  
WCV immunized NECre luc mice induce a more robust Th1 immune response 
compared to ACV immunized mice.  
It has been previously documented that upon B. pertussis challenge, WCV immunized 
mice elicit a Th1/Th17 immune response, similar to a naïve infection while ACV 
immunized mice generate primarily a Th2 response10–12,34. We hypothesized that similar 
responses are triggered by WCV and ACV in the NECre luc model. To test this 
hypothesis, we determined the cytokine profiles in lungs of immunized and challenged 
mice using electrochemiluminescent sandwich immunoassays. The Th1 response was 
determined by increased levels of IFN-γ, IL-12p70, IL-1β and TNF-α (Fig. 5ab), while 
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the Th17 response was qualified by increased IL-17A and IL-6 (Fig. 5cde). Th2 
responses were associated to increased levels in IL-4 and IL-5.  
As expected, we observed an increased Th1 response in the WCV vaccinated NECre 
luc mice compared to the ACV group. We also observed an increase in the Th1 
response in naive challenged mice compared to non-challenged mice or the ACV group. 
Interestingly, the highest levels of IL-17 were observed in WCV NECre luc mice (Fig. 
5c). The levels of Th2-associated cytokines, IL-4 and IL5 were similar between the 
WCV and ACV groups. (Supplementary Fig. 3). The lung cytokine profile from NECre 
luc mice immunized with RTX resembled a profile of naïve B. pertussis challenged mice 
with the exception of IL-6, which was lower in the RTX group. Taken together these 
data from the NECre luc mouse model corroborates previous findings by displaying a 
strong Th1/Th17 response in response to B. pertussis in WCV vaccinated mice.  
Characterizing the gene expression profiles of the lungs of immunized and naïve 
mice after B. pertussis challenge 
Current and past B. pertussis immune response studies have focused on a limited set of 
known immunological responses to B. pertussis challenge such as: bacterial burden, 
antibody response, recruitment of phagocytes, cytokine profiles, and others 35,36. 
Whooping cough is a toxin-mediated disease, due mainly to the activity of pertussis and 
adenylate cyclase toxins. These toxins are released and affect a wide array of host 
cells4,25. It is therefore conceivable that B. pertussis infection would have a broader 
effect on the respiratory tissue beyond the induction of predictable immune response 
factors. To address this, we employed RNA sequencing (RNAseq) to observe the effect 
of B. pertussis challenge on the lungs of immunized and naïve NECre luc mice at a 
transcriptomic level. This allowed us to characterize the transcriptome response to 
infection and vaccine-induced responses. We hypothesized that regardless of the 
vaccine administered, we would identify a set of genes differentially regulated in all 
challenged mice. Additionally, we sought to discern the unique gene expression profiles 
in response to challenge in each immunized group.  
To perform RNAseq analysis, lungs from NECre luc mice were harvested at an early 
time-point (day 1) following B. pertussis challenge and at a late time-point (day 6 or 9). 
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RNA from the lungs of the mice was isolated. Libraries were prepared and sequenced 
on the Illumina HiSeq 1500 platform. To characterize transcriptional responses to B. 
pertussis challenge in naïve or vaccine mice (ACV, WCV, RTX), we compared the 
challenged samples to control mice that were not immunized nor challenged. Based on 
this, we expected to determine both the immunological (innate and adaptive) and the 
non-immunological responses to B. pertussis challenge. We determined the 
differentially expressed genes (DEGs) for both early (day 1) and late (day 6 or 9 
depending on group) time-points. The total numbers of differentially regulated genes are 
shown in Fig. 6ac. Overall, there were more differentially genes at the later time-point 
than early after challenge (Fig. 6ac). At day 1 post-challenge, the WCV group had the 
most genes activated (Fig. 6a, Supplementary Fig. 5). Of the genes that were 
upregulated at day 1 in the WCV, 29.7% were not found upregulated in the other groups 
(464 of 1,560). At the late time-points, there were more common upregulated genes and 
only 14.1% of the genes were unique to the WCV. We found that 12.6% of unique 
upregulated genes (196) were common to all groups either challenged with B. pertussis 
following immunization or naïve challenge, suggesting that these genes were common 
to infection (Fig. 6b). At the later time-point, 19.8% of unique upregulated genes (867 of 
6,595) were shared by the WCV, ACV, RTX groups, while this number was much lower 
at the early time point (8.5% of DEGs, 133 of 1,560) (Fig. 6bd). Cumulatively, this data 
suggests that: 1) WCV vaccination induces a more diverse early response to B. 
pertussis challenge due to the higher number of unique genes compared to other 
groups, and 2) at the later time-point all vaccinated groups have a more similar lung 
transcriptome.  
Ingenuity Pathway Analysis (IPA) was performed to determine enrichment analyses of 
gene expression signatures in the context of each immunization. Using IPA Knowledge-
based enrichment analysis, statistically significant genes were grouped into disease and 
function categories. A system of genes was considered enriched based on Fisher’s 
exact test on the ratio of represented genes. At the early time-point we, observed that 
the largest changes were associated with genes involved in immune cell trafficking of 
the WCV group (Fig 7a). Genes with the highest fold changes within this system were 
associated with activation and migration of leukocytes (Fig. 7b). Additionally, we 
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observed significant enrichment of genes associated with the humoral and cell-
mediated immune responses (Fig. 7b). Pertussis toxin affects multiple aspects of the 
cardiovascular system such as blood pressure, leukocyte migration, etc7,37,38. In both 
naïve and immunized mice, we observed gene expression signatures related to 
cardiovascular diseases (Fig. 7ab). ACV immunization results in high amounts of anti-
PT antibodies (Fig. 4d), and we observed fewer genes significantly altered in the ACV 
immunized mice, suggesting positive effects of anti-PT antibodies on neutralization of 
toxin activity. At the late time-point, immune cell trafficking gene expression seemed to 
decrease in naïve, ACV, and RTX groups; however, the expression of these genes was 
still high in the WCV group. As expected, immune-related gene signatures dominated 
the responses to B. pertussis infection. However, thousands of genes significantly 
dysregulated due to infection at both time-points were not related to immune response 
or were not sufficiently characterized to be assigned a function. Analysis of the lung 
transcriptomes corroborated the findings of flow cytometry and cytokine profile 
analyses, further supporting that there is an increase in leukocyte activity in the 
respiratory tissue of WCV immunized mice compared to ACV or RTX immunized mice 
following B. pertussis challenge.  
Analysis of neutrophil-specific gene signatures 
Since we observed that neutrophils accumulate in the lung of WCV immunized NECre 
luc mice, we chose to delve further into the changes in expression of genes associated 
with neutrophil activity. To compare the neutrophil response between the groups, we 
selected genes with GO terms associated with neutrophil migration and activation and 
plotted the relative fold changes for this subset of genes for each immunization group 
(Fig. 8). The expression levels of these genes from either the naïve challenged, or 
immunized and challenged groups was compared to naïve, not infected control mice 
(Fig. 8).  
Cxcl2 is a chemokine produced by monocytes and neutrophils at sites of infection39. 
Previously it has been shown that convalescent mice previously challenged with B. 
pertussis express lower amounts of cxcl2 when re-challenged with B. pertussis than 
naïve mice40. This suggests that the adaptive responses in these mice negate the need 
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for the innate production of Cxcl2. Supporting this hypothesis, we observed the highest 
expression levels of Cxcl2 in naïve and RTX immunized mice, which had similar 
bacterial burdens (Fig. 7bd and Fig. 8be). The induction of Cxcl2 expression was lower 
in ACV vaccinated mice than naïve mice (Fig. 8ac). The expression of Cxcl2 also 
increased in the WCV mice, but remained high at the late time-point (Fig. 8b). Our 
serological analysis indicated that WCV immunization only induced minimal anti-PT 
production, whereas ACV induced high amounts of anti-PT (Fig. 3d). PT has been 
shown to induce production of Cxcl2 in TY10 cerebral endothelial cells which further 
suggests a causal relationship between non-neutralized PT and Cxcl2 production41.  
All of the groups showed increases in a number of other C-X-C and C-C family 
chemokines (cxcl3, cxcl1, ccl3, ccl4, ccl6, and ccl17). Cxcl1 gene expression was 
increased at day 1 in all groups compared to the non-infected control (Fig. 8). We also 
observed an increase in IL-23 expression in the WCV group (Fig. 7b), which might be 
associated with the IL-17 cytokine response measured in the WCV lung tissue. Tumor 
necrosis factor (tnf) gene expression was increased in WCV, RTX, and ACV mice 
compared to non-infected mice. However, Tnf expression levels decreased in ACV mice 
and were lower than those observed in uninfected mice at day 9 (Supplementary Fig. 
4). Ross et al. demonstrated that IL-17A promotes production of CXCL1 during B. 
pertussis challenge10. In our cytokine analysis, only the WCV mice had sufficient IL-17 
to be detected in the lung homogenates (Fig. 5c). Taken together these data suggest 
that although we did not observe high IL-17A gene expression in the transcriptome or in 
the IL-17 cytokine analysis, there could still be sufficient IL-17A in the Naïve, ACV, and 
RTX challenged mice that could account for the increased Cxcl1 gene expression.  
We observed that S100a9 and S100a8 were highly upregulated in WCV and RTX 
groups (Fig. 7 and Fig. 8b). S100a9 is a major calcium-binding protein of neutrophils, 
which forms a heterodimer with S100a8, and promotes polymerization of microtubules. 
Interestingly, S100a8/a9 is produced mainly by neutrophils and high plasma levels of 
S100a8/a9 correlate with higher blood neutrophil blood levels in heathy human adults42. 
S100a8/a9 promotes transendothial phagocyte migration by promoting tubulin 
polymerization43. Additionally, monocytes isolated from human patients with cardiac 
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injury have been found to be particularly responsive to S100a8/a9 and secrete 
increased amounts of TNF-α and IL-644. S100a8/a9 can induce neutrophil chemotaxis 
and adherence, but PT can block this function of S100a8/a945. These data suggest that 
PT induction of leukocytosis may be related to the role of S100a8/a9 in leukocyte 
recruitment. S100a8/a9 expression was lowest in the ACV mice which had the highest 
amount of serum anti-PT.   
Overall the WCV mice had higher expression of more neutrophil genes than any of the 
other groups (Fig. 7). Expression of these neutrophil signatures did not return to 
uninfected levels. These observations corroborates IVIS (Fig. 4de) and flow cytometry 
analyses (Fig. 4fg). Neutrophil gene expression in ACV mice was dynamic and returned 
to levels lower than uninfected mice by day 9. ACV mice did not have detectable B. 
pertussis in their lungs at day 9, indicating that the initial challenge does had been 
cleared (Fig. 3). ACV and WCV signatures were the most dissimilar, while the RTX and 
naïve mice transcriptome profiles were the most similar (Fig. 7). This correlates with the 
fact that RTX mice still have detectable B. pertussis in their nares, trachea and lungs at 
day 9 at levels similar to those observed in non-vaccinated mice. These data confirm 
our neutrophil observations but also enhance our analysis of the neutrophil dynamic in 
the context of vaccination status and B. pertussis challenge.           
B cell gene expression signatures in relation to immunization status.  
It has been established that B cells are required for the clearance of B. pertussis in mice 
and that ACV immunization protects through neutralizing antibodies46,47. To further 
investigate antibody production between WCV and ACV immunized mice, we aimed to 
determine the diversity of B cell clone expansion between vaccinated and non-
vaccinated challenged mice. Using MiXCR software, the same illumina sequenced 
reads mentioned above were analyzed specifically for immunoglobulin profiling48. 
Individual B cell clones were identified by B cell receptor sequence and clonal 
expansion was accessed by immunoglobulin diversity and frequency between the 
vaccinated and challenged, naïve challenged, and non-challenged control groups. At 
the early time-point day 1 post-challenge, immunoglobulin diversity and frequency of B 
cells depicted a close relation between the ACV and RTX vaccination groups, as also 
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did WCV and naïve challenged mice (Supplementary Fig. 6a). This response shifted by 
the late time-point (days 6 or 9), when we observed that WCV and ACV groups were 
more similar. Using this approach, we were able to determine the individual variable and 
joining segments abundance, and the frequency of which a particular was found. Not 
surprisingly, we observed the highest degree of diversity at the late time-point. WCV 
and ACV were the most similar due to a higher number and abundance of clonotypes 
(Supplementary Fig. 6b). We focused our analysis on the diversity of the third 
complementarity-determining region (CDR3) of the heavy Ig chain, because this region 
has been shown to be necessary for antigen specificity49. The highest abundant CDR3 
region sequence, NQHLFW, was present only in the WCV immunized mice, while the 
other 10 highest CDR3 regions were shared across vaccine groups at the early and late 
time-points (Supplementary Table 6 and Supplementary Table 7). Together this data 
suggests that clones generated from acellular based vaccines (ACT and RTX) are more 
closely related because they are generated to a limited number of antigens. However, 
by the late time-point, proliferation of specific B cell clones generated from WCV has 
created the same diversity seen in the ACV clones. The B cell clonotype analysis 
suggests that we can aim to further understand these populations in the future, but we 
will need to increase our sequencing depth by directly isolating the cell populations from 
the immunized mice instead of analyzing the full lung tissue. It may also be interesting 
to probe the T cell receptor clonotypes using the same method.  
Discussion  
In this study, we compared the innate and adaptive immune responses of immunized 
NECre luc mice vaccinated with ACV or WCV vaccines, to mice immunized with a 
truncated ACT toxin absorbed to alum (RTX), or non-vaccinated naïve mice following 
challenge with B. pertussis. ACV and WCV immunized mice cleared B. pertussis 
challenge but distinctive immune responses were observed. We also determined that 
the RTX antigen alone was not protective as a single antigen vaccine with alum 
adjuvant in NeCre luc mice. We utilized IVIS imaging to track the recruitment of 
neutrophils to the respiratory tract of challenged mice from days 1 to 9 post-challenge. 
The data obtained illustrated a dramatic increase in the amount of neutrophils recruited 
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to the lungs and nasal cavity of WCV immunized mice compared to ACV immunized 
mice when followed by B. pertussis challenge. These data were also supported by flow 
cytometry and cytokine analysis. Furthermore, by performing RNA sequencing on the 
lung transcriptome during infection in vaccinated or naïve mice, we described unique 
gene expression profiles depending on the vaccination status of the mice. We also used 
RNA sequencing to begin to describe the immunoglobulin diversity induced by each 
vaccine.  
Upon initial B. pertussis challenge, we observed activation of neutrophil associated 
genes in all groups, however it was only in the WCV immunized mice that we saw 
increased neutrophil genes expression still elevated at the late time-point. Neutrophilia 
and elevated neutrophil related genes expression at the late time-point, when bacterial 
numbers in the airways are greatly reduced, indicates either over activation of neutrophil 
“chemokine storm,” or possibly a lack of neutralization of bacterial toxins. Multiple 
studies suggest that PT is responsible for neutrophilia and leukocytosis following B. 
pertussis infection13,32,50,51. Immunization with the ACV induced 1,146-fold more anti-PT 
antibody production than WCV immunization at day 2 (Fig. 3d). It is possible that the 
low levels of anti-PT production in WCV mice resulted in insufficient neutralization of 
PT, resulting in exacerbated neutrophilia. Surprisingly, the highest neutrophil 
accumulation was determined at day 6 post-challenge when bacterial levels were 
similar to those of ACV protected mice (Fig. 3). These findings suggest that while WCV 
immunization is protective at clearing infection in NECre luc mice, it also induced severe 
neutrophilia. Interestingly, the neutrophil response in WCV mice decreased at days 2 
and 4 but highly increased at day 6 (Fig. 4). At day 2, we observed a significant 
increase in IL-17 in the lungs of WCV mice (Fig. 5c) that could result from the increased 
IL-17 expression in these mice.  Stephen Morse observed dose-dependent leukocytosis 
in mice following vaccination with killed B. pertussis31. In this study, NECre luc mice 
were immunized with 1/5th the human dose of WCV. We now realize that this dose is 
likely well above the proportional weight of a mouse compared to a human. It is possible 
that this high vaccine dose induced the hyper leukocytosis, similar to the dose-
dependent increase that Morse observed. It is known that hyperleukocytosis is 
associated with death in infant cases, and that PT is responsible for inducing 
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leukocytosis1,7,52. Furthermore, mice and baboons infected with B. pertussis and then 
treated with anti-PT antibodies had lower levels of leukocytosis compared to non-
infected controls50. An epidemiological study found that in unvaccinated individuals with 
pertussis, 72% of patients experienced leukocytosis53. In this study, we observed that 
WCV immunized NECre luc mice experienced neutrophilia and morbidity, which 
highlights the potential issues of using WCVs. It would be interesting to determine the 
relationship of neutrophilia and WCV immunization in epidemiological past studies but 
we have not been successful in identifying a study that specifically looked at 
neutrophilia because studies most note general leukocytosis.   
In NECre luc mice, the ACV was clearly more protective and less detrimental to the 
mice than the WCV. Truncated and full-length ACT purified from B. pertussis culture 
has been shown to be a protective antigen21. Wang et al. described the RTX region of 
ACT as highly immunogenic and easily purified as a recombinant protein22. We have 
observed that immunization of CD1 mice with RTX and alum adjuvant results in high 
anti-RTX titers (data not shown). Here, we immunized NECreluc mice with RTX and 
alum, but no protection was observed (Fig. 3abc). The previous studies were performed 
with strain 18323 and the antigen was directly isolated from B. pertussis21,54. It is now 
known that strain 18323, is an outlier compared to most other global B. pertussis strains 
and Guiso et a21l. noted that strain 18323 produces less PT than the Tohama I type 
strain. From our work, we know that UT25 produces more PT and ACT than Tohama I 
(data not shown). It is possible that due to the increased PT levels produced by UT25, 
vaccination with RTX was not sufficient to block colonization and proliferation in vivo. 
Although RTX immunization did not result in clearance of B. pertussis from NECre luc 
mice, we did observe a reduction in the pro-inflammatory cytokine IL-6 in the RTX group 
compared to not vaccinated and WCV vaccinated and challenged mice (Fig. 5e). PT 
and ACT have both been shown to induce the production of IL-6 in human cell lines55,56. 
The anti-ACT antibodies generated by RTX vaccination may play a role in reducing the 
levels of IL-6 due to reducing the activity of ACT. We hypothesize that it is necessary to 
neutralize both PT and ACT to provide optimal protection and in future studies, we will 
test RTX as an antigen in a multivalent ACV containing PT antigen.  
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Using standard immunological analyses, we observed typical Th2 and Th1/17 
responses in ACV and WCV immunized mice respectively. B. pertussis utilizes PT and 
ACT to facilitate survival in the host and most studies about the PT/ACT specific effects 
have been perform on cell cultures in vitro. Microarray analysis has been used to profile 
the lung transcriptome of mice challenged with B. pertussis40,57. Here, we sought to use 
RNAseq to investigate the overall gene expression profiles of the murine lung in 
response to B. pertussis challenge. Analysis of the lung transcriptome 1 day after B. 
pertussis challenged exhibited a distinct profile in mice vaccinated with WCV compared 
to ACV, RTX, or naïve infected mice. This response was consistent with our WCV 
cytokine profile demonstrating a strong pro-inflammatory response. Similarly, 
transcriptome data from others during early B. pertussis infection noted an increase in 
chemokines such as Cxcl2, Cxcl10, Cxcl3, Ccl3, Cxcl1, and Ccl457,58. In Raeven et al, 
convalescent mice previously infected with B. pertussis exhibited higher expression of 
these chemokines compared to naïve mice, similar to our whole cell transcriptome 
where these chemokines are consistently higher than the naïve mice (Fig. 7 and Fig. 8). 
We observed the highest expression of these chemokines in the naïve and RTX mice 
groups, where these groups had a similar gene profile of genes belonging to the 
immune cell trafficking and cardiovascular disease annotations (Fig. 7). These findings, 
along with higher bacterial burden (Fig. 3) suggest that RTX-alum immunization does 
not provide sufficient protection.  
Our overall transcriptomic profiling revealed thousands of significant gene expression 
changes (Fig. 6). After analyzing the neutrophil (Fig. 8), and innate gene changes 
(Supplementary Fig. 4), we then sought to specifically characterize B cell clone 
diversity. The RNAseq reads were re-processed with the MiXCR algorithm and we 
analyzed the abundance and diversity of VDJ clonotypes (Supplementary Fig 5). 
Besides the T cell response differences of the ACV and WCV (Th2 v. Th1/Th17) 
another significant difference between these two vaccines is the number of antigens. 
ACVs have 3-5 antigens (PT, FHA, PRN, FIM2/3) but the WCV hypothetically has 
~3,000 antigens. In light of this, it would be logical to hypothesize that the WCV would 
induce a vast antibody repertoire as measured by many VDJ clonotypes. However, we 
observed a greater diversity and abundance in the ACV group compared to the WCV at 
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both early and late time-points (Supplementary Fig. S6). It is important to point out that 
this analysis was performed on total lung RNA. If we were to isolate B cells and 
sequence deeper we would expect to more thoroughly characterize the repertoire. 
These data are interesting but we do not know which clone types result in functional 
antibodies that protect against B. pertussis. Further analysis is required to bridge the 
gap between clonotypes and functional/protective antibodies.         
Using NeCRE luc mice, we performed tracking neutrophil recruitment during a B. 
pertussis respiratory infection. These data demonstrate how analysis of cellular 
responses through in vivo imaging can be used to provide a quantitative parameter 
throughout a study. This model can be applied to other bacterial infection models or 
cancer tumor progression models where following the same mouse throughout a study 
would be beneficial. In this study, we also added next generation sequencing 
technology to expand upon the immunological findings. RNAseq analysis can be further 
employed to understand key cell populations and how they are impacted by both 
immunization and B. pertussis challenge. Our current goal is to continue to refine the 
murine challenge models with new technological approaches in order to facilitate 
formulation of new pertussis vaccines. The findings of this study suggest that by 
integrating RNAseq analysis with classic immunological techniques, it is possible to 
illuminate novel intricacies of vaccine induced immunity to B. pertussis.  
Methods 
Bacteria and culture conditions 
B. pertussis strain UT25 (UT25Sm1) were cultured on Bordet-Gengou (BG) agar (1906) 
supplemented with 15% defibrinated sheep blood (Hemostat Laboratories) for 48 h at 
36°C59. B. pertussis was then transferred from BG plates to three flasks of 12 ml of 
modified Stainer-Scholte liquid medium (SSM)60. SSM cultures were not supplemented 
with cyclodextrin (Heptakis(2,6-di-O-methyl)-β-cyclodextrin). SSM cultures were grown 
for ~22 h at 36°C with shaking at 180 rpm until the OD600 reached 0.5 on a 1 cm path 
width spectrophotometer (Beckman Coulter DU 530). The cultures were then diluted to 





 All mouse strains used were bred in a specific pathogen-free experimental conditions 
within the Office of Laboratory Animal Resources vivarium at West Virginia University. 
Mice were aged 8 – 12 weeks, male and female sex mice were equally assigned to all 
vaccination groups. 129-Elanetm1(cre)Roes/H mice (Medical Research Council, London, 
UK) were crossed with FVB.129S6(B6)-Gt(ROSA)26Sortm1(luc)kael/J mice (Jackson 
labs; 0051225) resulting in NECre luc progeny. NECre luc mice were injected with 
CycLuc 1 lucferin (EMD Millipore, Darmstadt, Germany) and confirmed to be 
luminescent using Xenogen Lumina II61. Upon intraperitoneal injection of a luciferase 
substrate (luciferin), neutrophils emit luminescence that is detectable using a high 
sensitivity live animal imaging system (Xenogen IVIS Lumina II).  
Vaccines used in study and administration 
 All vaccines were formulated into 200 µl doses with the antigen content described 
below. 100 µl of INFANRIX (GSK) human vaccine (DTaP) which is 1/5 human dose of 
the vaccine, was mixed in 100 µl of PBS. The NIBSC WHO standard Bordetella 
pertussis  whole-cell vaccine (NIBSC code 94/532) was received lyphophilzed and 
reconstituted in 1ml of PBS. At this concentration one human dose is 100 µl therefore, 
20 µl was mixed with 180 µl of PBS, which is 1/5 of the human dose (66 µg of total 
protein). A truncated ACT protein (RTX) was purified as previously described 22 5.6 ug 
of RTX was combined with 100 µl alum adjuvant (Alhydrogel®, InvivoGen) 
corresponding to 1 mg of aluminum hydroxide. All immunizations occurred by 
intraperitoneal injection. Unvaccinated mice received 200 µl of sterile PBS.  
Vaccination and Challenge with Bordetella pertussis  
NECre luc mice were bred to ages ranging from (8-12 weeks). Mice were vaccinated at 
day 0, and then boosted 21 days later. Thirty-five days post initial vaccination, B. 
pertussis UT25 was grown as described above, and provided as a challenge dose at 2 x 
107 CFU in 20 µl. Mice were anesthetized by intraperitoneal injection of 200 µl of 
ketamine (6.7 mg/ml) and xylazine (1.3 mg/ml) in 0.9% saline. Two 10 µl doses of 
bacteria were administered through nasal inhalation into each nostril of the mouse. Mice 
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from each of the groups were challenged WCV (8), ACV (8), RTX (6), and naïve control 
(PBS injection) (5).  
Collection of murine samples and determination of bacterial burden  
On days 1,2,4,6, and 9 pc, mice were euthanized by intraperitoneal injection of 
pentobarbital and dissected in a biosafety cabinet under BSL-2 conditions. Blood was 
collected by cardiac puncture, serum was separated by centrifugation through a BD 
Microtainer SST blood collector (BD), or blood for complete blood cell counts were 
collected in BD Microtainer Tubes with K2EDTA (BD). Trachea and lungs were 
removed, placed in 1 ml PBS, and then homogenized. Trachea tissue was 
homogenized by a Brinkman Homogenizer (Polytron), while lung tissue was dissociated 
using a Dounce homogenizer (Kimble Chase). To determine viable B. pertussis in the 
nares, 1 ml of PBS was flushed through the nares and collected. In order to determine 
bacterial burden 100 µl of homogenate or nasal lavage was serial diluted in sterile PBS. 
Four 10 µl aliquots of each serial dilutions were plated on BG containing streptomycin 
(100 µg/ml) to ensure only UT25 B. pertussis grew on the plates. After 72 h at 36°C 
colony forming units (CFUs) were counted and the bacterial burden per tissue was 
calculated. Due to the serial dilutions plated our limit of detection was 103 CFUs per ml 
or organ. CFUs from experimental groups at each time-point were compared to the 
naive (PBS injected) and challenged group by a two-tailed unpaired t test using the 
software package Prism 7 (GraphPad, La Jolla, CA). All experiments were performed in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. All murine infection experiments were performed per protocols 
approved by the West Virginia University Institutional Animal Care and Use Committee 
(protocol number Damron 14-1211). 
IVIS imaging 
NECre luc mice received 83 mg/kg of CycLuc1 luciferin by IP injection (100 µl). Five 
minutes after injection mice were anesthetized with 3% isoflurane, mixed with oxygen 
from the XGI-8 gas anesthesia system supplied with a Xenogen IVIS Lumina II. 
Luminescent signals were acquired during a five-minute exposure. Acquisition was 
performed using Living Image 2.5 software (Xenogen). Images were acquired with a 
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binning of 4. Following imaging, mice were either euthanized for dissection and 
extraction of tissue samples or returned to the vivarium. Luminescence was determined 
by quantification of photons emitted per second generated in each region of interest 
(ROI): whole mouse image or nasal cavity. The background of each image was 
subtracted from the ROI, background photons were defined by the average of two ROIs 
away from the mouse, for the same image. Data was expressed as relative fold change 
between target ROIs from experimental groups to an average of ROIs from control mice 
that were not vaccinated or challenged. Group comparisons were analyzed by one-way 
analysis of variance (ANOVA) followed by a Tukey’s multiple-comparison test using 
Prism 7.  
Preparation of tissue and flow cytometry analysis 
Blood, lung, and cells isolated from nasal lavage were analyzed by flow cytometry. A 
100 µl sample was removed from lung homogenate of all samples and filtered through a 
70 µm cell strainer, then centrifuged at 1000 x g for 5 mins to pellet cells. Supernatant 
was removed, and RBC lysis buffer (BD Pharm lysis) added incubated at 37ᵒC for 2 min, 
then pelleted using the same centrifugation conditions. Cells were resuspended in 500 
µl of PBS + 1% FBS, 100µl was aliquoted for antibody staining. After cardiac puncture 
blood was placed in EDTA containing tube (BD Bioscience), RBC were lysed using 
Pharmlyse (BD Biosciences) with a 15 min room temperature incubation and then 
prepared in a similar manner to other tissues. All cell suspension samples were 
incubated on ice in PBS and 1% FBS for blocking. Antibodies against specific cell 
surface markers: PE-conjugated GR-1 (BD, 553128) Alexa Fluor 700-conjugated 
CD11b (Biolegend, 101222) were added to cell suspensions and incubated in the dark 
for 1 h at 4ᵒC. Lung, blood, and nasal wash suspensions were pelleted, and 
resuspended in PBS prior to analysis. Samples were read using LSR Fortessa (BD), 
and analyzed using FlowJo v10 (FlowJo, LLC). PMNs were classified as CD11b+Gr-1+ 
single, live cells.  
Cytokine Quantification 
Lung homogenates were pelleted by centrifugation and then supernatant was collected 
and stored at -80ᵒC until analysis. Concentration of cytokines in the lungs of vaccinated 
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and challenged mice were determined by quantitative sandwich immunoassays, Meso 
Scale Discovery (Rockville, MD) V-PLEX Proinflammatory Panel (K15048G-1) and 
Mouse IL-17 Ultra-Sensitive kits (K152ATC-1), following manufacturer’s instructions. 
Data was analyzed by one-way ANOVA, with a Tukey’s multiple-comparison test for 
each time-point.  
Serology 
Vaccinated and challenged mouse serological responses to RTX, and PT were 
determined by qualitative ELISA. High-binding 96-well ELISA plates were coated 
overnight at 4ᵒC with 50 µl of purified RTX or Pt in PBS at a concentration of 1 µg/mL. 
Purified B. pertussis antigens, were obtained from Dr. Jennifer Maynard. Serum 
samples from NVNC, PBS, ACV, and WCV serum titers were analyzed for PT, as the 
RTX group had no PT in vaccine. Samples from NVNC, PBS, WCV, and RTX were 
analyzed for serum antibody titers to RTX, as ACV would not be expected to have RTX 
titers because no RTX was included in vaccine. Plates were then washed with PBS + 
1% Tween 20 (PBS-T), then blocked with 5% milk in PBS-T for 1 hour at room 
temperature. Sera were diluted to a concentration in the linear dose range for each 
antigen. Plates were incubated for 2 h at 37⁰C with serial diluted serum samples from 
vaccinated groups. Following 3 PBS-T washes, 1:4000 goat anti-mouse IgG-AP 
(Southern Biotech), secondary antibody was added and incubated 1 h at 37⁰C. Plates 
were washed, then developed for 30 min with 100 µl p-nitrophenyl phosphate. 
Colorimetric signal was measured using Spectramax i3 (Molecular Devices) at 450nm. 
An average of blanks was subtracted from all absorbances and used as a baseline 
detection limit. The minimum detection limit above the baseline was analyzed by one-
way ANOVA, with a Tukey’s multiple-comparison test for each time-point using Prism 7.  
Isolation of Lung RNA, illumina library preparation, and sequencing  
Lung RNA was prepared similar to previously reported62 with the following 
modifications. The freshly isolated NECre luc mice lungs were homogenized and RNA 
was prepared immediately using RNeasy purification kit (Qiagen). Each lung was 
placed in 1 ml of sterile PBS and then 2 ml of TE lysozyme (1mg/ml) was added and 
allowed to incubate for 10 min on ice. 2 ml of RLT buffer was added and incubated for 
55 
 
another 10 min on ice. The homogenate was then pushed through a syringe needle. 
The homogenates were pelleted by centrifugation at 20,800g (max speed microfuge) for 
10 min. The supernatant was extracted and then 2.8ml of 100% EtOH was added to 
each tube. This supernatant of each mouse sample was then disturbed to four RNeasy 
tubes for RNA isolation. The RNA was eluted and pooled into one sample per mouse. 
The resulting RNA was quantified on a Qubit 3.0 (ThermoFisher) with the high intensity 
assay kit. Next, the RNA integrity was assessed using Agilent BioAnalyzer RNA Pico 
chip. All samples were then submitted Ribo-zero rRNA depletion (illumina) and 
reassessed for RNA integrity. rRNA depleted mRNA samples were then fragmented 
and prepared into libraries using illumina ScriptSeq Complete Gold (Epidemiology). 
Libraries were checked for quality control with KAPA qPCR QC assay (KAPA 
Biosystems). The libraries (33 total) were then sequenced on an illumina HiSeq at the 
Marshall University Genomics Core facility on 2 lanes of 2x50B. pertussis. Sequencing 
data were deposited to the Sequence Read Archive (SRA) and are available under the 
reference number SRA587785, BioProject number PPJNA394758.  
RNAseq bioinformatics analyses 
The reads were analyzed using the software CLC Genomics workbench 9.5. Mus 
musculus genome was downloaded from NCBI (version GRCm38.78). Reads were 
mapped against the genome using the following settings for mapping: mismatch cost = 
2, insertion cost = 3, deletion cost = 3, length fraction = 0.8, similarity fraction = 0.8. 
RPKM values were generated using default parameters for CLC Genomics. On average 
~20 million reads were obtained for each sample and with stringent parameters ~73% 
mapped to the murine genome with our mapping parameters. Fold changes in gene 
expression and statistical analyses were performed using an Extraction of Differential 
Gene Expression (EDGE) test p value. Expression data for each gene was considered 
significant if the p value was less than 0.05. Venn diagrams were generated using 
Venny 2.163. Fold-change of gene expression data was plotted relative to non-
challenged control groups at each time-point. Supplementary Table 8 contains the 
exported gene expression analysis worksheets and statistical analyses. Gene list were 
created using GO terms acquired though AmiGO 2 database including neutrophil 
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(CL:000075), neutrophil activation (GO:0042119), neutrophil migration (GO:1990266), 
innate immune response (GO: 0045087), T-helper 1 type immune response 
(GO:0042088), type 2 immune response (GO:0042092), and T-helper 17 type immune 
response (GO:0072538)64. 
Pathway Enrichment Analysis  
Ingenuity Pathway Analysis (Qiagen) was utilized to map lung transcriptomes to 
biological and disease functions. Lung transcriptomes were loaded to IPA, and 
comparative analyses were performed at early and late time-points. Gene expression 
fold-changes were mapped to higher-order disease and function defined by the IPA 
knowledge base, and a gene enrichment analysis was performed on early and late time-
points. A Fisher Exact T-test was used to determine statistically significant (p < 0.05) p-
values of the functions that made up the higher-order disease category and represented 
as a range of p-values. The relative fold-change of these identified genes was 
determined, and the 10 highest fold-changes were represented as heat maps.  
 
Immunoglobulin and T-cell receptor profiling  
B cell clones were identified using MiXCR software (MiLabratory), capable of generating 
quantitated clonotypes of immunoglobulins48. The same paired-end Illumina sequenced 
reads mentioned above were merged using concatenation, then imported into MiXCR 
software. Merged reads were aligned to each other to generate clonotypes of based on 
VDJ segment regions of unique immunoglobins specific to each sample. Clone data for 
each sample was grouped based on vaccine received, and time-point. Clonotypes from 
each sample were then separated into T and B cells, based on T-cell receptor or B-cell 
receptor specific sequences. Prepared data files were then imported into VDJtools 
(MiLabratory), for data representation according to established protocol65. Briefly, data 
was represented to show V-J diversity, and quantify unique clonotypes using 
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Figure 1: Experimental workflow for vaccination, B. pertussis challenge, sample 
acquisition, and analysis of this study. 
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Figure 1: Experimental workflow for vaccination, B. pertussis challenge, sample 
acquisition, and analysis of this study. Schematic diagram of experimental design 
showing vaccination schedule, immunization groups, B. pertussis challenge, 
euthanasia, sampling, and analysis method on days 1,2,4, 6, and 9 days pc in NECre 
luc mouse model. Mice were initially vaccinated and then given a booster dose of the 
same vaccine at day 21. A challenge dose of 2 x 107 viable bacteria was administered 
by intranasal inhalation at day 35. IVIS imaging of neutrophils was monitored throughout 
study. The overall numbers of mice per group are indicated. At time-points shown 
bacterial burden, complete blood cell counts, lung cytokine profiles, lung and nasal 
wash neutrophil cells, serum antibody titers, and lung transcriptome were determined. 
To characterize the effects of vaccination, the vaccinated groups were compared to a 




Figure 2: Kaplan- Meier survival curves of NECre luc mice according to 
immunization group. 






















Figure 2: Kaplan- Meier survival curves of NECre luc mice according to 
immunization group. The survival percentage of remaining NECre luc mice (prior to 
scheduled euthanasia) immunized with WCV, ACV, RTX, and B. pertussis challenged, 
or not vaccinated and challenged with B. pertussis. Log-rank (Mantel-Cox) test: ***p< 
0.0005. In Fig. 1 the time-points where mice were euthanized for analysis are indicated. 
In this survival curve, we are only showing the mice became morbid throughout the 




Figure 3: Bacterial burden in respiratory tissue and serological responses to B. 
pertussis challenge of immunized and naïve NECre luc mice. 
 
Figure 3: Bacterial burden in respiratory tissue and serological responses to B. 
pertussis challenge of immunized and naïve NECre luc mice. Mice were vaccinated 
with PBS control vehicle, WCV, ACV, or RTX then B. pertussis challenged. At days 
1,2,4,6 and 9 pc the bacterial burdens were determined by culturing of (A) nasal lavage, 
homogenates of (B) trachea and (C) lung on BG agar. The dashed line at 1000 CFUs 
represents the lower limit of detection, due to plating. Data in each group were 
compared to PBS control using an unpaired two-tailed t-test. Significant differences are 





Figure 4: IVIS imaging and flow cytometric analysis of naïve and immunized 
NECre luc mice post challenge with B. pertussis. 
 
Figure 4: IVIS imaging and flow cytometric analysis of naïve and immunized 
NECre luc mice post challenge with B. pertussis. IVIS imaging of luminescent 
neutrophils in anesthetized mice following luciferin injection. (A) Representative images 
of naïve, not B. pertussis challenged NECre luc mice. (B) Representative images of 
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PBS control, WCV, ACV, and RTX immunized and B. pertussis challenged NECre luc 
mice at day 1 pc and (C) day 6 pc (D and E). Luminescence was measured on Xenogen 
IVIS Lumina II. Relative luminescence levels quantified by fold change of emitted 
photons/second of NECre luc mice following B. pertussis challenge (N=3-5) compared 
to average luminescence of naïve, not challenged NECre luc mice (N=5). Neutrophil 
luminescence of (D) whole animal signal and (E) nasal cavity was determined at days 
1,2,4,6, and 9 pc. (f) Quantification of the percentage of live, single cells classified as 
neutrophils (GR-1+CD11b+) detected in nasal lavage (f) and lung homogenate (g). 
Significant differences are not indicated on the graphs for clarity, but are included in 




Figure 5: Analysis of cytokine profiles from lungs of naïve and immunized NECre 























Figure 5: Analysis of cytokine profiles from lungs of naïve and immunized NECre 
luc mice post challenge with B. pertussis. Th1 associated cytokines from the 
supernatant of lung homogenates were analyzed at days 1,2,4 and 9 pc. Cytokines (a) 
IFN-γ, (b) IL-12p70, (c) IL-17, (d) IL-6, (e) IL-1β, (f) TNF-α were quantified using 
electrochemiluminescence immunoassays. Significant differences are not indicated on 
the graphs for clarity but, are included in Supplementary Table 4. ND: Sample not 








Figure 6: Lung transcriptome profile of vaccinated and challenged NECre luc 
mice. RNA sequencing was performed on total RNA from homogenized lung on days 1 
(Early) or 6/9 (Late) following challenge with B. pertussis. (a) The total number of 
statically differentiated genes found in lung transcriptome at early (a) or late (c) time-
points. Statistically differentiated genes were categorized as those that were activated 
or repressed. Venn diagram of statistically differentiated genes either unique or 




Figure 7: Enrichment analysis and relative fold-changes of genes upregulated 
following B. pertussis challenge.  
 
Figure 7: Enrichment analysis and relative fold-changes of genes upregulated 
following B. pertussis challenge. Early (day 1)(a), and late (day 9)(b) IPA 
comparative analysis of lung transcriptomes from vaccinated and non-
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vaccinated/challenged groups was performed, gene enrichment p-values are 
represented in –log scale. P-value was calculated by IPA software based on the number 
of genes found in a certain data set to the total number of genes associated to a 
particular function in the IPA knowledge base. Threshold indicates the significance 
(p<0.05, Fisher’s exact t-test) Black-PBS, Blue – WCV, Yellow-ACV, Red – RTX. 
Relative fold changes of ten highest genes associated with a particular function 




Fig. 8: Differentiated genes associated with neutrophil recruitment at early and 
late time-points following B. pertussis challenge. 
 
Fig. 8: Differentiated genes associated with neutrophil recruitment at early and 
late time-points following B. pertussis challenge. Gene expression profiles are 
shown for (a) Naïve, (b) WCV, (c) ACV, and (d) RTX immunized and challenged mice. 
Blue and gold bars indicate the fold change compared to control non-challenge non-
vaccinated mice at early and late time-points, respectively. Genes shown are the 25 
genes with the highest variance across all groups between early and late time-point. 
Genes were ranked based on variance in fold change across groups for the early and 
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Supplementary Fig. 1: IVIS imaging of naïve and immunized NECre luc mice post 
challenge with Bp as image was acquired from Xenogen IVIS Lumina II. 
 
 
Supplementary Fig. 1: IVIS imaging of naïve and immunized NECre luc mice post 
challenge with Bp as image was acquired from Xenogen IVIS Lumina II. Images at 
day (a) 1, (b) 2, (c) 4, and (d) 6 – WCV or 9 – Control (Non-vaccinated/ no challenge), 
PBS, and ACV. Relative luminescence was quantified based on region of interest 
luminescence in these non-adjusted images.  
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Vaccine component* aP (1/5th human dose) wP** RTX + alum
Pertussis Toxoid*** 5 0.4 0
Filamentous Hemagglutinin 5 3.5 0
Pertactin 1.6 0.3 0
RTX 0 0.2 10
Aluminum hydroxide 125 0 1 (mg)
Other antigens/adjuvants 0 62 0
Vaccine groups
 





*All masses of antigens or adjuvant are indicated in μg  
** This estimate is based on the number of peptides identified for each antigen in the 
wP. The percentage is then used to estimate the potential mass based on the fact that 
the wP dose used in this study contained 66 μg of total protein. 




Supplementary Table 2. Statistical analysis from Figure 3abc. 
Day 1 Day 2 Day 4 
ACV 0.0524 WCV 0.0341
WCV 0.059
RTX 0.0729
ACV 0.0984 ACV 0.0764 ACV 0.0567








 Supplementary Table 3: Relevant statistical differences in relative fold changes 
of neutrophil luminescence of Bp challenged mice.  
Luminescence was analyzed by one-way ANOVA with a Tukey’s multiple comparison 




Supplementary Fig. 2: Representative images and gating strategy for neutrophils 











Supplementary Fig. 2: Representative images and gating strategy for neutrophils 
from lung and nasal lavage tissues. Neutrophils were gated as live, single cells (data 
not shown), quadrants demonstrate positively labeled cells determined by single marker 
flow cytometry controls. Region of interest shows neutrophil population (Gr-1+CD11b+). 




Supplementary Fig. 3: Analysis of Treg and Th2 associated cytokines from lungs 
of naïve and immunized NECre luc mice post challenge with B. pertussis 
 
 
Supplementary Fig. 3: Analysis of Treg and Th2 associated cytokines from lungs 
of naïve and immunized NECre luc mice post challenge with B. pertussis. 
Cytokines were analyzed at days 1, 2, 4 and 9 pc, then quantified using 
electrochemiluminescence immunoassays. (a) Cytokines IL-10 and IL-5 associated with 
Treg immune response. (b) Cytokines IL-2 and IL-4 associated with a Th2 immune 





Supplementary Table 4: Relevant statistical differences between cytokine 
production in lungs of immunized and Bp challenged NECre luc mice.  
Samples were analyzed by one-way ANOVA with a Tukey’s multiple comparison test at 
















Supplemental Fig. 4: Volcano plot analysis of differentiated genes at early and 
late time-points of immunized or naïve mice following challenge. 
 
 
Supplemental Figure 4: Volcano plot analysis of differentiated genes at early and 
late time-points of immunized or naïve mice following challenge. Upregulated 
genes are represented in red, repressed gens are in blue. Relative fold change was 




Supplementary Fig. 5: Gene expression profiles of T helper cell immune 
responses at early time point. 
 Supplementary Fig. 5: Gene expression profiles of T helper cell immune 
responses at early time point. Differentiated genes associated with (a) Th1, (b) Th2, 
and (c) Th17 immune responses. Fold changes are relative to NVNC mice. Genes 
represented are significantly different in at least one group, genes were sorted based on 




Supplementary Fig. 6: Repertoire of B cell clones identified from experimental 
groups at late time point. 
 
Supplemental Fig. 6: Repertoire of B cell clones identified from experimental 
groups at late time point. (a) Relativeness of immunoglobulin profiles between 
vaccinated and challenged, challenged, or non-challenged groups at late time point. (b) 
Immunoglobulin diversity and frequency of non-challenged control, experimental groups 
at late time points. Chord diagrams are used to visualize variable – joining segment 
diversity. Outer arcs demonstrate overall count of a particular variable (upper portion of 
chord diagram) or joining segment (lower portion of chord diagram) in each group. Inner 
ribbons represent the linked segments of a clonotype, while the thickness of the ribbon 
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Bordetella pertussis  (B. pertussis) is the primary causative agent of pertussis 
(whooping cough), which is a respiratory infection that leads to a violent cough and can 
be fatal in infants. There is a need to develop more effective vaccines because of the 
resurgence of cases of pertussis in the US since the switch from the whole cell 
pertussis vaccines (wP) to the acellular pertussis vaccines (aP; DTaP/Tdap). Adenylate 
Cyclase Toxin (ACT) is a major virulence factor of B. pertussis that is: 1) required for 
establishment of infection, 2) an effective immunogen, 3) a protective antigen. The C-
terminal Repeats-In-Toxin domain (RTX) of ACT is sufficient to induce production of 
toxin neutralizing antibodies. In this study, we characterized the effectiveness of 
vaccines containing the RTX antigen against experimental murine infection with B. 
pertussis. RTX was not protective as a single-antigen vaccine against B. pertussis 
challenge, and adding RTX to 1/5th human dose of aP vaccine did not enhance 
protection. Since the doses of aP used in murine studies are not proportionate to 
mouse/human body masses, we titrated the aP vaccine from 1/20th to 1/160th of the 
human dose. Mice receiving 1/80th human aP dose had bacterial burden comparable to 
naïve controls. Adding RTX antigen to the 1/80th aP base resulted in enhanced bacterial 
clearance. Inclusion of RTX induced: production of antibodies recognizing RTX, 
enhanced production of anti-PT, decreased secretion of pro-inflammatory cytokines 
such as IL-6, and decreased recruitment of total macrophages in the lung. This study 
shows that adding RTX antigen to an appropriate dose of aP vaccine can enhance 







Whooping cough is a disease caused by an upper respiratory tract infection that is 
primarily caused by the Gram-negative pathogen, Bordetella pertussis  (B. pertussis) 
and several other Bordetellae. These infections, commonly referred to as pertussis, can 
be fatal in infants, but can also cause significant suffering in children, adolescents, and 
adults. Fortunately, two generations of vaccines have been developed and have greatly 
reduced the incidence of pertussis in the US and worldwide. Killed whole cell vaccines 
(wP) were first reported in 1933 1. With the development of the Kendrick test in 1947, 
wPs were standardized leading to an increase in vaccine efficacy such 80% of those 
immunized developed long-term immunity to pertussis 2. Use of the wP resulted in 
drastic reduction of the incidence of whooping cough in the second half of the twentieth 
century. However, in the 1990s, due to reactogenicity and public concern, wPs were 
replaced with acellular vaccines (aP; DTaP; Tdap) containing 3-5 pertussis protein 
antigens and alum adjuvant 3. Since the introduction of aPs, increases in pertussis 
cases throughout the US and Europe have been observed and a number of reasons 
have been postulated to explain their lack of complete efficacy of the aPs 4.  
One of the major issues with the aPs is that their efficacy wanes each year after 
administration 5,6. Recent data from the non-human primate model of pertussis 
demonstrates that while the aPs prevent the paroxysmal whooping cough, they do not 
protect from colonization and transmission 7. In light of the increased incidence and our 
appreciation of the lack of efficacy of the aP, there is a need to develop another 
generation of vaccines with improved efficacy and duration of protection. Various 
approaches have been considered for the development of the new generation of 
pertussis vaccines, including: 1) addition of new antigens to the current aPs, 2) 
repolarization of the host Th-2 response triggered by alum-adjuvanted aPs to a Th-1/Th-
17 response by changing the adjuvant and adding new antigens, or 3) re-introduction of 




B. pertussis expresses pertussis toxin (PT) and adenylate cyclase toxin (ACT) to 
facilitate infection and impair the host immune response in a variety of ways. Detoxified 
PT antigens are included in all commercial aPs. When the aP was developed, ACT was 
recognized as an essential virulence factor, but as of the late 1980s, ACT had not been 
extensively evaluated as protective antigen and was not available in purified form. It 
was therefore not included in aP formulations. The cyaA gene encodes ACT, a soluble 
toxin of 1,706 amino acids 8, comprised of an adenylate cyclase (AC) domain and a 
Repeats in Toxin (RTX) domain 9. The RTX domain is responsible for the hemolytic 
activity of ACT 10. The cyclase domain can be delivered to eukaryotic cells where it 
catalyzes ATP into supraphysiological concentrations of cAMP, which impairs many cell 
functions and leads to cell death 9. B. pertussis requires ACT to establish lethal infection 
in neonatal mice 11, where the toxin targets macrophages, neutrophils, dendritic cells, 
and other integrin αMβ2 expressing cells 9. ACT has both adenylate cyclase and 
hemolytic activities and its hemolytic activity is required for B. pertussis penetration into 
the lung parenchyma 12. Underscoring its role in disease, AC enzyme activity has been 
detected in airway samples from a non-human primate model of pertussis infection 13, 
and humans 13, and convalescent humans have antibodies against ACT 14,15. 
Furthermore, adenylate cyclase activity can be detected in wPs 16 and in our own mass 
spectral analysis we have confirmed the presence of ACT in wP vaccines 
(unpublished).   
In light of the role of ACT in virulence and the fact that B. pertussis infection induces 
production of anti-ACT antibodies, ACT has been evaluated as a protective antigen in 
pre-clinical murine immunization/challenge models. Before aPs replaced wPs in the US 
and Europe, Guiso et al. demonstrated that a polypeptide consisting of the AC domain 
purified from B. pertussis was a protective antigen in mice 17. The same group 
demonstrated that full length toxin purified from B. pertussis was protective (16). 
Subsequent studies showed that recombinant ACT was also a protective antigen 18,19 
and an adjuvant 20. While immunization with ACT results in toxin neutralizing antibodies, 
the presence of these antibodies do not correlate directly with protection. However, 
antibodies that recognize the C-terminal domain (RTX) are protective 19. These studies 
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were further supported by evidence that the hemolytic domain only antigen (RTX) was 
protective in mice against sub-lethal and lethal challenge with B. pertussis 19. In all of 
the aforementioned studies, ACT antigens were evaluated as single antigen 
formulations without any of the aP antigens. Cheung et al. observed that inclusion of 
enzymatically inactive recombinant ACT enhanced protection of the aP 21, and that 
unlike previous single antigen studies, neither active nor enzymatically inactive ACT 
protected alone 21. The study also showed that inclusion of ACT in the aP skewed the T-
helper cell responses from a humoral Th2 response to a more cell-mediated Th1 
response 21.  
Multiple studies have demonstrated the protective capacity of ACT 8. In order to 
determine the appropriate form of ACT for use in a human vaccine, it is necessary to 
identify a protective toxoid form that would be readily purified for mass production. 
Genetic mutation of the ACT coding sequence results in an enzymatically inactive 
form/molecule that is protective in mice 21. However, the use of a full length ACT would 
be problematic to for use in human vaccines due to: 1) the susceptibility of the toxin to 
proteolytic degradation 22 and 2) overexpression of ACT leads to formation of inclusion 
bodies in the E. coli cytoplasm 23-25. A recent study confirmed that ACT is prone to 
aggregation and proteolysis 9. Wang et al. characterized a recombinant RTX antigen 
that was 1) readily purified, 2) immunodominant, and 3) elicited neutralizing antibody 
production 26. While these results are very promising, it is essential to determine the 
efficacy of recombinant RTX antigen in pre-clinical models of pertussis, both alone and 
in combination with aP. It is likely that a new aP vaccine would still include PT, FHA, 
and FIM antigens. Our objective was to investigate the RTX antigen with the standard 
aP antigens as a multivalent formulation. In this present study, inclusion of the RTX 
antigen into an aP formulation was evaluated with a murine immunization and challenge 
model. We observed that immunization with RTX alone was not protective and 
furthermore when either RTX or full length ACT was added to the 1/5th human dose, no 
significant enhancement of protection occurred. The use of high amounts of the human 
aP in mice (such as 1/4th, 1/5th, or 1/10th human dose) relates back to doses intended 
for commercial vaccine lot validation. It is known that as little as 1/50th human dose of 
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aP is protective in mice 27. We hypothesized that identification of the minimal protective 
and maximal non-protective aP doses would allow us to investigate enhancement of 
protection by inclusion of new antigens, thereby refining this evaluation platform. By 
performing a vaccine titration study using two-fold dilutions, we were able to identify 
1/80th human dose of aP as a minimal protective dose. When the RTX antigen was 
added into the 1/80th human dose, improved bacterial clearance was observed. 
Inclusion of RTX antigen also enhanced antibody production to PT demonstrating the 
adjuvant capacity of RTX. The enhanced protection correlated with 1) decreased pro-
inflammatory cytokine production, 2) decreased blood and lung neutrophils, and 3) 
decreased macrophages in the lung. This study begins to redefine murine immunization 
and B. pertussis challenge model for evaluation of pertussis vaccines and sheds light on 
the positive effects of including RTX as an antigen in the acellular vaccines.  
Materials and Methods 
ACT and RTX antigen expression and purification  
ACT and RTX antigens were expressed and purified as previously described 9. 
Following purification, antigens were stripped of endotoxin with Dextoxi-GelTM Endotoxin 
Removing Gel (Thermo Scientific, 20399) and Zeba Spin columns (Thermo Scientific, 
89896). Endotoxin purity was quantified with Pierce® LAL Chromogenic Endotoxin 
Quantitation Kit (Thermo Scientific, 88282). 
Composition of vaccines used in study and administration 
The INFANRIX (GSK) human vaccine (diphtheria, tetanus, and pertussis) was the aP 
used in this study. For the purpose of vaccinating mice, 1/5th of the human dose was 
used (100 μl). To test ACT as an additional antigen, full length ACT or RTX-ACT were 
purified as previously described 9. Equimolar amounts of full length ACT (10 μg) or RTX 
(5.6 μg) were used for vaccination. Vaccine compositions are shown in Table S1. Alum 
and MPLA were obtained from InvivoGen. The National Institute for Biological 
Standards and Control WHO standard whole cell pertussis vaccine (NIBSC code 
94/532) was used as the wP. One ampule of NIBSC wP contains 40 IU (10 human 
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doses). For murine vaccination, the whole ampule was diluted in 1 ml of sterile PBS and 
20 μl (1/5th of the human dose, 66 μg of total protein) were used. The NIBSC wP 
standard used in this study has been used in other studies as a wP vaccine 28. The 
NIBSC wP does not contain alum adjuvant, whereas commercial wP vaccine contain 
alum to induce antibody production to the Diptheria and Tetanus toxoids. The adjuvant 
alum was only added to single antigen vaccines (Table S1). INFANRIX is formulated 
with alum, thus we did not include additional alum for aP titration and aP 
supplementation with RTX. Unvaccinated mice received 200 μl of sterile phosphate 
buffered saline (PBS) as vehicle control. Prior to administration, aP, aP-ACT, aP-RTX, 
and wP doses were all diluted into a final volume of 200 μl with sterile PBS and 
administered by intraperitoneal injection.  
B. pertussis strains and growth conditions 
B. pertussis strain UT25 (UT25Sm1) 29 was cultured on Bordet Gengou (BG) agar 
(Remel) 30 supplemented with 15% de-fibrinated sheep blood (Hemostat Laboratories) 
for 48 h at 36 °C. Bacteria were transferred from BG plates to a flask with 20 ml of 
modified Stainer-Scholte liquid medium (SSM) 31. SSM cultures were not supplemented 
with cyclodextrin (heptakis). B. pertussis cultures in SSM were grown for ~22 h at 36°C 
with shaking at 180 rpm at which time the OD600 was ~0.6.   
Vaccination and challenge with B. pertussis 
Four week old CD-1 (outbred; strain code 022) mice were obtained from Charles River. 
Mice were vaccinated at 5 weeks of age with the vaccines described (Table S1), and 
then boosted with the same vaccines 21 days later. Thirty-eight days post initial 
vaccination, B. pertussis UT25 was grown as described above, and cultures were 
diluted to provide a challenge dose of 2 x 107 colony forming units (CFU) in 20 μl. Mice 
were anesthetized by intraperitoneal injection of 200 μl of ketamine (6.7 mg/ml) and 
xylazine (1.3 mg/ml) in 0.9 % saline. Mice received 20 μl total challenge dose by 
pipetting 10 μl directly into each nostril of the mouse. Four to eight mice per group were 
challenged, and at 1, 3, and 8 days post infection, mice were euthanized. Blood was 
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collected by cardiac puncture and serum was separated by centrifugation through a BD 
Microtainer blood collector and stored at -80°C until analysis. Trachea and lungs were 
removed and separately homogenized with Dounce homogenizers for determination of 
bacterial burden in each tissue. To determine the number of B. pertussis in the nares, 1 
ml of PBS was flushed through the nares and collected. Serial dilutions in PBS were 
plated on BG containing streptomycin (100 μg/ml) to ensure that only UT25 B. pertussis 
were cultured. All murine infection experiments were performed according to protocols 
approved by the West Virginia University Animal Care and Use Committee (protocol 
number 14-1211.10). 
Cytokine analysis 
Lung homogenates were pelleted by centrifugation and the supernatants were collected 
and stored at -80°C until analysis. The concentration of cytokines in the lungs and 
serum of vaccinated and challenged mice was determined by Raybiotech Mouse 
Inflammation Array C1 (AAM-INF-1-8) following the manufacturer’s instructions. A total 
of 100 μl of lung homogenate supernatants or serum were pooled from 4 mice for each 
analysis. Quantitative analysis of the concentration of cytokines in the lungs mice was 
determined Meso Scale Discovery V-PLEX Proinflammatory Panel (K15048G-1) or 
Mouse IL-17 Ultra-Sensitive kits (K152ATC-1) per the manufacturer’s instructions.    
Adenylate cyclase toxin neutralization assay  
ACT is, through a combination of mechanisms, cytotoxic for J774A.1 (ATCC® TIB-67™) 
macrophage-like cells and protection against this effect is the basis for the toxin 
neutralization assay 32. J774A.1 cells were cultured in Dulbecco’s modified Eagle’s 
medium with 25 mM glucose (Gibco). J774A.1 cells (30,000 in 90 μl) were seeded in 
each well of a 96-well plate and allowed to attach overnight. ACT was incubated with 
serum samples for 10 min with mixing at 4°C, and added to the cells at a final ACT 
concentration of 80 ng/ml. Cells were then incubated at 37°C for 2 h. The number of 
viable cells was determined using the CCK8 assay (Dojindo Laboratories), which 
measures reduction of WST-8, a water-soluble tetrazolium salt, by dehydrogenases in 
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viable cells. Percent viable cells was determined for ACT alone and for serum + ACT 
compared to control cells by the following equation [(treatment - media without cells) / 
(control - media without cells)] × 100.  
Preparation of flow cytometry samples and analysis  
Blood, lung, and cells isolated from nasal lavage or lung were analyzed by flow 
cytometry. A 100 µl sample was removed from lung homogenate of all samples and 
filtered through a 70 µm cell strainer, then centrifuged at 1,000 x g for 5 min to pellet 
cells. Supernatant was removed, Pharmlyse red blood cell (RBC) lysis buffer (BD 
Biosciences) was added, and samples were incubated at 37°C for 2 min before being 
pelleted by centrifugation at 1,000 x g for 5 min. Cells were finally re-suspended in PBS 
+ 1% Fetal Bovine Serum (FBS). To prepare blood samples for flow cytometry, blood 
collected by cardiac puncture was placed in ethylenediaminetetraacetic acid (EDTA) 
containing tube (BD Biosciences) and RBC were lysed using Pharmlyse with a 15 min 
room temperature incubation. Cells were then pelleted by centrifugation at 1,000 x g for 
5 min and re-suspended in PBS + 1% FBS. Cells isolated by nasal lavage are in a 
single cell suspension by nature, thus only required centrifugation at 1,000 x g for 5 min 
to concentrate samples. All cell suspension samples were incubated on ice in PBS and 
1% FBS for blocking for 15 min. Antibodies against specific cell surface markers were 
added to cell suspensions and incubated in the dark for 1 h at 4°C: PE-conjugated GR-1 
(BD, 553128), Alexa Fluor 700-conjugated CD-11b (Biolegend, 101222), PerCP/Cy5.5-
conjugated F4/80 (Biolegend, 123128). Lung, blood, and nasal lavage suspensions 
were pelleted and resuspended in PBS prior to analysis. Samples were read using an 
LSR Fortessa (BD) flow cytometer, and analyzed using the software FlowJo v10 
(FlowJo, LLC). Neutrophils and macrophages were classified as CD-11b+Gr-1+ single, 
live cells or CD-11b+F4/80+ single, live cells, respectively.  
Serological analysis of B. pertussis specific antibodies  
Vaccinated and challenged mouse serological responses to RTX 26, PT (LIST 
Biologicals), filamentous hemagglutinin (FHA; Enzo Life Sciences), and 
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lipooligosaccharide (LOS; LIST Biologicals) were determined by enzyme-linked 
immunosorbent assays (ELISA). High-binding 96-well ELISA plates were coated 
overnight at 4°C with 50 µl of purified RTX, PT, FHA in PBS at a concentration of 1 
µg/mL or LOS at 5 μg/ml. IgG2a monoclonal m1B733 (anti-PT) and IgG2a monoclonal 
M1H5 26 (anti-RTX) were obtained from Dr. Jennifer Maynard. To measure FHA or LOS 
responses, polyclonal murine anti-FHA (Cat #JNIH-11, NIBSC) or murine IgG3 
monoclonal antibody D26E (Thermo Scientific) were used, respectively. Plates were 
washed with PBS + 1% Tween 20 (PBS-T), then blocked with 5% milk in PBS-T for 2 hr 
at 37°C. Sera were diluted to a concentration in the linear detection range for each 
antigen. Plates were incubated for 2 hr at 37°C with serially diluted serum samples from 
vaccinated groups. Following 3 PBS-T washes, goat anti-mouse IgG secondary 
antibody conjugated to alkaline phosphatase (AP) (Southern Biotech) was diluted at 
1:2,000 in blocking buffer and added to each well, and incubated 1 h at 37°C. Antibody 
standards were prepared from anti-PT, anti-FHA, anti-LOS, anti-RTX by 2-fold dilutions 
from 100 µg/mL. Plates were washed, then developed for 30 min with 100 µl p-
nitrophenyl phosphate. Colorimetric signal was determined by measuring sample 
absorbance at 450nm using Spectramax i3 (Molecular Devices). Serum antibody 
concentration was calculated by plotting absorbance values of samples to absorbance 
of known concentrations of control antibodies. Values were plotted using a logarithmic 
scale, and fit to a four-parameter equation. Relative EC50 was determined by fitting the 
absorbance values of half of the maximal response to the four-parameter equation. 
Dilution of EC50 was determined by plotting the calculated antibody sample 
concentrations to sample dilution factors and fit to a four-parameter logistic curve 34. 
Dilutions were accounted for by multiplying antibody concentration by dilution factor.  
Statistical Analysis 
Experiments in this study were performed with a minimum of four biological replicates. 
Data were statistically analyzed with GraphPad Prizm 7. Comparisons between single 
groups were performed using unpaired two-tailed t-tests and comparisons between 




Heat map modeling and visualization of the effects of immunization on correlates 
of protection 
A master file containing all of the data collected during this project was compiled and 
linear regressions were performed for each variable measured in response to 
vaccination and challenge (Matlab, Mathworks) to identify variables that correlate with 
overall protection against B. pertussis challenge. A subset of those variables were then 
extracted and used to plot visual representations of the overall correlates of protection. 
For each variable, modulations were calculated as the difference between the averaged 
responses of the non-challenged / non-vaccinated mice, and the averaged response of 
the mice in each experimental group. To establish a colorimetric scale, green was set 
as equal to the non-challenged / non-vaccinated mice, red was used for the maximal 
relative increase for that variable, and blue was used for the minimal relative value for 
that variable.  
Results 
Immunization with RTX alone does not enhance clearance of B. pertussis in CD-1 
mice. 
ACT plays a key role in the pathogenesis of B. pertussis and many studies have shown 
that both native and recombinant ACTs can be adjuvants and/or antigens for protection 
against pertussis in murine challenge studies 17-20,35-39. In this study, we aimed to 
systematically evaluate the RTX antigen (toxoid version of ACT) for inclusion into the 
acellular pertussis vaccine. Wang et al. previously described that recombinant RTX 
antigen was immunogenic and readily purified, making it an attractive candidate for 
further evaluation. In our previous study using NECre luc mice (transgenic strain 
specifically used for tracking neutrophils in live mice 40), we did not observe protection 
when mice were immunized with RTX + alum adjuvant but we did observe the presence 
of antibodies that recognize RTX antigens via ELISA (manuscript in review). Here, we 
immunized outbred CD-1 mice with the RTX antigen (Table S1) formulated with alum, 
which is a Th2 adjuvant, or monophosphoryl lipid A, (MPLA) which is a TLR4 agonist 
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that induces Th1 responses. CD-1 mice were immunized intraperitoneally with PBS 
vehicle control (naïve) or 1/5th human dose of aP as a positive control for protection. 
Twenty one days later the mice were boosted with the same vaccines. Two weeks after 
boost, each of these groups of mice were challenged with 2 x 107 CFU of B. pertussis 
strain UT25 by intranasal administration. When this challenge dose of B. pertussis is 
intranasally administered to anesthetized mice, 26% of the initial dose is recoverable 
from the lung at 30 min post challenge and only 5% (106 CFU) is recoverable at 4 h post 
challenge (data not shown). These data suggest that many of the B. pertussis that were 
instilled by intranasal administration are killed by innate immune responses during the 
early stages of infection. However, this dose is sufficient to establish respiratory 
infection, as 4 x 106 CFU can be recovered in the airways 24 hr post challenge in naïve 
(PBS control immunized) CD-1 mice (Fig. 1A).    
At one and three days post B. pertussis challenge, we enumerated the viable bacteria in 
the lungs, nares and trachea of naïve, aP, RTX+alum, and RTX+MPLA immunized CD-
1 mice (Fig. 1A and Fig. S1). The aP immunized mice had 99.75% less B. pertussis at 
day 1 post challenge than naïve mice (Fig. 1A), and by day 3, the bacterial load was at 
or below our detection limit of 100 CFUs. However, mice immunized with RTX+alum or 
RTX+MPLA, were not significantly protected as they contained the same amount of 
viable B. pertussis as naïve mice (Fig. 1A and Fig. S1AB). Interestingly, ELISAs were 
performed to measure anti-ACT antibodies and showed that mice vaccinated with RTX 
in combination with alum or MPLA induced detectable levels of antibodies in sera and 
lung homogenates (data not shown).      
Vaccination with wP, aP, aP+RTX, and or aP+ACT protect against B. pertussis 
challenge. We hypothesized that inclusion of RTX into a standard acellular formulation 
would enhance protection against B. pertussis challenge in mice. To test this 
hypothesis, we compared aP and wP to aP supplemented with ACT or RTX in a murine 
vaccination challenge study. CD-1 mice were immunized as indicated in Table S1 and 
boosted three weeks post initial vaccination. At day 38 post initial vaccination, the mice 
were challenged with the B. pertussis strain UT25. At 1, 3, and 8 days post challenge, 
mice were euthanized for determination of bacterial burden and collection of tissues and 
99 
 
samples for analysis. Naïve mice harbored similar amounts of B. pertussis in the lungs 
(Fig.1B), trachea and nares (Fig. S1CD) as those observed previously (Fig. 1A). wP and 
aP-vaccinated mice had significantly lower bacterial loads in the airways than non-
vaccinated mice, and aP mice had the lowest bacterial burden at day 1 and 3. By day 8, 
all wP or aP immunized mice had cleared the infection to our detection limit. (Fig. 1B). 
Overall these data show that in CD-1 mice with UT25 as challenge strain, the 1/5th 
human dose of aP is protective and that at that dose, adding RTX or ACT does not 
enhance bacterial clearance. 
Serological analysis of naïve, wP, aP, aP+ACT, and aP+RTX immunized mice.  
ELISAs were performed and we observed that alum and MPLA formulated RTX or ACT 
vaccines, induced antibodies that recognize ACT (data not shown). Additionally, 1/5th 
aP supplemented with either RTX or ACT also induced detectable antibody production. 
Surprisingly, we did not observe any antibodies that would recognize ACT in the wP 
immunized mice (data not shown). The lack of anti-ACT in wP immunized mice is likely 
due to the fact that when we analyze the wP with shotgun proteomics, we only observe 
4 peptides of ACT per 1,000 total peptides in the whole cell vaccine, which shows ACT 
makes up a minor amount of the total protein content (data not shown).  
AC toxin neutralizing capacity of serum antibodies. 
Due to the lack of noticeable effects on the rate of clearance of B. pertussis, it was 
unclear that those antibodies influenced clearance of B. pertussis in the mouse. ACT 
has potent toxic effects against CD-11b/CD-18-expressing phagocytes, such as 
macrophages or neutrophils 41-43. To determine the functional capacity of the serum 
antibodies induced via immunization, we utilized the AC toxin neutralization assay with 
J774A.1 cells 32. Only sera obtained from mice vaccinated with aP+ACT or aP+RTX 
were able to neutralize the toxicity of ACT in J774A.1 macrophages (Fig. 1C). We did 
not observe detectable anti-ACT antibodies in the serum from wP mice, and this serum 
did not neutralize ACT in vitro (Fig. 1C). The AC toxin neutralization data suggest that 
immunization with RTX can induce production of antibodies that can neutralize the AC 
toxin in vitro. 
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Identification of the optimal aP murine dose to determine synergy between aP 
and RTX. Our data and previous published studies 9 show that RTX is immunogenic 
and could contribute to protection against B. pertussis when used as an antigen. 
However, we hypothesized that the dose of aP used (1/5th human) in these studies is 
too high to observe synergy between the aP and RTX. Therefore, we sought to define a 
physiologically appropriate aP dose, for the mouse, that could be used to evaluate the 
effects of inclusion of new antigens into the aP. Guiso et al. demonstrated that 1 full 
human dose of DTaP was most protective (SmithKline Beecham Biologicals) 44 and that 
1/4th and 1/10th of the human dose were protective yet required more time to result in 
sterilizing immunity compared to a full human dose. Alvarez et al. 45 used 1/5th human 
dose and supplemented with an iron regulated protein, AfuA (BP1605) and observed 
modest improvement in bacteria clearance compared to 1/5th human DTaP 
(INFANRIX®; GSK). In other recent studies, 1/50th human human DTaP (INFANRIX®; 
GSK) was partially protective in BALB/c mice challenged with B3 lineage strain B1917 
27,46. These two studies encouraged us to determine if lowering the aP dose could allow 
us to detect measurable improvements in bacterial clearance when additional antigens 
improve the vaccine.  
CD-1 mice were immunized mice with aP doses of 1/20, 1/40, 1/80, and 1/160th human 
dose (Table S2) to titrate the vaccine and identify both the effective or non-effective 
doses. These mice were challenged with B. pertussis, and viable bacteria in the lungs, 
trachea, and nasal lavage were determined at 1 and 3 days post challenge (Fig. 2). At 
day 1 post challenge, the 1/20th aP group had the least bacterial burden and at day 3, 
both the 1/20th and 1/40th were near our detection limit (Fig. 2AB) in the lungs. A similar 
trend was observed in the trachea and nasal washes (Fig. 2CDEF). However, the 1/80th 
aP group had 3.5 log more viable B. pertussis in the lungs than the 1/40th aP group, 
suggesting 1/80th was below the aP dose for maximum protection in CD-1 mice (Fig. 
2B). The non-effective dose for trachea seemed to be higher than 1/160th (Fig. 2CD), 
whereas the non-effective dose for the nasal lavage was 1/160th (Fig. 2EF). Based on 
these data, we selected the 1/40th (minimal effective dose) and the 1/80th (maximal non-
effective dose) to supplement with AC toxoid antigen (RTX).  
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We hypothesized that neutralization of ACT in vivo would enhance bacterial clearance 
and that inclusion of RTX would improve the protection provided by the 1/80th dose as 
demonstrated by decreasing viable bacteria in the lung. Testing the inclusion of RTX in 
the 1/40th dose would allow for evaluation of other subtler variables such as cytokines 
production, phagocyte recruitment, and serology. CD-1 mice were therefore immunized 
with either 1/40th or 1/80th dose aP supplemented with RTX antigen (Table S2). 
Inclusion of RTX into the 1/40th aP did not affect the bacterial burden at day 3 in the 
lungs (Fig. 2B) compared to 1/40th aP alone, as we predicted. When RTX was added to 
1/80th aP, we saw a significant decrease in viable bacteria in the lungs at day 3 (Fig. 
2B). In light of this observation, it was necessary to measure other metrics in addition to 
viable bacteria to further support this finding. 
In the trachea and nasal lavage, we observed the similar inverse relationship between 
bacterial burden and decreasing vaccine concentration as in the lungs. In the trachea, 
there was minimal improvement of bacterial clearance with inclusion of RTX to the 
1/40th or 1/80th base aP. In the nares, adding RTX to 1/40th aP decreased the bacterial 
burden at day 1 but this difference was not significant (p = 0.29), and no differences 
were observed at day 3. Overall, these data highlight the need to consider the location 
of B. pertussis in the host in respect to vaccine efficacy in a challenge trial and also the 
utility of identifying sub-effective murine vaccine doses to determine if there are effects 
of adding new antigens into a formulation.  
Serological analysis of antibodies recognizing PT and RTX antigens.  
In our aP immunization titration strategy, we expected that as the aP dose decreased, 
the concentration of anti-PT in the serum of immunized and challenged mice would also 
decrease. Given that mice immunized with 1/40th aP had minimal bacterial burden in all 
respiratory tract locations (Fig. 2), we hypothesized that 1/40th aP would induce 
production of high concentrations of anti-PT antibodies in serum. We also hypothesized 
that inclusion of the RTX antigen into the 1/40th dose would result in production of 
significant amount of anti-RTX antibodies. As expected, immunization with RTX in both 
1/40th and 1/80th aP doses induced production of antibodies that recognize the RTX 
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antigen (Fig. 3AB). Surprisingly, there was very little difference between the amounts of 
detectable anti-RTX in 1/40th and 1/80th despite the fact that there was 50% less alum 
adjuvant in 1/80th compared to 1/40th. We also observed that as we decreased PT 
antigen and alum adjuvant by diluting the vaccine, less anti-PT was produced in 
response to B. pertussis challenge (Fig.3CD). At day 1 we saw a dose response curve 
for anti-PT respective of the aP dose (Fig. 3C). Anti-PT decreased as would be 
expected since PT antigen and alum adjuvant are decreasing respective to the vaccine 
dose.   
The addition of RTX into the 1/40th and 1/80th doses significantly increased antibody 
production to PT compared to same dilution of aP alone (p = 0.045 and p = 0.0039, 
respectively) at day 1 post challenge. Yet these levels of anti-PT drastically decreased 
at day 3 post challenge (Fig. 3D). This was a puzzling observation. There are several 
possibilities to explain this phenomenon. These ELISAs are from serum samples and it 
is possible that the high amounts of anti-PT have left the serum and are in the lung or 
upper respiratory tract closer to where the pathogens are infecting. The second 
possibility is that neutralization of ACT in vivo could decrease antibody production, 
which is less required due to bacterial clearance. More kinetics studies should be 
performed on these dual antigen considerations, especially with antigens like PT and 
RTX which both are classified as immunogens due to their adjuvant properties.   
Analysis of cytokine secretion as a function of aP immunization and inclusion of 
RTX antigen.  
Due to the fact that including RTX into the 1/80th aP dose helps lower the bacterial 
burden in the lungs, we then characterized lung cytokine profiles to better understand 
the type of immune signaling factors released during infection and their association with 
bacterial clearance. To do so, we measured cytokines in lung homogenate of 
vaccinated and naïve mice at 1 and 3 days post-challenge. IL-6 is one of the most 
important cytokines involved in the immune response to B. pertussis. Respiratory 
epithelial cells and macrophages have increased IL-6 mRNA and protein in response to 
B. pertussis in vitro 47,48 and C57BL/6 mice have high IL-6 secretion in response to B. 
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pertussis infection 48. Specifically, ACT has been shown to induce IL-6 expression 49. 
Furthermore, IL-6 knockout mice have increased B. pertussis burden in the respiratory 
tract compared to wild type mice due to decreased recruitment of leukocytes 48. Based 
on these studies and our preliminary cytokine data (Fig. S2), we anticipated that as we 
titrated the aP dose down, we would observe increased IL-6 correlating with the 
increased bacterial burden (Fig. 4AB). If antibodies against RTX can neutralize ACT in 
vivo, we expected to observe decreased IL-6 levels in RTX vaccinated mice. Our data 
confirmed this idea at day 1, but at day 3 post challenge, RTX did not affect IL-6 
secretion in the 1/80th vaccine dilution group (Fig. 4B).  
IL-6 is related to induction of Th17 responses, and in the case of B. pertussis infection, 
PT facilitates induction of IL-17 production typically around 7 days post B. pertussis 
challenge 50. At day 1, there were no statistically significant changes were observed in 
IL-17 across the groups. However, at day 3, as the aP dose decreased, IL-17 was 
slightly increased until it was significantly different at 1/160th human dose (Fig. 4D). It 
was surprising to observe that naïve infected mice did not have significantly more IL-17 
than mice vaccinated with the 1/160th dose. We interpret these data to mean that: 1) 1 
and 3 days are early for IL-17 responses to B. pertussis as we saw biological variability 
within the groups and 2) these diluted vaccines are likely capable of eliciting PT-
neutralizing antibodies. We did not observe any effect on IL-17 concentrations due to 
including RTX into either the 1/40th or 1/80th (Fig. 4CD). 
B. pertussis challenge of mice induces interferon gamma (IFN-γ) expression, which is 
necessary for clearance of B. pertussis from mice 51. Furthermore, IFN-γ receptor 
deficient mice challenged with B. pertussis display atypical disease leading to 
dissemination of B. pertussis and death of the mice within several weeks 52. Since aP 
immunization results in Th2 polarization, we expected that as the aP vaccine was 
titrated to less effective doses, we would see an increase in IFN-γ induced by the 
natural Th1 response to B. pertussis infection 53. At day 1, the 1/40th aP and the 1/80th 
aP displayed similar IFN-γ levels in the lung. However, when RTX was added to the 
1/80th we observed a striking reduction of IFN-γ at day 1 only. It is also interesting to 
note that naïve infected mice had lower IFN-γ than 1/40th, 1/80th, or 1/160th aP groups at 
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day 1 (Fig. 4E), yet high IFN-γ was observed in the naïve infected mice at day 3 (Fig. 
4F).  
IL-1β mediates clearance of B. pertussis and resolution of inflammation in mice 54. IL-1β 
deficient mice have high amounts of IL-17 that are observed at 7 days post challenge 
and high IFN-γ at 14 days post challenge 54. We wondered if neutralization of ACT in 
vivo would alter IL-1β production in the lungs of the mice. All challenged mice had very 
similar IL-1β levels at day 1 (Fig. 4G) and the levels of IL-1β were lowest in the 1/20th 
aP group at day 3. Addition of RTX did not significantly decrease IL-1β which suggests 
IL-1β may be induced independently of ACT activity or bacterial burden.  
We measured other cytokines such as IL-5, TNF-α, KC Gro, IL-12p70, IL-10, IL-2, and 
IL-4, in the lung homogenates of the vaccine groups (Fig. S3 and S4). Vaccination with 
aP+RTX resulted in lower IL-5 at day 1 in both 1/40th and 1/80th groups, yet these 
groups returned to base aP IL-5 levels at day 5 (Fig. S4). IL-2 followed a similar trend 
as IL-5 (Fig. S4). We observed that Th1 related responses such as IFN-γ were 
decreased by the addition of RTX to the aP.  
Neutrophil infiltration kinetics are not affected by inclusion of RTX into the aP.  
Pertussis is characterized by an increase in the number of circulating white blood cells. 
This phenomenon known as leukocytosis can lead to lung hypertension and death in 
the most severe cases. ACT targets the CR3 receptor expressed on many cell types 
including neutrophils 55. Based on this, we hypothesize that neutralization of ACT in vivo 
would alter neutrophil kinetics and recruitment profiles in the blood and airway. 
Andreasen and Carbonetti reported that in naïve mice, neutrophils did not play a role in 
clearance of B. pertussis from the airway 50,56. On the other hand, neutrophils played an 
essential role in immune mice in the same study. Another study showed: 1) that PT 
inhibited recruitment of neutrophils to the lung and neutrophils played a role in antibody 
directed clearance of B. pertussis by the Fcγ receptor 57. As the dose of the aP 
decreased, we observed an increase in lung and blood neutrophils by the 1/160th 
neutrophil percentages were similar to those of naïve B. pertussis challenged mice. It is 
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likely that as the aP dose decreased, there was less PT neutralization due to a 
decrease in anti-PT titers. Lung neutrophil populations of mice immunized with inclusion 
of RTX into the 1/40th and 1/80th doses were significantly reduced (p = 0.0142 and p = 
0.008, respectively) compared to mice immunized with aP only at the same doses (Fig. 
5C); however, by day 3, this reduction was no longer significant because neutrophil 
levels had returned to levels observed in non-challenged mice (Fig. 5D). We observed 
lower circulating neutrophil populations in the blood at both days when RTX was 
included compared to aP only doses (Fig. 5F) (1/40th: p = 0.018, 1/80th: p = 0.071). 
Collectively, these data suggest that inclusion of RTX into the aP vaccine impacts the 
neutrophil populations in the respiratory tissues and circulating neutrophils in the blood.  
Decreased macrophages in the respiratory tract due to inclusion of RTX into the 
aP.  
Macrophages are a primary target of ACT and are readily killed by the toxin 41,43. We 
hypothesized that as ACT is neutralized in vivo, that there would be an increase in 
macrophages due to their increased survival. However, our data did not support that 
hypothesis, and instead we saw that both RTX supplemented aP groups had lower 
macrophages in the nasal lavage at day 1 compared to aP only. Inclusion of RTX 
decreased the overall numbers of macrophages in both the 1/40th and 1/80th base aP 
groups (Fig. 6AB). At day 3, we observed that mice vaccinated with 1/40th , 1/80th and 
1/160th aP showed increasing amounts of macrophages compared to naïve and naïve 
challenged mice. As observed for other parameters measured, this effect might be due 
to an induction of a naïve Th1 response due to insufficient aP driven Th2 as a result of 
our decrease in aP dose.    
Visualizing and modeling the relationships between: antibodies against B. 
pertussis toxins, pro-inflammatory signals, phagocytes, and clearance of B. 
pertussis from the murine respiratory tract. 
 The Kendrick test was used to establish units of efficacy for whole cell vaccines in mice 
to estimate the dose to be used in humans 2. The murine intranasal infection model was 
106 
 
then developed to validate aP vaccines 44,58. Since the introduction Tdap, numerous 
pre-clinical studies have been performed to evaluate new antigens or adjuvants to 
improve aPs. However, we argue that there is a need for standardization of the murine 
evaluation platform to facilitate the development of these formulations, and transition to 
other models such as the baboon. In this study, we titrated DTaP and found a dose 
(1/80th human) that was partially protective with the B. pertussis strain (UT25) and the 
challenge dose of 2x107 CFU that were used. It is clear that decreases in bacterial 
burden are indicative of protection; however, we aimed to visually represent all the data 
collected to support our conclusions. For this comparison, we represented the increases 
and decreases for each variable relative to the no vaccine / no challenge group using a 
64 color scheme (Fig. 7). If the relative units increases, the color changes to red, or if it 
decreases then the value is represented in blue. We then plotted the average values 
per each immunization group (1/20-1/160th) in relation to the RTX supplemented 
groups. As one visually compares 1/80th to 1/80th+RTX at day 1 or 3, it is apparent that 
adding RTX relatively decreases all values towards the green or no relative change, 
which we interpret as overall protection. It is also important to note that values at day 1 
are relatively higher than day 3 and this relates to the fact that the total amount of 
bacteria are decreasing. The amount of anti-PT or anti-RTX is shown in black to grey to 
white color scale (Fig. 7). There is a clear correlation with amount of anti-PT and overall 
protection. In addition, it is interesting to see that inclusion of RTX enhanced the anti-PT 
levels in the aP+RTX groups. Overall, variables associated with inflammation such as 
cytokines or phagocytes tend to return to green or naïve non-infected levels in mice 
vaccinated with aP+RTX. We only observed five relatively large decreases (indicated in 
blue). The 1/20th aP group had relatively lower KC/GRO which could be associated with 
the anti-inflammatory Th2 response due to the high amount of alum in the immunized 
mice. We also saw a relative decrease in number of macrophages present in the nasal 
wash at day 3 in the naïve group. This decrease could be attributed to high amounts of 
PT and ACT secreted during infection which could be impairing normal macrophage 
recruitment in the airway. We also saw large relative decreases in macrophages in the 
RTX supplemented 1/40th and 1/80th groups at day 3 and reasons for these changes 
were described above. Combining these data allow us to consider the overall 
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inflammatory response in relation to the vaccination status, to further demonstrate the 
effects of including RTX into aP formulations, and to begin to establish a multi-variable 
approach to determining efficacy of experimental vaccines in the mouse.  
Discussion 
There is a resurgence of whooping cough that coincides with the switch to the use of aP 
vaccines. In this study, we aimed to accomplish two goals. First, we sought to define an 
aP vaccine dose, or doses, that allow the evaluation of synergy between the current aP 
and potential new antigens. The second goal was to evaluate RTX as an antigen for 
inclusion in acellular pertussis vaccines in the murine challenge model. As a result of 
these studies, we now better appreciate the need to continue to refine the 
methodologies of improving aP vaccines.   
We initiated this study by evaluating the efficacy of ACT and RTX as single vaccine 
antigens. Immunization with ACT or RTX alone did not induce significant protection in 
CD-1 mice with the UT25 B. pertussis challenge strain (Fig. 1). The AC domain of ACT 
was first described as a protective antigen by Guiso et al 17. In that study, the antigen 
preparation that was used consisted of two polypeptides of 43 and 45 kDa. We now 
know that these polypeptides corresponded to the AC domain of ACT. In those studies, 
BALB/c mice were vaccinated twice with AC polypeptide absorbed on aluminum 
hydroxide adjuvant and it was observed that 80% of the AC-vaccinated mice survived B. 
pertussis challenge with strain 18323 17. The aforementioned study was then further 
supported by a subsequent study by the same group that showed the protective 
capacity of the AC domain and full length recombinant ACT protein 35. Several more 
studies showed that: 1) CyaC acylation of ACT was required for the protective activity 18 
and 2) that the C-terminal domain was also required for protection with recombinant 
ACT. Full length recombinant ACT was protective when 15 µg of antigen were mixed 
and absorbed with 250 µg of alum 19. We used less antigen and adjuvant than Betsou et 
al. (either 10 µg of ACT or 5.6 µg of RTX with 125 µg of alum) and we did not observe 
protection in CD-1 mice (Fig. 1A), and the use of the MPLA adjuvant did not improve 
bacterial clearance compared to alum. An apparent difference between our study and 
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that of Betsou et al. is that strain 18323 was used, which has been suggested to be an 
outlier compared to most other global B. pertussis strains. Guiso et al. noted that strain 
18323 produces less PT than the Tohama I type strain 35. From our own studies, we 
know that UT25 produces more PT and ACT than Tohama I (data not shown). This 
information highlights the importance of the challenge strain. Another caveat of our 
study is that Betsou et al. absorbed the ACT antigen to alum, which we did not with 
RTX. It is possible that absorbing RTX to the aP could further enhance the synergistic 
protection observed in this study when RTX was combined with the alum-containing aP. 
Another key aspect to consider is the potential endotoxin contamination in recombinant 
ACT preparations. Villarino et al. used recombinant ACT but did not observe the same 
bacterial clearance as Betsou et al. 19. ACT used by Cheung et al. was highly purified of 
endotoxin 21, as was the RTX that we used in this study 9. It is possible that endotoxin 
levels in ACT preparations may influence the overall protection afforded by such 
antigens as they may induce a more Th1-biased response.  
Several of the aforementioned studies indicated that single antigen vaccines containing 
ACT were protective but the study by Cheung et al. and our RTX-only study (Fig. 1) 
were not in concordance. Other recent studies testing single antigen vaccines 
composed of proteins expressed during biofilm or in response to iron starvation showed 
that very few of these single antigen formulations were protective on their own 27,46. 
Given that the aP antigens of either DTaP or Tdap (PT, FHA, PRN, and +/- FIM) do 
provide some protection against disease, we hypothesize that new antigens to be 
included in the aP should be tested not only alone, but also in combination with aP 
antigens. Only one study has investigated ACT as an antigen in combination with the 
aP in mice 21. Cheung et al. reported that adding 12.5 or 25 µg to 1/8th aP, significantly 
decreased bacterial burden in mice at 7 days post challenge with strain 18323 21. PT 
and FHA are formulated in the DTaP (INFANRIX®) at 25 µg each in 1 human dose. 
Therefore, the use of 25 µg ACT is roughly equal to 1 human dose of antigen (assuming 
no adjustment for molar mass of each antigen). We chose to test the utility of RTX 
antigen with lower antigen doses in an effort to best model what would be scaled 
towards a commercial vaccine dose. To do so, we identified a partially protective dose 
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of aP, so synergistic effects of addition of the antigen to be tested. We titrated the aP 
vaccine from 1/20th to 1/160th human dose. As decreasing aP doses were tested, we 
saw an increase in innate immune responses to levels observed in naïve challenged 
mice (Fig. 7). From the bacterial burden in the lung, we determined that 1/40th dose of 
aP is protective, while 1/80th is only partially protective. However, it is important to note 
that 1/40th aP immunization was non-protective in the nares at day 1, but at that dose, 
B. pertussis was cleared by day 3 (Fig. 2EF). These data show that the protective 
capacity of an aP dose in the mouse is dependent on the location in the airway and the 
time elapsed since B. pertussis challenge. Using total clearance in all locations, 1/40th 
aP immunization results in sterilizing immunity against our challenge dose as observed 
at three days post challenge. Based on these data, we selected the 1/40th (minimal 
effective dose) and the 1/80th (maximal non-effective dose) to supplement with AC 
toxoid antigen (RTX).  
We identified the 1/80th aP dose that would allow us to tease out RTX antigen effects 
that would otherwise be masked by the use of a high mouse to human aP dose (e.g. 
1/5th). With the 1/80th aP dose, it is clear that innate responses are occurring due to the 
lack of protection provided by the immunization. We hypothesize that decrease in innate 
responses would correlated with induction of antibody production that either: neutralizes 
the effects of the pathogen (e.g. toxins: PT or ACT) or results in killing of the pathogen 
(e.g. opsonization, phagocytosis, or complement killing). We were able to detect 
antibodies that recognized RTX (Fig. 3AB) and we saw that adding RTX enhanced 
production of anti-PT (Fig. 3A). When we supplemented the 1/80th aP dose with RTX, 
we were able to observe positive effects on the response to B. pertussis challenge such 
as decreased: bacterial burden (Fig 2B), IL-6 secretion (Fig. 4A), IFN-γ (Fig. 4E), IL-5 
(Fig. S4), IL-2 (Fig. S4). We speculate that the neutralization of ACT in vivo leads to a 
decrease in the innate immune responses at day 1 post challenge, but at day 3, the 
levels of these pro-inflammatory cytokine were not affected by the inclusion of RTX (Fig. 
4BF and S4). We observed that B. pertussis challenge increased neutrophil levels in the 
nasal lavage and that these levels were not reduced to non-challenged levels during our 
study (Fig. 5AB). Neutrophils in both the nares and lungs were overall decreased by day 
110 
 
3 post challenge in the RTX supplemented groups. Adding RTX antigen to the 1/40th 
and 1/80th vaccines decreased the total neutrophils in the lungs at day 1 and same 
trend was observed for blood neutrophils (Fig. 5EF). Interestingly, we observed that 
adding RTX to aP (1/40th nor 1/80th) did not affect nasal neutrophils amounts (Fig. 5AB). 
We speculate that ACT may have specific effects in the lung and not in the nares of 
mice, but more experiments are necessary test this hypothesis.   
ACT can induce apoptosis in macrophages 59 and it is also known that IL-12 production 
by macrophages plays a role in vaccine-mediated clearance of B. pertussis 60. We 
measured the number of macrophages in the lungs and nasal lavages of aP or RTX 
supplemented aPs and saw less macrophages when RTX was added to the aP (Fig. 
6ABCD). This data was somewhat counterintuitive but Skopova et al. have shown that 
cAMP signaling and hemolysin activity synergize and provoke PMN and macrophage 
influx into the lungs 12. Our macrophage observations suggest anti-RTX may be 
neutralizing ACT in vivo. There are also two more possibilities: 1) there may be less 
macrophage recruitment because there are less bacteria or 2) if macrophages are less 
impaired (due to ACT neutralization), they may be effectively migrating to the lymph 
nodes to present antigens. At this point, we do not have sufficient data to fully 
understand the relationships between the amount of macrophages in the airway and if 
that is an indication of protection and/or an effect of ACT neutralization.   
B. pertussis strains have evolved in response to aP immunization 61. Pertactin is no 
longer expressed by circulating B. pertussis strains 62 and recently, a B. pertussis strain 
was isolated and sequenced that lacked PT 63. B. parapertussis is not capable of 
expressing PT 64 but causes as many as ~15% of whooping cough cases. B. holmesii is 
an underappreciated pathogen that cause whooping cough-like illness and does not 
express PT 65. In addition, there are unpublished reports of strains sequenced by the 
CDC that lack expression of filamentous hemagglutinin. Given the potential rise of triple 
mutant strains that do not make pertactin, FHA, or PT, it is possible that the efficacy of 
aP protection will further decline if strains arise that lack the main antigens that most aP 
vaccines contain. Based on these possibilities, we propose that adding additional 
antigens that are both immunogenic and important for bacterial virulence is necessary 
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to slow the progression of B. pertussis evolution 66, and the resistance to aP-mediated 
immunity.  
We aimed to investigate ACT as a vaccine antigen and we developed a new evaluation 
approach involving analysis of multiple correlates of protection (Fig. 7). Our data 
suggest that RTX antigen may enhance protection of aP vaccines, based on what we 
observed in CD-1 mice. The different protection levels observed in each of the regions 
of the airway (nares, trachea, and lungs) suggest that it may also be advantageous to 
consider the development of mucosal B. pertussis vaccines. This would allow for the 
pathogen to be neutralized rapidly in the upper airway before infection is fully 
established when highly potent PT and ACT are impairing the innate and adaptive 
immune responses. Higgs et al. 67 proposed that aP vaccines containing antigens that 
direct a more diverse response, may be more effective. While we have focused on 
adding RTX to a Th2 inducing aP, it would be very interesting to formulate and test RTX 
containing vaccines with Th1 adjuvants. Neutralization of ACT along with a cellular 
response would likely be an ideal protection profile and possibly address the waning 
protection issue of the aP. Our study was focused on RTX but there are other 
candidates that should be evaluated as well. Our study highlights the importance of 
titrating the vaccine dose and we expect this will provide new methodologies for the 
development of pertussis vaccines. Significant research is still necessary to formulate 
and evaluate safe and more effective next generation pertussis vaccines, which could 
include ACT as an antigen.  
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Figure 1. RTX only immunization does not protect against B. pertussis challenge 
in CD-1 mice nor does including RTX with 1/5th aP improve clearance kinetics but 
ACT neutralizing antibodies are produced.  
 
Fig
ure 1. RTX only immunization does not protect against B. pertussis challenge in 
CD-1 mice nor does including RTX with 1/5th aP improve clearance kinetics but 
ACT neutralizing antibodies are produced. (A) CD-1 mice were vaccinated with PBS 
vehicle, 1/5th human dose of aP, RTX (5.6 µg) + MPLA (20 µg), RTX (5.6 µg) + Alum 
(125 µg), or PBS as control vehicle (naïve)(n=4, with 4 technical replicates). Mice were 
IN challenged with 2x107 Bp (UT25Sm1). At days 1 and 3 pc the bacterial burdens were 
determined by culturing of homogenates of the lungs on BG agar. The dashed line 
represents the lower limit of detection due to plating. Bacterial loads in mice vaccinated 
with aP were significantly lower than the PBS control group at day 1 (p = <0.0001) and 
day 3 (p = <0.0001) in the lung. (B) CD-1 mice were vaccinated with PBS control 
vehicle, wP, aP, aP + ACT or aP + RTX and challenged intranasally with UT25Sm1 
(n=4, with 4 technical replicates). Mice vaccinated with aP, aP+ACT, and aP+RTX had 
a significantly lower bacteria burden than the PBS control group at day 1 (p <0.0003, p 
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<0.0006, p <0.0013) in the lung. Bacterial loads in all immunized mice were significantly 
lower than PBS group at day 3 and 8 (p <0.0001; all groups) in the lung. Data in each 
group were compared to every other group at day 1, 3, or 8 pc using one-way ANOVA 
with Tukey’s post hoc test. (C) Serum from vaccinated/challenged mice was used to 
determine if ACT neutralizing antibodies were produced following RTX or ACT inclusion 
in aP vaccine by adenylate cyclase toxin neutralization assay. J774A.1 macrophages 
were cultured with active ACT, and serum from mice. Neutralization of ACT results in 
increase of macrophage survival. Serum from vaccinated mice with aP+ACT and 
aP+RTX resulted in neutralization of ACT, compared to unvaccinated, aP, and wP 





Figure 2. Respiratory tract bacterial burden of CD-1 mice immunized with aP 
vaccines or aPs supplemented with RTX antigen. 
 
Figure 2. Respiratory tract bacterial burden of CD-1 mice immunized with aP 
vaccines or aPs supplemented with RTX antigen. Immunization with 1/20th, 1/40th, 
1/80th, and 1/160th of human dose aP was used to titrate the minimal effective dose and 
the maximum non-effective dose. RTX (5.6 µg) was included into 1/40th and 1/80th aP 
doses. Vaccinated CD-1 mice were challenged with 2 x 107 Bp, and bacterial burden 
was determined at days 1 and 3. CFU counts were determined from (AB) lung 
homogenate, (CD) trachea homogenate, and nasal lavage (EF). Results are mean ± 
SEM (n=4-8, with 4 technical replicates) from independent experiments, ****, p<0.0001 
*** p< 0.001, **p<0.01, * p<0.05 determined by one-way ANOVA with Tukey post hoc 
test compared to naïve mice (PBS control). The dashed line represents the lower limit of 
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detection due to plating. The blue boxes indicate aP groups whereas aP+RTX are 
indicated by gold triangles. Gray squares indicate mock vaccinated, and challenged 
mice. In E and F there were no statistically significant comparisons between the aP 




Figure 3: Serological responses from mice immunized with aP titrations or aPs 
supplemented with RTX. 
 
Figure 3: Serological responses from mice immunized with aP titrations or aPs 
supplemented with RTX. (AB) ELISA was used to determine the anti-RTX IgG titers in 
serum of immunized and challenged mice at 1 and 3 days pc. (CD) Anti-PT IgG titers in 
serum of immunized and challenged mice at indicated time points. Titrations of aP were 
compared by one-way ANOVA with Tukey’s post hoc test, shown below graphs and 
compared to PBS group. Unpaired two-way T test was used to compare addition of RTX 
to aP titrations, shown by brackets. Results plotted on graph are mean ± SEM, *** p< 
0.001 **p<0.01, *p<0.05. 
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Figure 4: Analysis of proinflammatory cytokines from lungs of mice immunized 





Figure 4: Analysis of proinflammatory cytokines from lungs of mice immunized 
with aP titrations or aPs supplemented with RTX. Th1 associated cytokines from 
supernatant of lung homogenates analyzed at days 1 and 3 pc. Cytokines (AB) IL-6, 
(CD) IL-17, (EF) IFN-γ, and (GH) IL-1β. The blue boxes indicate aP groups whereas 
aP+RTX are indicated by gold triangles. Gray squares indicate mock vaccinated, and 
challenged mice, while white squares represent non-vaccinated and non-challenged 
mice (NC). Results are mean ± SEM, **** p<0.0001, *** p< 0.001, *p<0.05 by one-way 
ANOVA with Tukey post hoc test compared to PBS (naïve) but challenged mice. 
Brackets between two points represent unpaired two-way T test. Dashed line indicates 




Figure 5: Flow cytometric analysis of blood, pulmonary, and nasal lavage 
neutrophils from mice immunized with aP titrations or aPs supplemented with 
RTX. 
 
Figure 5: Flow cytometric analysis of blood, pulmonary, and nasal lavage 
neutrophils from mice immunized with aP titrations or aPs supplemented with 
RTX. Quantification of the percentage of live, single cells that were classified as 
neutrophils (GR-1hiCD-11b+) from (AB) nasal lavage, (CD) lung homogenate, or (EF) 
blood. Results are mean ± SEM, *** p< 0.001 ,** p<0.01, *p<0.05 by one-way ANOVA 
with Tukey post hoc test compared to PBS (naïve) but challenged mice. Brackets 





Figure 6: Flow cytometric analysis of macrophages from lung and nasal lavage of 
mice immunized with aP titrations or aPs supplemented with RTX. 
 
 
Figure 6: Flow cytometric analysis of macrophages from lung and nasal lavage of 
mice immunized with aP titrations or aPs supplemented with RTX.  Percentage of 
macrophages (defined as CD-11b+F4/80+) from live, single cells from (AB) nasal lavage 
and (CD) single cell suspension prepared from lung homogenate. Results shown are 
mean ± SEM, *p<0.05 by one-way ANOVA with Tukey post hoc test compared to PBS 


































Figure S1. RTX only nor RTX supplemented aP immunizations alter B. pertussis 
clearance in CD1 mice.  
 
Figure S1. RTX only nor RTX supplemented aP immunizations alter B. pertussis 
clearance in CD1 mice. (A-B) CD1 mice were vaccinated with PBS vehicle, aP, RTX 
adjuvanted with alum or MPLA and challenged intranasally with B. pertussis strain 
UT25. At days 1 and 3 post challenge the bacterial burdens were determined by 
culturing of nasal wash, homogenates of trachea on Bordet Gengou (BG) agar. 
Experiments were performed with 4 mice per group with 4 technical replicates. The 
dashed line represents the lower limit of detection. (CD) CD1 mice were vaccinated with 
PBS control vehicle, wP, aP, aP + ACT or aP + RTX and challenged intranasally with 
UT25. At days 1, 3, and 8 post challenge the bacterial burdens were determined. 




Figure S2. Mouse inflammatory cytokine array of lung homogenate supernatant. 
 
Figure S2. Mouse inflammatory cytokine array of lung homogenate supernatant. 
Lung homogenate supernatant from 4 mice in each group were pooled and used to 
probe membranes labelled with antibodies for 40 inflammatory cytokines. Pseudocolor 
image of day 3 cytokine production are shown in duplicate. The control group is not 








Figure S3. Cytokine analysis of lung homogenates of CD1 mice immunized with 
various aP doses and supplemented with RTX antigen.  
 
 
Figure S3. Cytokine analysis of lung homogenates of CD1 mice immunized with 
various aP doses and supplemented with RTX antigen. Lung homogenates were 
collected from mice of each of the groups indicated and the concentration of each 
cytokine indicated was determined. Minimal detection limits are indicated. Error bars 
show standard error of the mean. The blue boxes indicate aP groups whereas aP+RTX 




Figure S4. Cytokine analysis of lung homogenates of CD1 mice immunized with 
various aP doses and supplemented with RTX antigen.  
 
Figure S4. Cytokine analysis of lung homogenates of CD1 mice immunized with 
various aP doses and supplemented with RTX antigen. Lung homogenates were 
collected from mice of each of the groups indicated and the concentration of each 
cytokine indicated was determined. Minimal detection limits are indicated. Error bars 
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show standard error of the mean. The blue boxes indicate aP groups whereas aP+RTX 
are indicated in gold.  
Figure S5: Serological responses from mice immunized with aP titrations or aPs 
supplemented with RTX. 
 
Figure S5: Serological responses from mice immunized with aP titrations or aPs 
supplemented with RTX. (AB) ELISA was used to determine the anti-RTX IgG levels 
in serum of immunized and challenged mice at 1 and 3 days pc. (CD) Anti-PT IgG levels 
in serum of immunized and challenged mice at indicated time points. Antibody 
concentration (µg/ml) represented were determined using relative EC50. Serum 
absorbance values were logarithmically plotted to known antibody standards using a 
four-parameter logistic curve. Relative EC50 was then determined by fitting serum 
concentration to dilutions of samples using a four-parameter logistic curve. Titrations of 
aP were compared by one-way ANOVA with Tukey’s post hoc test, shown below 
graphs. Unpaired two-way T test was used to compare addition of RTX to aP tritrations, 







































Figure S6. Representative images and gating strategy for neutrophils from blood 
of CD1 mice immunized with various aP doses and supplemented with RTX 
antigen. (A) Cells were first gated on live, single cells. Then classified as either (B) 
neutrophils (CD11b+Gr-1Hi) or (C) macrophages (CD11b+F4/80+). Quadrants 
demonstrate positively labeled cells determined by single label controls marker flow 




Figure S7. Heat map modeling of the effects of base aP dose and 
supplementation of RTX antigen on correlates of protection in mice.  
 
 
Figure S7. Heat map modeling of the effects of base aP dose and 
supplementation of RTX antigen on correlates of protection in mice. In order to 
understand the key variables collected in this study, in relation to base aP dose and the 
effects of adding RTX, we developed a heat map that shows the relative increase or 
decrease of each variable. The color scale indicates relative changes in bacterial 
burden, cytokines, or phagocytes whereas the black-grey-white scale indicates relative 
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Current acellular pertussis vaccines fall short of optimal protection against the human 
respiratory pathogen Bordetella pertussis  resulting in increased incidence of a 
previously controlled vaccine preventable disease. Natural infection is known to induce 
a protective mucosal immunity. Therefore, in this study, we aimed to use acellular 
pertussis vaccines to recapitulate these mucosal immune responses. We utilized a 
murine immunization and challenge model to characterize the efficacy of intranasal 
immunization (IN) with DTaP vaccine or DTaP vaccine supplemented with curdlan, a 
known Th1/Th17 promoting adjuvant. Protection from IN delivered DTaP was compared 
to protection mediated by intraperitoneal injection of DTaP and whole-cell pertussis 
vaccines. We tracked fluorescently labeled DTaP after immunization and detected that 
DTaP localized preferentially in the lungs while DTaP with curdlan was predominantly in 
the nasal turbinates. IN immunization with DTaP, with or without curdlan adjuvant, 
resulted in anti-B. pertussis and anti-pertussis toxin IgG titers at the same level as 
intraperitoneally administered DTaP. IN immunization was able to protect against B. 
pertussis challenge and we observed decreased pulmonary pro-inflammatory cytokines, 
macrophage and neutrophil infiltrates in the lung, and bacterial burden in the upper and 
lower respiratory tract at day 3 post challenge. Furthermore, IN immunization with DTaP 
triggered mucosal immune responses such as production of B. pertussis-specific IgA, 
and increased IL-17A. Together, the induction of a mucosal immune response and 
humoral antibody-mediated protection associated with an IN administered DTaP and 









Pertussis is a human upper respiratory disease, primarily caused by the Gram-negative 
pathogen Bordetella pertussis. The disease is most severe in unvaccinated infants, 
where it manifests as fits of paroxysmal coughs followed by the classical whoop as air 
re-enters the respiratory system, leading to the more commonly known name: whooping 
cough.1 Additional complications include vomiting, increased mucus production, and 
apneic episodes. In severe cases, these symptoms can lead to elevated leukocytosis, 
pulmonary hypertension, hypoxia, and in some cases death.1–3 Furthermore there is 
speculation that pertussis may enhance development of neurodegenerative diseases 
later in life.4  
In the pre-vaccine era, pertussis was responsible for 200,000 deaths annually in the 
United States.5 Widespread use of diphtheria tetanus whole-cell pertussis (DTP; wP) 
vaccines controlled the incidence of pertussis.6 However, adverse side effects 
associated with wP immunization1 led to the development of an acellular pertussis 
vaccine (DTaP; aP) that was introduced into the schedule in 1996. In the United States 
the number of pertussis cases has been increasing since the 1990s, despite high 
vaccine coverage.7 Additionally, increasing numbers of cases have been documented in 
older children, adolescents and adults.8 The increase in incidence of pertussis cases 
suggests that current aP vaccines do not offer complete protection from B. pertussis 
infection. Multiple hypotheses have been proposed explaining the resurgence of 
pertussis cases including: (1) waning of protective immunity from DTaP/tdap9–11, (2) 
vaccine driven evolution of B. pertussis strains12, (3) increased carriage and 
transmission through asymptomatic carriers13, and (4) increased surveillance and more 
accurate diagnoses technology.  
Vaccine-induced protection in aP immunized individuals has been associated with a 
robust antigen-specific IgG response to the components of the aP vaccines.14–17 
Likewise, wP immunization also resulted in antigen-specific IgG responses; with the 
addition of a shift to a more diverse T cell response, inducing cell-mediated immunity.18 
In the murine model, immunization through intramuscular (IM) and intraperitoneal (IP) 
administration has been well characterized demonstrating a Th1/Th17 response from 
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wP immunized mice, and a Th2 with weak Th17 mediated response in aP immunized 
mice following B. pertussis challenge.19 However, these immunizations fail to induce the 
mucosal immune responses elicited from natural infection. Recent studies have 
revealed that protection correlates with tissue resident memory T (TRM) cells in the lung 
and nasal cavity of convalescent mice, that produce interleukin-17 (IL-17) and 
interferon-gamma (IFN-γ).20 TRM cells have been shown to persist in the respiratory 
tissue and expand upon re-challenge of a convalescent mouse with B. pertussis, as well 
as decrease bacterial burden upon adoptive transfer to naïve mouse.21 The study of this 
population has renewed interest in the induction of a mucosal immune response 
capable of decreasing bacterial burden at the site of infection.  
The induction of a mucosal immune response to B. pertussis is associated with the 
production of secretory IgA antibodies (sIgA) in the nasal cavity. In humans previously 
infected with B. pertussis, IgA antibodies have been isolated from nasal secretions.22 B. 
pertussis-specific IgA antibodies isolated from convalescent patients have been shown 
to inhibit adherence of B. pertussis to respiratory epithelial cells in vitro23, suggesting a 
protective role of IgA antibodies in mucosal immunity. Initial studies using IgA-deficient 
mice did not show strong support for a critical role in bacterial clearance of the 
respiratory tract.24 However, work with a live-attenuated IN pertussis vaccine (BPZE1) 
recently demonstrated protective role of sIgA antibodies in the respiratory tract.25  
DTaP vaccine does not contain a strong pro-inflammatory adjuvant such as endotoxin 
of wP vaccine or BPZE1. We aimed to investigate IN DTaP immunization alone or with 
an additional pro-inflammatory adjuvant. We formulated vaccines containing the 
adjuvant curdlan, a 1,3 β-glucan, derived from Alcaligenes faecalis. This polysaccharide 
has immunostimulatory properties and forms a “sticky” gel at a neutral pH. Importantly, 
curdlan has been shown to bind to dendritic cells through the ligand Dectin-1, thereby 
inducing expression of NF-κB26 leading to a Th1/Th17 mediated immune response as 
well as production of antigen-specific respiratory IgA antibodies and serum IgG 
antibodies. 26–29 Our objective was to determine whether IN DTaP immunization would 
induce a protective immune response in a murine model. We observed that the gel 
properties of curdlan facilitated DTaP localization in the upper respiratory tract. We 
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measured serum and respiratory antibody responses that correlated with protection 
from bacterial challenge. This study suggests mucosal vaccination with acellular 
vaccine may be a strategy for decreasing incidence of pertussis.  
Results 
Acellular pertussis vaccine was retained in the upper and lower respiratory tract when 
administered by intranasal administration. 
Pertussis toxin facilitates infection by disrupting innate immune responses in the airway. 
30 Therefore, we hypothesized that neutralization of pertussis toxin at the site of 
infection is essential for protection against B. pertussis. We propose that intranasal 
immunization would prime a protective mucosal immune response. Furthermore, the 
gel-like properties of curdlan may have a beneficial role in increasing antigen uptake. To 
determine if use of curdlan would increase vaccine retention in the respiratory system, 
we IN vaccinated CD-1 mice with commercially available DTaP (IN-aP), DTaP with 
curdlan (IN-caP), or PBS (mock vaccinated) and tracked the vaccine up to 48 h after 
vaccination (Fig. 1a). Using in vivo animal imaging, we observed fluorescently labeled 
DTaP particles in the nasal cavity at 6, 12 and 24 h post-vaccination (Fig. 1b). At 12 h 
post-vaccination, we detected significantly higher levels of fluorescence in IN-caP 
vaccinated mice compared to IN-aP mice (Fig. 1c), suggesting more DTaP particles 
were retained in the nasal cavity. This method resulted in the quantification of total 
particles in nasal cavity. To quantify DTaP particles that were bound to innate immune 
cells we utilized flow cytometry. Single-cell suspensions were prepared from 
homogenized lung tissue and antigen presenting cells (APCs) bound to DTaP were 
quantified as live, single cells positive for CD11b+DTaP+ (Fig. 1d). We observed a 
significant increase in CD11b+ cells that were bound to or contained DTaP particles in 
IN-aP mice compared to IN-caP (Fig. 1e). Together, these data suggest a higher 
deposition of DTaP in the lung with IN-aP when compared to IN-caP. Conversely, in the 
nasal cavity we measured higher levels of DTaP when mice were vaccinated with IN-
caP, compared to IN-aP. These findings suggest that addition of curdlan to the DTaP 
vaccine causes retention in the nasal cavity, but without it, the vaccine components are 
more readily detected in the lung.  
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To visualize the deposition of DTaP particles, sections from the lung and nasal cavity 
were imaged using confocal microscopy. Vaccinated mice were euthanized after 6 h, 
lung tissue was flash frozen and skulls were embedded in paraffin for sectioning. 
Sections from the lung and nasal cavity were counterstained with NucBlue and 
ActinGreen to visualize epithelial tissue and fluorescent DTaP particles (Fig. 2ac). 
Vaccine particles were quantified by measuring the percentage of total image field 
emitting DTaP fluorescence. We detected a significant increase of fluorescent particles 
in the lungs of mice that were vaccinated with IN-aP compared to IN-caP (Fig. 2b). 
Using microscopy, there was no significant difference in the number of particles 
detected in the nares comparing IN-aP to IN-caP (Fig. 2d). Interestingly, we observed 
that DTaP particles from the IN-aP vaccinated mice were localized in the lumen of the 
nasal passages, while particles from IN-caP vaccinated mice were deposited into the 
epithelial cells (Fig. 2c). Overall these data suggest curdlan impacts localization of 
DTaP in the airway.   
Intranasal immunization induces production of anti-PT and anti-FHA IgG in serum 
To determine vaccine induced protection, we utilized an established vaccine and 
challenge protocol.31 CD-1 mice were immunized IN with either IN-aP or IN-caP. These 
groups were compared to pertussis immunizations that are known to be protective: 
DTaP (IP-aP) and whole-cell pertussis (IP-wP) administered intraperitoneally (IP). 
Additionally, we aimed to determine if the effects of curdlan were dependent by route, 
thus we included mice immunized with IP delivered DTaP and curdlan (IP-caP). Lastly, 
we compared the findings to mock vaccinated mice, with IN delivered PBS, or mice IN 
immunized with curdlan only (IN-curdlan). All mice were immunized with 1/12th of the 
antigen load contained in the human vaccine dose. Mice were vaccinated at day 0, then 
received a booster vaccine at day 21. Mice were challenged on day 35 with B. 
pertussis.  
We first sought to determine if an IN delivered DTaP vaccine would induce a systemic 
immune response. To answer this, we performed enzyme-linked immunosorbent assays 
(ELISAs) with serum from vaccinated and challenged mice against B. pertussis antigens 
found in the vaccine: pertussis toxin (PT) and filamentous hemagglutinin (FHA). We did 
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not detect a significant difference in serum IgG titers between collection timepoints at 
days 1 and 3 post challenge (pc) (data not shown). Serum anti-PT IgG titers were 
similar between mice immunized with IP-aP and those immunized through IN 
administration, as no significant differences were determined between IP-aP, IN-aP or 
IN-caP (Fig. 3a). Similarly, we observed a robust titer response to the bacterial adhesin 
FHA in IN vaccinated mice; however, IN-aP serum anti-FHA titer was 7-fold higher than 
IN-caP (Fig. 3b). We next determined if IN administration of DTaP (with or without 
curdlan) would lead to an increased Th1 immune response resulting in a higher ratio of 
IgG2a compared to IgG1 antibodies. Neither route nor adjuvant impacted the ratio of 
IgG2a to IgG1.   
Intranasal immunization induces production of anti-B. pertussis IgA in lung 
In the murine model, recent data has pointed to the importance of IgA and a local 
mucosal immune response in the lung and nasal cavity.32–36 We aimed to measure the 
presence of IgA antibodies in the murine respiratory tissue due to IN immunization. 
Using ELISAs we measured B. pertussis specific IgA titers in homogenized lung tissue 
supernatant and nasal lavage fluid. Interestingly, we detected a robust IgA response in 
the lung only when mice were immunized through the IN route (Fig. 4a). Antigen-
specific IgA response was not observed in mice immunized with curdlan alone. We 
observed detectable IgA B. pertussis-titer in the nasal lavage fluid from both IN-aP and 
IN-caP vaccinated groups, although only IN-aP resulted in a significant increase 
compared to baseline levels (Fig. 4b). The presence of B. pertussis binding IgA in the 
lungs and nasal cavity suggests that IN DTaP is capable of priming a mucosal immune 
response in the upper and lower murine respiratory systems.  
Intranasal immunization decreased pulmonary pro-inflammatory environment 
It has been well established that neutralization of PT and inhibition of bacterial adhesins 
associated with DTaP protection leads to a markedly reduced pro-inflammatory 
environment at the site of infection when compared to a natural infection.17 Conversely, 
challenge in whole-cell protected animals resulted in a severe pro-inflammatory 
response, similar to the natural infection of B. pertussis. 37 We hypothesized that the 
immunostimulatory properties of curdlan would induce a more pro-inflammatory 
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response following challenge with B. pertussis compared to IP-aP. Cytokine 
concentrations were determined from supernatant of lung homogenate at day 3 pc. The 
pro-inflammatory interleukin-6 (IL-6) has been shown to be increased following B. 
pertussis infection of a naïve mouse, while DTaP induced protection drastically 
decreases IL-6 production.31,38 Our results demonstrate a significant reduction of IL-6 in 
the lungs of either IN-aP or IN-caP immunized mice when compared to mock 
vaccinated or IN-curdlan control mice, and are comparable to levels observed in IP 
immunized groups (Fig. 5a). We measured a similar reduction in the Th1 associated 
cytokine IFN-γ in the IN administered groups, IN-aP and IN-caP; although, these levels 
were higher in IN-caP immunized mice (Fig. 5b). We only observed a significant 
increase in the Th2 associated interleukin-5 in IN-wP immunized mice compared to 
mock vaccinated mice (Fig. 5c).  
IN administration of curdlan, and moreover, vaccine administration through the IN route 
regardless of adjuvant has been shown to induce an increased IL-17 response.27,28 
Thus, we hypothesized that we would observe increased levels of IL-17 in mice 
immunized with IN-caP compared to IN-aP or IP-aP. We quantified IL-17A in lung 
supernatant and observed significant increases of IL-17A with the addition of curdlan in 
IP-caP and IN-caP immunized mice supporting our hypothesis (Fig. 5d). Furthermore, 
we observed that IN administration induced a significant increase in IL-17A compared to 
IP immunization. This IL-17A response was lower than the robust IL-17A induced by IP-
wP (Fig. 5d).  
Natural infection with B. pertussis is known to cause severe leukocytosis in the murine 
model39, which can be measured by elevated neutrophils in the peripheral blood. 
Following B. pertussis challenge, we observed that all vaccinated groups ameliorated 
symptoms of leukocytosis; however, only the administration of DTaP either by IP or IN 
administration significantly reduced CD11b+Gr-1hi neutrophils in the peripheral blood 
(Fig. 6a). In the lungs, neutrophils were decreased in IN-aP, IN-caP, and IP-aP 
immunized groups compared to mock vaccinated mice.  We observed a similar finding 
in pulmonary macrophages, although we only determined a significant decrease in mice 
immunized with IN-caP compared to mock vaccinated mice (Fig. 6c). Taken together 
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these data suggest that immunization with DTaP through the IN route reduces the pro-
inflammatory environment of the murine lung during B. pertussis challenge.  
Intranasal immunization reduced respiratory B. pertussis bacterial burden. 
Lastly, we examined the clearance of B. pertussis from the respiratory tract following IN 
immunization. At days 1 and 3 pc, viable bacterial burden was quantified by counting of 
CFU in the lung, trachea, and nasal lavage fluid. We observed a significant reduction in 
viable bacteria recovered from the lung in all immunized groups by day 3 pc; however, 
these changes were not observed at day 1 pc (Fig. 7ab). IN-aP and IN-caP immunized 
mice bacterial burdens were reduced by 99.4% and 99.7%, respectively, compared to 
mock vaccinated mice. This reduction in viable bacterial burden was similar to that of 
mice immunized by IP-aP, an immunization that is known to be effective (Fig. 7b). 
Importantly, this reduction in bacterial burden was not observed following immunization 
with curdlan alone, further suggesting an antigen-specific response. Similar trends were 
observed in the trachea homogenate (Fig. 7cd), and nasal lavage fluid (Fig. 7ef), as all 
immunized groups regardless of IP or IN delivery cleared B. pertussis to the limits of 
detection. In summary, we observed similar clearance of B. pertussis from the 
respiratory tract of mice immunized IN compared to mice immunized with vaccines 
known to be protection delivered by the IP route.  
Discussion 
The natural immune response to B. pertussis is initiated by the colonization of the 
respiratory tract, which leads to a cascade of inflammatory cytokines such as; IL-6, IFN-
γ, TNF-α, and IL-1β leading to increased inflammatory infiltrate consisting of: dendritic 
cells, macrophages, neutrophils, and lymphocytes.31,40 Numerous studies suggest the 
infection is cleared through opsonization of bacteria by the humoral immune response, 
combined with a Th1/Th17 cell-mediated response.15,19,41,42 Additionally, factors 
associated with a local immune responses have been observed in convalescent mice 
following challenge with B. pertussis, such as antigen-specific IgA titers and TRM cells, 




The induction of a protective immune response also has been observed through 
mucosal immunizations against B. pertussis. Oral vaccination with heat-killed B. 
pertussis in newborn infants resulted in the production of B. pertussis specific serum 
and mucosal antibodies; although, this protection was not long lived.43 In the mouse 
model, a live-attenuated IN pertussis vaccine, BPZE1, has shown protection up to one 
year after immunization44, and is in clinical trials.45 Furthermore, BPZE1 vaccine 
produced antigen-specific IgA antibodies in the baboon model, indicative of elicitation of 
mucosal immune response.46 The mucosal immune response was further explored in a 
murine model where BPZE1 induced a protective secretory IgA immune response, and 
the generation of long lasting IL-17 secreting TRM cells in the respiratory system.25 
Similarly, this population of antigen-specific memory cells was found to be expanded by 
an acellular pertussis vaccine (LP-GMP) consisting of a TLR2 agonist and intracellular 
receptor stimulator of interferon genes (STING) agonist, which correlated with the IL-17 
secreting TRM population.47 Promisingly, generation of the IL-17 secreting TRM cell 
population was observed following whole-cell immunization through IP administration; 
however, Tdap administration through the same route did not generate this population.20  
In our study, we demonstrate that by altering the administration route of DTaP 
immunization from IP to IN delivery, the vaccine still induced a protective immune 
response. Using fluorescent labeled DTaP particles we visualized that IN-aP was 
readily detectable (Fig. 1). In vivo imaging analysis demonstrated significantly more 
labeled IN-caP present in the nasal cavity of mice. We detected a higher proportion of 
IN-caP particles compared to IN-aP particles that embedded in the epithelium of the 
nasal turbinates (Fig. 2). These particles had a smaller diameter, which may suggest 
that when the curdlan adjuvant was included DTaP particles were more readily 
phagocytosed by APCs compared to IN-aP particles. Further work examining the lymph 
nodes responsible for antigen priming would be beneficial to determine the role of nasal 
associated lymphoid tissue compared to vaccination of the lung, and trafficking to 
mediastinal lymph nodes. The location of antigen priming following IN immunization 
may play a critical role in the optimization of future human IN vaccines. Determining if 
antigen uptake in the nasal cavity is essential to induce a protective immune response 
would play a key role in the development of a human IN pertussis vaccines.  
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We determined that while IN-caP vaccinated mice had significantly lower detection of 
DTaP in the lungs compared to IN-aP immunized mice that the bacterial clearance was 
similar between the two groups (Fig. 7), suggesting that antigen priming still occurred. 
This was further demonstrated through seroconversion as robust antigen-specific serum 
IgG antibody titers were detected from the two IN immunized groups (Fig. 3). The IgG 
subclass data (Fig. 3) suggest that immunization with IN-aP most likely induces a Th2 
response. Other studies with BPZE1 or LP-GMP adjuvants have observed shifts to Th1 
response using IN route. 20,25  
A key finding of our current study was the production of antigen-specific IgA in the 
respiratory system only in mice that were administered DTaP through IN administration: 
IN-aP and IN-caP (Fig. 4). Another difference between the IN-aP and IN-caP groups 
was the level of IL-17A present in the lung homogenate (Fig. 5). We found that inclusion 
of curdlan in DTaP resulted in higher levels of IL-17A whether administered through IN 
or IP route although IL-17A was highest in IN-caP. These findings correlate with results 
from others suggesting a role of curdlan and IN administration in IL-17 production.27,28 
Together these data demonstrate induction of mucosal immune response specific to B. 
pertussis in the respiratory system.  
In our model, addition of curdlan to DTaP increased IL-17 responses but did not 
improve clearance (Fig. 7). A caveat of the current work is role of aluminum hydroxide 
was not addressed. All IN immunizations consisted of DTaP, which contains alum, 
observations from IN-caP may be affected by the presence of alum. Understanding the 
role of aluminum hydroxide, along with other potential adjuvants in the mucosal immune 
response needs to be further studied. Our work does not address long-term protection 
mediated by IN administration of DTaP or the inclusion of curdlan adjuvant. Future 
studies will focus on the longevity of IN immunity.  
In conclusion, we observed that by altering the route of administration from IP to IN a 
protective response was reproduced, resulting in clearance of the pathogen to limits of 
detection. Furthermore, we determined that IN delivery of DTaP was sufficient to prime 
a local mucosal immune response at site of infection. The inclusion of the adjuvant 
curdlan in DTaP immunization did increase IL-17 production in the lung; however, we 
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did not observe a shift in the type of immune response compared to DTaP alone. In 
humans, DTaP and tdap do not provide perfect protection against pertussis; however, 
there is no clear path forward to the next generation vaccine. It is clear that developing 
a new vaccine will take considerable efforts. Here in our study we observed a surprising 
result, that IN DTaP vaccine could protect mice against B. pertussis. These data cause 
us to wonder if a change in the route of DTaP immunization would be a promising 
booster vaccine strategy.   
Materials and Methods 
Composition and administration of vaccines used in study 
The vaccines administered in the study were prepared no longer than 1 h before 
administration. INFANRIX (GSK) human vaccine (DTaP), and the National Institute for 
Biological Standards and Control WHO whole-cell pertussis vaccine (NIBSC code 
94/532) were used in the study. Vaccines were diluted with PBS to 1/12th of the human 
dose (based on total antigen content). Curdlan (Invivogen, tlrl-curd) was prepared by 
dissolving 50 mg in 2.5 ml sterile purified water. Curdlan preparation was brought into 
solution by adding 100 µl 1N NaOH and vortexing. The curdlan suspension (20 mg/ml) 
was then sonicated for 10 mins and placed in 37°C water bath until administration. 
Curdlan adjuvant was administered at 200 µg per mouse. These experiments were 
conducted in accordance with the National Institutes of Health Guide for the care and 
use of laboratory animals. The protocols used were approved by West Virginia 
University Institutional Animal Care and Use Committees (WVU-ACUC protocol 
1602000797). 
Vaccination of mice for vaccine particle tracking  
CD-1 (outbred; strain code 022) mice aged four weeks were obtained from Charles 
River Laboratories. At five weeks mice were anesthetized with 77 mg/kg ketamine and 
7.7 mg/kg xylazine. Mice were administered 50 µl of vaccine or control, with 25 µl into 
each nostril (IN).  
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Tracking of DTaP in respiratory system  
DTaP vaccine particles were labeled using the Alexa Fluor 660 Protein Labeling Kit 
(Molecular Probes). Briefly, 0.5 ml of DTaP vaccine was added to 50 µl of 1 M sodium 
bicarbonate, then added to Alexa Fluor 660 dye stock. The mixture was incubated for 1 
h at room temperature with agitation. The solution was concentrated by dialysis in 
phosphate-buffered saline overnight to remove unlabeled dye. Labeled vaccine was 
used to immunize mice. At 0, 6, 12 and 24 h post vaccination fluorescent signal was 
measured using an IVIS Spectrum (Xenogen). Mice were anesthetized using 3% 
isoflurane, mixed with oxygen prior to and throughout imaging. The following 
parameters were used: 1) A binning setting of 4 was kept constant for all images, 2) 
each image was quantified using the automatic image setting, 3) fluorescence photons 
were measured using total radiant efficiency of a common region of interest placed on 
the nasal cavity, and 4) measurements were normalized using Living Image (Xenogen 
ver. 2.5). Use of this quantification method accounted for variations in exposure 
between images.  
At 6, 12, 24, and 48 h post vaccination, animals were euthanized to quantify DTaP in 
lungs by flow cytometry analysis. Lungs were removed, and homogenized using 
gentleMACS C tubes (Miltenyi Biotec) with enzymatic lung dissociation kit (Miltenyi 
Biotec, 130-095-927). All samples were blocked using Fc Block (BD), then labelled with 
Alexa Fluor 700 – conjugated CD11b (Biolegend, 101222), DTaP particles were 
detected with Cy5 channel. Following a 1 h dark incubation labeled samples were 
washed, then fixed using 0.4% w/v paraformaldehyde overnight. Samples were 
resuspended in PBS and analyzed on a LSR Fortessa flow cytometer (BD). DTaP 
containing myeloid cells were classified as CD11b+DTaP+ single, live cells.  
Detection of DTaP particles in lung and nasal cavity  
Detection of DTaP particles in the lung and nasal cavity were confirmed using confocal 
imaging. Mock vaccinated and challenged mice were euthanized at 6 h post 
vaccination. Prior to homogenization, the post-caval lobe of the mouse lung was 
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removed. The post-caval lobe was flash frozen in OCT medium (Tissue Plus, Fisher 
Healthcare), using liquid nitrogen. The samples were stored at -80°C until sectioning. 
Sectioned samples (6 µm) were fixed in acetone, then stained with ActinGreen Ready 
Probes (Invitrogen) and NucBlue Ready Probes (Invitrogen), using manufacturer 
protocols.  
Skulls were removed from mouse, and the lower jawbone discarded. The skulls were 
fixed in formalin for 12 h at 4°C, then de-calcified at room temperature for 24 h, before 
samples were embedded in paraffin. Sectioned samples were de-paraffinized and 
rehydrated using xylene, and washes with decreasing ethanol concentrations (100 to 
70%). An antigen retrieval step was performed using citrate buffer, where samples were 
heated to 98°C for 20 mins. Samples were then stained as mentioned above. Samples 
were analyzed for DTaP particles in tissue and airway mucus using a Nikon A1R 
confocal microscope. DTaP particles were quantified using ImageJ (version 1.52a). 
Briefly, the threshold tool was used to select only the fluorescent particles above 
background levels. Then, the threshold adjusted area was quantified using the analyze 
particles tool. Thus, the data is represented as the percentage of fluorescent particles 
per area of the total image field. Three image fields per sample were quantified and 
averaged per mouse.  
B. pertussis strains and growth conditions 
B. pertussis strain UT25Sm148 was used for murine challenge in all experiments. 
UT25Sm1 was cultured as described previously.31 Briefly, UT25Sm1 was cultured on 
Bordet Gengou agar plus 15% defibrinated sheep’s blood (Remel) with streptomycin 
100 mg/ml. B. pertussis was incubated at 36°C for 48h, then transferred to modified 
Stainer-Scholte liquid medium49, without the cyclodextrin, heptakis. Liquid cultures were 
incubated for 24 h at 36°C, with shaking until reaching an OD600 of ~0.6, at which time 





Vaccination and B. pertussis challenge 
IN immunized mice received 50 µl of vaccine as described above. IP immunized mice 
received 200 µl of vaccine injected into the peritoneal cavity. IN and IP immunized mice 
received the same antigen dose of 1/12th. Mice received a boost of the vaccines with 
the same concentrations twenty-one days after initial immunization. At thirty-five days 
post initial vaccination, mice were challenged with 2x107 CFU B. pertussis administered 
in 20 µl through nostrils. At days 1 and 3 pc mice were euthanized, blood and 
respiratory tissue were isolated as previously described.31 
Serological analysis of B. pertussis specific antibodies 
Serological responses specific to B. pertussis antigens were quantified by ELISA. High-
binding microtiter plates were coated with PT (50ng/well)(LIST Biologicals) and FHA 
(50ng/well)(Enzo Life Sciences), as described in Boehm et al.31 Serological responses 
against UT25Sm1 were cultured to an OD600 of 0.24 and microtiter plates coated with 
50µl of bacteria per well. Bound antibodies were detected using goat anti-mouse IgG, 
IgA, IgG2a, and IgG1 antibody conjugated to alkaline phosphatase (Southern Biotech). 
Positive antibody titers were determined using a baseline set at two times the average 
of blanks.  
Quantification of pulmonary and blood APCs 
To determine cell types infiltrating the lung and leukocytes present in peripheral blood, 
single cell suspensions from the tissues mentioned above were prepared, as described 
previously.31 Briefly, lung tissue was homogenized by Dounce homogenizers, filtered 
with a 100 µm filter, and red blood cells were lysed for 2 min at 37°C (Pharmlyse). Cell 
populations were determined using antibodies to cell surface markers: PE-conjugated 
GR-1 (BD, 553128), Alexa Fluor 700-conjugated CD11b (Biolegend, 101222), 
PerCP/Cy5.5-conjugated F4/80 (Biolegend, 123128). Neutrophils and macrophages 





Lung homogenate cytokine analysis 
To quantify inflammatory cytokines at the site of infection, lung homogenate supernatant 
was prepared and stored at -80°C, as described in prior work.31 Quantitative analysis of 
cytokines was performed using Meso Scale Discovery cytokine kits: V-PLEX pro-
inflammatory panel (K15048D) and IL-17A V-PLEX (K152RFD), per the manufacturer’s 
instructions.  
Statistical Analysis 
Experiments in the study were performed with 3 to 8 biological replicates. Data were 
analyzed using GraphPad Prism 7. Comparisons between groups were performed using 
one-way analysis of variance (ANOVA) with Dunnett’s and Tukey’s post hoc tests. 
Comparisons between groups with or without curdlan were analyzed by two-tailed 
unpaired t-test, when applicable multiple T-tests with Holm-Sidak post hoc test were 
applied to curdlan inclusion groups.  
Data Availability  
Data for all figures are available upon reasonable request to the corresponding author.  
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Figure 1: Localization of acellular pertussis vaccine in the upper and lower 
respiratory system after IN vaccination. 
 
Figure 1: Localization of acellular pertussis vaccine in the upper and lower 
respiratory system after IN vaccination. (a) Schematic of vaccine tracking protocol. 
CD-1 mice were intranasally vaccinated with either fluorescent DTaP alone (IN-aP) or 
fluorescent DTaP with curdlan (IN-caP). Vaccine particle deposition in the lungs and 
nasal cavity was measured at 0, 6, 12, 24, and 48 h after immunization. (b) 
Representative images of nasal cavity fluorescence at 6, 12, and 24 h. The region of 
interest used for fluorescence quantification is shown in blue. (c) Fluorescence 
measurements normalized to PBS control at 6, 12, and 24 h. Results shown as mean ± 
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SEM of total radiant efficiency, *P < 0.05. P values were determined by multiple T-tests 
with Holm-Sidak post hoc test between IN-aP and IN-caP vaccinated mice. (d) 
Representative plots showing live, single cells that are CD11b+DTaP+. (e) Flow 
cytometric analysis of CD11b+ cells from the lung that contain or are bound to DTaP 
particles at 6, 12, 24, and 48 h post immunization. Results shown as mean ± SEM, *P < 
0.05, *** P < 0.001, ****P < 0.0001. P values were determined by one-way ANOVA with 





Figure 2: Acellular pertussis vaccine particle localization altered by curdlan 
adjuvant. 
 
Figure 2: Acellular pertussis vaccine particle localization altered by curdlan 
adjuvant. (a) Representative images of flash frozen lung sections 6 h after 
immunization with IN-aP or IN-caP. Fluorescent particles were detected using a 660 
laser, samples were counter-stained with NucBlue (blue) and ActinGreen (green). (b) 
Fluorescent DTaP particles were quantified by determining the percentage area of 
particles per field of view. (n=3-4, with averages of 3 images per lung). Results are 
shown as mean ± SEM, *P < 0.05. (c) Representative images of paraffin embedded 
nasal cavity sections 6 h after immunization with IN-aP or IN-caP. (d) Fluorescent DTaP 
particles quantified by determining the percentage area of particles per field of view. 
(n=3-4, with averages of 3 images per lung). P values were determined by one-way 




Figure 3: Intranasal immunization induces production of anti-PT and anti-FHA IgG 
in serum. 
 
Figure 3: Intranasal immunization induces production of anti-PT and anti-FHA IgG 
in serum. ELISAs were used to compare serological responses from mice immunized 
through IN or IP routes to mock vaccinated mice. Total IgG serum antibody titers from 
immunized and challenged mice were quantified against (a) PT and (b) FHA at day 3 
pc. Serum (c) IgG1 and (d) IgG2 antibody titers against B. pertussis were compared to 
mock vaccinated mice at day 3. Results shown as mean ± SEM, **P < 0.01, *** P < 
0.001, ****P < 0.0001. P values were determined by one-way ANOVA with Dunnett’s 
post hoc test compared to mock vaccinated mice.  
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Figure 4: Intranasal immunization induces production of anti-B. pertussis IgA in 
respiratory system. 
 
Figure 4: Intranasal immunization induces production of anti-B. pertussis IgA in 
respiratory system. ELISAs were performed using (a) lung homogenate supernatant 
and (b) nasal lavage fluid from vaccinated and challenged mice at day 3 pc. IgA titers 
were determined against whole-cell B. pertussis. Results are shown as averages of two 
independent experiments, represented on a log10 scale for lung and linear scale of 
nasal lavage with mean ± SEM (n = 4-8). ****P < 0.0001. P values were determined by 




Figure 5: Intranasal immunization decreased pulmonary pro-inflammatory 
cytokines during challenge. 
 
Figure 5: Intranasal immunization decreased pulmonary pro-inflammatory 
cytokines during challenge. Analysis of cytokines from supernatant of lung 
homogenate at day 3 pc. Cytokines (a) IL-6, (b) IFN-γ, (c) IL-5, (d) IL-17A were 
quantified by electrochemiluminescence assay. Results shown as mean ± SEM, *P < 
0.05, **P < 0.01, *** P < 0.001, ****P < 0.0001. P values were determined by one-way 
ANOVA with Dunnett’s post hoc test compared to mock vaccinated mice. Bars 
connecting groups indicate values determined by two-tailed un-paired t-test. Upper and 
lower limits of detection shown as dash or dotted lines, respectively if data points 




Figure 6: Intranasal immunization reduced neutrophil and macrophage 
accumulation in the lung and circulating neutrophils after B. pertussis challenge.  
 
Figure 6: Intranasal immunization reduced neutrophil and macrophage 
accumulation in the lung and circulating neutrophils after B. pertussis challenge. 
(a) The percentage of live, CD11b+Gr-1hi neutrophils from a single cell suspension of 
the peripheral blood. Percentages of (b) CD11b+Gr-1hi neutrophils and (c) 
CD11b+F4/80+ macrophages in single cell lung homogenates. Results shown as 
means ± SEM, *P < 0.05 **P < 0.01, *** P < 0.001, ****P < 0.0001. P values were 
determined by one-way ANOVA with Dunnett’s post hoc test compared to mock 




Figure 7: Intranasal immunization reduced respiratory B. pertussis bacterial 
burden 
 
Figure 7: Intranasal immunization reduced respiratory B. pertussis bacterial 
burden. Analysis of bacterial burden was determined at days 1 and 3 pc. Bacteria were 
quantified by counting of serially diluted CFUs following immunization and challenge. 
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CFU counts were determined from lung homogenate (A and B), trachea homogenate (C 
and D), and nasal lavage fluid (E and F). Results are mean ± SEM (n = 4 – 8, with 4 
averaged technical replicates) from two independent experiments. *P < 0.05, ** P < 
0.01, *** P < 0.001, ****P < 0.0001. P values were determined by one-way ANOVA with 
Tukey’s post hoc test compared to mock vaccinated mice, or between connected 
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Chapter 5 - Discussion  
 
Pertussis is a bacterial disease that only exists in the human population. Thousands of 
years of evolution have optimized B. pertussis to the microenvironment of the human 
respiratory system. This is understandably so, Homo sapiens are a species that fit the 
niche of B. pertussis. We are a social species that live in close quarters thereby 
permitting the dissemination of bacteria that spreads through respiratory droplets. 
Human offspring are born without fully developed immune symptoms, leaving them 
more susceptible compared to their adult counterparts. When one individual becomes 
sick others congregate to care for that person, more so in the case of an infant. Thus, 
giving rise for bacteria to spread to a new host and continue the infectious cycle.  
However, the same forces of evolution that lead to the specialized niche of B. pertussis 
in the human respiratory system, confined the bacteria to life in only one host reservoir. 
As, scientists this is a flaw we can exploit, and have done so in the past. When Edward 
Jenner developed the smallpox vaccine, he initiated a mechanism of eradication of the 
disease by protecting the only species capable of spreading the smallpox virus. In 1980, 
natural occurring smallpox was declared eradicated through years of widespread whole-
cell vaccination 1. It may now be surprising to some that pertussis, now classified as a 
re-emerging infectious disease by the CDC in the United States, was once a proposed 
target for eradication in the 1970s 2,3. Like smallpox, pertussis incidence was well-
controlled though widespread immunization with a wP vaccine 4. The resurgence of 
pertussis began to occur in the US in the mid-1980s, and cases have remained well 
above that level since. This increase in cases coincides with the switch to aP in 
developed countries. One of the hypotheses on why this increase is occurring is that aP 
immunization inhibits the toxin-mediated symptoms the disease, but not colonization of 
the bacteria. This realization has renewed interest in the development of a vaccine that 
can inhibit colonization of B. pertussis, with the ultimate goal of reducing the number of 
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cases to levels seen in the wP era, thereby re-opening the door the possible eradication 
of pertussis.  
A major long-term goal of this work was to make progress on developing a vaccine that 
improved upon the shortcomings of current acellular pertussis vaccines covered in 
chapter 1. In this work we demonstrate the protective effects of neutralizing ACT, a key 
virulence factor of B. pertussis, through an IP administered vaccine. We then explored 
another route of administration, finding that IN administration of DTaP induced a 
systemic protective response and a mucosal immune response in the respiratory tissue. 
This work demonstrates that the neutralization of toxins achieved through parenteral 
vaccination can be reciprocated by vaccinating the nasal cavity directly, thereby 
inhibiting PT before it disseminates beyond the respiratory system. This work suggests 
that the mechanisms of protection in either of the vaccine strategies should be further 
elucidated and incorporated into future pertussis vaccines.  
Lessons learned from Ne Cre luc mouse model 
The mouse model has been used for vaccine optimization since the development of wP 
vaccines5. Naturally, along the way, improvements to the mouse model have enabled a 
better understanding of vaccine-induced protection. In setting out to improve the current 
vaccines, we aimed to design experiments that were capable of showing this 
improvement. In a landmark study, Guiso et al. developed the intranasal pertussis 
challenge murine model 6. In that study, the authors found similar protection from a 
dose of 1/4th and 1/10th of the human antigen concentration compared to a group 
receiving the full human dose 6. We based our initial experiments on these vaccine 
concentrations. 
One of the aims of chapter 2, was to use the NeCre luc, neutrophil reporter mouse 
model to trace the real-time kinetics of the neutrophil response between DTaP and wP 
immunized mice. In these experiments, we immunized the reporter mice with 1/5th the 
human dose of DTaP and wP. At this high vaccine dose, we observed an aggressive 
pro-inflammatory response following B. pertussis challenge of wP immunized compared 
to DTaP immunized mice (Chap. 2, Figure 4,5). Transcriptional analysis of the lung 
during early and late phases of an acute infection revealed the highest pro-inflammatory 
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associated gene changes in the wP-primed mice. Strikingly, we observed the highest 
levels of neutrophil recruitment occurred after the bacterial burden was cleared to limits 
of detection, while in comparison to the DTaP-primed group the percentage of 
neutrophils in the lung had returned to baseline levels following clearance of the 
infection (Chap. 2, Figure 3,7). The intensity of the neutrophil response may have 
overwhelmed this group, as we observed severe morbidity in wP-primed mice at day 6, 
which required euthanasia. The clearance of the pathogen prior to the recruitment of 
neutrophils suggests that morbidity was due to the immune response elicited. The 
NeCre luc model provided a novel method of visualizing the spatiotemporal localization 
of neutrophils in immunized mice. In these studies, we compared the quantification of 
neutrophils using the luminescence of the luciferase-induced reporter to the 
quantification of neutrophils through flow cytometry. We determined that using flow 
cytometry we could accurately depict the neutrophil response over time, with the benefit 
of using a more standard mouse strain. The NeCre luc reporter mouse may be the most 
beneficial to those study the neutrophils recruited to a concentrated site, such as those 
studying the role of innate immune cells in the tumor microenvironment, or acute topical 
infections. In completing this aim of the study, we concluded that a wP vaccine 
concentration of 1/5th the human dose may be too high to properly characterize the 
response of neutrophils overtime.  
A second aim of the NeCre luc study was to determine the protective role of a purified 
toxoid of ACT, RTX, as a single antigen vaccine administered with aluminum hydroxide. 
We hypothesized that antibodies generated against the antigen would neutralize the 
toxin activity of ACT, thereby inhibiting the ACT mediated suppression of neutrophils 
discussed in chapter 1. RTX immunization generated a strong IgG antibody response 
specific to the RTX antigen; however, RTX as a single antigen vaccine alone was not 
protective because we did not observe a reduction of bacterial burden in these 
experimental conditions. Immunization with only RTX would not address PT, thus in 
these experiments, PT would still be active. Thereby, inhibiting neutrophil and 
macrophage chemotaxis to the site of infection. We reasoned that while RTX as a single 
antigen did not induce protection the benefits of neutralizing ACT may be more evident 
when PT is neutralized as well. In this scenario when macrophages and neutrophils 
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were recruited to the lung, their bactericidal activity would not be inhibited. This 
realization caused us to re-craft our approach to a vaccine where we could study the 
synergistic effects of neutralizing ACT, along with the protective activity of DTaP 
vaccines.  
Optimization of the mouse model 
In chapter 3, we built upon our observations learned in the NeCre luc immunization and 
challenge model. In these experiments we aimed to determine the protective effects of 
incorporated RTX in a DTaP vaccine. In initial experiments, we included the RTX toxoid 
discussed in chapter 2, into a 1/5th human dose of DTaP. In these results, we measured 
an antigen-specific immune response but did not observe an increase in protection 
compared to DTaP immunized mice. It occurred to us, that the use of such a high dose 
of vaccine in the mouse model is not relevant to the dose that is administered to 
humans. This reflection led us to the idea that to establish a relevant model, we needed 
to determine the lowest vaccine dose that induced protection. We proposed performing 
a vaccine dose titration to find this dose in mice. This would lead to a vaccine dose that 
would: 1) more accurately depict the vaccine concentration administered to humans, 
and 2) establish a sub-protective dose to incorporate future vaccine antigens, such as 
RTX to determine protection. In chapter 3, we determined that 1/40th of the human dose 
of DTaP vaccine protected mice while, the 1/80th dose did not. We were then able to 
add RTX to 1/80th human dose DTaP vaccine. This finding does correlate with others 
suggesting that 1/50th the human dose of DTaP was protective in mice, as we identified 
1/40th the human dose to be the lowest-protective dose by our 2-fold titration 7,8. 
Defining this sub-optimal dose is crucial in re-thinking the design of DTaP/TdaP 
immunizations. DTaP/TdaP are safe vaccines which protect individuals from classical 
pertussis. Therefore, if a potential vaccine is to replace either of these standards, the 
candidate vaccine would need to perform better, in addition to protecting an individual 
through a different mechanism. Defining a sub-optimal vaccine dose from which, 
synergistic effects of potential vaccine antigens can be observed, gives researchers a 
mechanism to demonstrate increased vaccine potency.  
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Incorporation of RTX with DTaP 
In chapter 1, we discussed the immunomodulatory activity of ACT. ACT increases 
intracellular cAMP of macrophages and neutrophils recruited to the site of infection. The 
levels of cAMP suppress the bactericidal activity of the macrophages and neutrophils 
including phagocytosis, oxidative burst and NET formation in neutrophils 9–11. We, along 
with others hypothesized that neutralizing ACT through vaccination would increase 
vaccine efficacy of current acellular vaccines 12,13. In chapter 3, we discussed the 
protective effects of including RTX into a DTaP vaccine. In these studies, we immunized 
mice using the outbred CD-1 mouse line. Incorporation of RTX into the DTaP vaccine 
resulted in the production of anti-ACT binding antibodies, that were capable of 
neutralizing ACT activity against murine macrophages (Chap. 3, Fig. 1,3). These in vitro 
observations translated to in vivo vaccine-mediated protection, as we observed 
decreased bacterial burden and pro-inflammatory responses with the inclusion of RTX 
compared to DTaP alone (Chap. 3, Fig. 2). Defining the sub-optimal vaccine dose was 
critical to this experiment. We observed synergic effects of RTX at 1/80th human vaccine 
dose; while those effects were masked at the higher doses of DTaP (Chap. 3, Fig. 1). 
We observed that the inclusion of RTX into the DTaP vaccine increased vaccine-
induced protection when compared to DTaP alone. We did not observe an increase in 
Th1 associated cytokines, suggesting that DTaP with RTX did not alter the vaccine-
induced immune response from the Th2 promoting DTaP. Overall, the immune 
response to B. pertussis was similar to DTaP induced protection. We observed strong 
IgG responses to the B. pertussis toxins, and a reduction in the pro-inflammatory 
response evident by a reduction in pro-inflammatory cytokines, macrophages, and 
neutrophils in the lung when RTX was included in DTaP compared to DTaP alone. The 
data suggests that the enhanced protection was due to the production of anti-ACT 
neutralizing antibodies. However, due to the nature of the Th2 response observed from 
DTaP with RTX, it seems unlikely that the inclusion of an additional antigen alone would 
increase the duration of protection compared to DTaP. We hypothesized that to alter the 
T-helper cell response and increase the duration of protection, we needed to continue 
investigating ways to promote a cell-mediated immune response.  
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The work performed in this dissertation was completed in the mouse model of pertussis. 
The use of animal models has vastly contributed to the understanding of the 
pathogenesis and the immune response elicited against B. pertussis and other 
Bordetella species. Mice and humans generate similar pro-inflammatory T-cell 
responses and antibody profiles upon infection with B. pertussis 14. In chapters 3 and 4, 
we utilized only female CD-1 outbred mice, compared to inbred mouse strains. The use 
of inbred mouse strains increases the reproducibility of experiments compared to 
experiments using outbred mice strains. Outbred strains were used in our experiments 
specifically to increase the genetic variability, to model the genetic variability seen in the 
human population. As a result, we observed increased variation in experiments 
performed using CD-1 mouse lines compared to inbred strains such as BALB/c (data 
not shown). In addition to genetic variability between mouse strains, future experiments 
should utilize both male and female sexes. Epidemiology pertussis studies have found a 
higher proportion of pertussis in female patients compared to male counterparts15. 
Classically, females are more susceptible to upper respiratory infection compared to 
males16 . However, females are known to induce greater innate immune cell activation 
and stronger humoral responses than males in both human and mice 17. It is possible 
that male mice may not reciprocate the strength of the immune response observed 
following immunization and challenge of female mice. In future experiments the 
incorporation of both male and female mice can address this concern.  
Importance of a Mucosal Response against B. pertussis  
In our studies, we found it interesting that bacteria were cleared earliest in the lungs 
compared to nares and trachea (Chap 3., Fig. 2). We began to investigate the possibility 
of a mucosal pertussis vaccine that could prime the respiratory tract directly. We 
hypothesized that by administering the vaccine intranasally, the primed local immune 
response could neutralize the pathogen before the impairment of the innate immune 
response by toxins of B. pertussis. 
Mucosal-vaccine induced immunity poses the benefit of preventing the establishment of 
an infection prior to PT entering the circulatory system. Conversely, parenteral pertussis 
vaccine-induced immunity requires circulating PT to encounter memory T and B cells 
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present in the draining lymph nodes, then mount a secondary immune response to the 
infection. It is well documented that natural infection of a human patient confers long-
term protection. While the human mucosal immune response is yet to be characterized, 
B. pertussis-specific IgA antibodies suggest a role for mucosal protection 18 . Evidence 
in support of a role of a mucosal immune response against B. pertussis from the 
baboon model find that convalescent baboons and mice clear the infection significantly 
earlier than any parental vaccine, wP or aP 19,20. The natural response to pertussis was 
discussed in chapter 1, but is known that natural infection with B. pertussis induces a 
strong mucosal response, which correlates to sterilizing immunity 21,22. Wendelboe et 
al., reviewed published data comparing the duration of protection from acellular and wP 
pertussis vaccines to convalescent protected individuals 23. The authors determined that 
humans who were previously infected with B. pertussis were protected up to 20 years, 
compared to up to 12 years following wP immunization, and 4 years from those 
immunized with various DTaP vaccines 23. We posed the question, “If we can mimic an 
infection with an acellular vaccine, could we induce a protective response?” Now, there 
are clear differences between an infection with pathogenic bacteria and a vaccine 
composed of purified protein. For one, not only does the pathogen express thousands 
of potential PAMPS, but the colonization of the respiratory tract produces additional 
damage-associated molecular patterns (DAMPS) that would be not produced following 
intramuscular acellular immunization. PAMPS/DAMPS associated with the natural 
infection recruit cells of the innate immune system to the infection, leading to 
phagocytosis of the bacteria, and ultimately antigen presentation of the many potential 
antigens to naïve T cells 24,25. This is unlikely to occur with a parenterally administered 
subunit vaccine, where a humoral response is generated against the specific antigens 
contained in the vaccine.  
As discussed previously, there has been promising pre-clinical success with a live-
attenuated B. pertussis intranasal vaccine, BPZE1 26–29. BPZE1 is a highly attenuated 
strain, lacking production of three functional virulence factors of B. pertussis: PT, 
dermonecrotic toxin, and tracheal cytotoxin 29. The strain is not pathogenic but is able to 
colonize the respiratory tract, before eventually cleared. The vaccine strain is protective 
in mice and baboons, and in mice has been shown to induce a Th1 mediated response 
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26,29,30. Recently, it has shown that immunization with this strain resulted in production of 
IL-17, IgA antibodies, and the TRM population in the nares of mice, each of these factors 
was shown to play a role in protection 28. The work performed by Solans et al. further 
demonstrates the importance of a local mucosal immune response in reducing 
colonization of the respiratory tract, and of generating a pro-inflammatory cell-mediated 
response in long-term protection against B. pertussis.  
Intranasal DTaP induced a protective immune response 
In chapter 4, we changed the route of vaccine administration from an intraperitoneally 
administered vaccine to an intranasally administered vaccine. In doing so, going from a 
vaccine response that was well characterized to the relativity unexplored vaccine route: 
mucosal vaccination 8,22,31–33. One of the challenges we were faced with was the 
number of potential antigens that encounter the nasal-associated lymphoid tissue 
(NALT) on a daily basis 34. Data from orally administered vaccines demonstrates that 
gut-associated lymphoid tissue promotes tolerance over immunogenicity 35. We 
reasoned that because the alum adjuvant is not optimal for mucosal vaccination, that IN 
administered DTaP may not induce enough inflammation to induce a protective immune 
response 36. It may be that in order to induce a systemic response, the vaccine would 
have to stimulate a pro-inflammatory response upon vacation, as was the case in the 
BPZE1 vaccine discussed above. To increase the pro-inflammatory properties of DTaP, 
we supplemented DTaP with the β-glucan curdlan. Curdlan was an attractive candidate 
as it had been previously tested as an intranasal adjuvant, and has been shown to 
promote a Th1/Th17 immune response in vitro and in vivo 37–40. Specifically, curdlan 
binds to the fungal receptor dectin-1 expressed on the surface of DCs, found at high 
concentrations in the NALT, along with macrophages 41,42. Also, lining the mucosal 
surface are microfold (M) cells, which specialize in phagocytosis of macromolecules, 
viruses, and bacteria. On the basal surface of the M cells are intraepithelial pockets, 
which can contain DCs, T and B cells 34,41. APCs from the mucosal tissue can then track 
to the draining lymph nodes, where they activate B cells, ideally inducing a systemic 
and mucosal immune response 34.  
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Mucosal immunizations provide a unique vaccination strategy because antigen priming 
can occur in multiple lymphoid organs and tissues. Furthermore, the appropriate tissue 
may change based on the type of vaccine and/or depending on the pathogen. In the 
case of pertussis, the appropriate tissue for vaccination is yet to be determined and all 
human vaccines are provided by IM injection. Since we aimed to vaccinate the airway, 
we thought it was necessary to track where the vaccine is going during IN immunization. 
In chapter 4, we accomplished this by fluorescently labeling the DTaP vaccine particles. 
In Chap. 4, Fig 1,2, we observed that the majority of DTaP alone (IN-aP) was deposited 
in the lung while DTaP with curdlan (IN-caP) was found mostly in the nares. Ultimately, 
we did not determine a difference in B. pertussis-specific IgG antibody titers present in 
the serum or IgA antibodies in the lung supernatant. Suggesting that whether antigen 
uptake occurred in the lungs or the nasal cavity, IN immunization elicited a systemic 
response not  
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Figure 1: Proposed model of IN-caP induced protection.  
The fungal polysaccharide curdlan is administered as a semi-gel state at a neutral pH. The 
immunostimulant properties of the β-glucan elicit a Th1/Th17 response. Curdlan binds to DCs through 
the dectin-1 receptor. The dectin-1 signaling pathway induces the non-canonical expression of NF-κB, 
promoting a Th1/Th17 immune response. Curdlan as an adjuvant induced antigen-specific serum IgG 




significantly different than IP. Furthermore, the inclusion did not further reduce the 
bacterial burden of the respiratory system (Chap. 4, Fig. 7). In these experiments we 
demonstrated that the IN administration of DTaP could induce the production of IgA 
antibodies. It is then possible that antibodies found in the lung homogenate and nasal 
lavage fluid could be neutralizing PT at the site of infection. Thus, leading the lower 
levels of pro-inflammatory cytokines found in the lung homogenate. These data suggest 
that IN-aP immunization alone is capable of generating a systemic and mucosal 
immune response.  
Role of curdlan in a mucosal immune response 
Curdlan has been shown to induce Th17 responses when administered through the 
intranasal route 37. In this study, we determined the highest amount of IL-17A in the 
lungs of groups that were IN immunized, with the DTaP with curdlan inducing the 
highest levels (Chap. 4. Fig. 5d). However, while significant, this response is not as 
strong as was observed following wP-induced IL-17A response as we demonstrated in 
this and other studies. What is interesting is that when we measured DTaP vaccine 
particles in the nares of the mice, more appeared to be embedded in the nasal cavity 
epithelium with IN-caP than compared to more particles in the lumen with IN-aP (Chap. 
4, Fig. 2c). Furthermore, the particles from IN-caP had a smaller, more, particulate 
appearance. It may be that curdlan played a role in antigen uptake in the nasal cavity. In 
this study, we only observe a correlation between the smaller particles in the mucosal 
tissue and the increased IL-17A production found in DTaP with curdlan. Future 
experiments will be needed to further elucidate this mechanism. One of the caveats of 
this experiment is that we did not identify the cell types that contained or bound vaccine 
particles in microscopy imaging. It is possible that when DTaP was administered with 
curdlan, the vaccine particles were more likely to be phagocytosed by M cells of the 
mucosa, which are known to endocytose particulate antigens 43. Thereby, it may be 





Future directions in pertussis vaccine development 
 
In this work, we demonstrated the induction of a protective response from an 
intranasally administered vaccine. This work suggests that mucosal immunization with 
the current DTaP vaccine alone produces a systemic immune response and the 
production of IgA antibodies and IL-17A in the respiratory tract. The next question to 
answer is, what is the mechanism of protection elicited from DTaP and DTaP with 
curdlan? In order to develop effective mucosal pertussis vaccines, a better 
understanding of the mucosal immune response to B. pertussis is needed.  
Identification of target vaccine tissue 
The use of fluorescent vaccine particles gave us the ability to track the vaccine in the 
nasal cavity of mice. Presumably, antigen uptake and presentation could be explored 
using a similar experimental design that could identify M cells and continued tracking of 
the vaccine particles. An experiment of this nature would also help to answer the 
question of appropriate tissue targeting. In our experiments, a volume of 50 µl of the 
vaccine was administered intranasally. This volume is known to reach the lungs in the 
mice, while the use of lower volumes results in the majority of detection of bacteria or 
labeled protein accumulating in the upper respiratory system 44,45. Thus, in the mouse 
model, this administration route has the potential of antigen priming occurring in the 
upper and lower respiratory system, as the dose is exposed to the two tissues. In 
performing the experiment mentioned above, one could elucidate whether either of the 
tissues plays a role in establishing the mucosal immune response. Additionally, upon 
antigen presentation either to TRM in the respiratory tissue or draining lymph node one 
would expect to measure a spike in pro-inflammatory cytokines following the 
immunization. Using a B. pertussis outer membrane vesicle vaccine (OMV) Raeven et 
al., measured the induction of a moderate pro-inflammatory response compared to wP 
immunization 46. This response was measured in serum 4 hours post-boost 
immunization, resulting in significant increases of G-CSF, KC, CXCL10, IL-6, IL-1β, IL-
5, MCP-1. Similarly, Warfel et al., measured increases of IL-6, IL-1β, IL-23, G-CSF, 
MCP-1, and MIP-1x from nasopharyngeal washes from baboons following challenge 
with B. pertussis 47. As early as 48 hours after challenge levels of IL-6 and G-CSF were 
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significantly increased compared to negative control baboons. It may be beneficial to 
study the production of cytokines and chemokines produced early in the immune 
response to B. pertussis infection in the context of immunizations. The rationale being, 
that the production of cytokines associated with antigen presentation measured in NALT 
tissue or the draining lymph nodes could further elucidate the generation of the B. 
pertussis-specific immune response. In the mouse model it may not seem to be of 
consequence, but in human applications targeting of the appropriate tissue depends on 
the delivery method used in vaccination. In humans, nasal droppers, nasal sprays, 
nebulizers, and dry powders have been used for delivery of vaccines to the upper 
respiratory tract 34,48. Vaccination of the lower respiratory system requires the use of a 
nebulizer-generated small-particle liquid or powder vaccines that are capable of 
reaching the lungs 34,49. Understanding the differences in the immune response elicited 
between antigen priming occurring in either tissue will be crucial for the translation to 




Figure 3: Summary of proposed mucosal immune response to B. pertussis.  
During the primary infection with B. pertussis innate immune cells are recruited nasal cavity. Bacteria 
and potential antigens can be phagocytosed by DC cells embedded in the epithelium layers, once 
activated DCs migrate to the draining lymph nodes where they present antigen to the naïve T cells. 
Specialized lymphoid tissue in the nasal cavity, NALT, line the nasal cavity. These NALT tissues contain M 
cells that endocytosis bacteria or particulate antigen and translocate the organism or macromolecule to 
DCs, B and T cells present on the basal surface of the cells. Antigen priming of naïve T cells differentiate 
to Th1, and Th17 effector cells in the draining lymph nodes or NALT tissue. TFH cells activate B cells which 
promote B. pertussis antigen specific IgG and IgA antibodies. Effector Th1 and Th17 migrate to 
respiratory tract, a subset of CD4 memory effector cells are retained in the tissue as TRM. Effector 
Th1/Th17 cells recruit macrophages and neutrophils phagocytose the now opsonized bacteria. Upon 
secondary infection by B. pertussis TRM recognized the pathogen proliferating to effector Th1 and Th17 T 
cells, secreting IL-17 and IFN-γ. IL-17-secreting T cells have also been shown to play a critical role in the 
secretion of SIgA antibodies. The activation of the mucosal memory response immediately recruits 
macrophages and neutrophils to the infection, which with help from SIgA antibodies can efficiently 
phagocytosis B. pertussis. Thus, limiting the extent of the secondary infection. Figure adapted from Wilk 
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et al.50 Solans and Locht51 and Neutra and Kozlowski41. PMN-polymorphonuclear neutrophils, Mφ-
macrophage, B- Naïve B cells, T-Naïve T cell, NALT-Nasal associated lymphoid tissue, Th17-Th17 T helper 
cell, Th1-Th1 T helper cell, DC-Dendritic cell, TFH -T follicular helper cell, TRM TH17- Tissue resident 
memory Th17 cell, TRM TH1- Tissue resident memory Th1 cell, Mem B- Antigen-specific Memory B cell 
Importance of nasal cavity specific analysis 
The findings presented in chapter 4 suggest that intranasal immunization is a viable 
strategy that needs to be further investigated. We and other groups are studying 
intranasal immunization against B. pertussis 28,52. It is clear that to continue down this 
avenue of research, the correlates of protection of the local mucosal immune response 
need to be fully characterized. Until recently, the majority of pertussis research has 
focused on characterizing the immune response in the lower respiratory tract in the 
mouse model; however, except in rare cases, B. pertussis infects the upper respiratory 
system 53. Wilk et al., have begun to focus on the immune response and bacterial 
clearance of the nasal cavity, specifically 8. This approach involves the intricate process 
of removal of the epithelial lining for analysis by flow cytometry and bacterial burden. 
Through this method, they have identified the role of IL-17 in promoting nasal cavity 
SIgA and IL-17-secreting TRM cells in vaccine-induced protection8,28. The role of TRM in 
protection against B. pertussis is yet to be fully understood. Data exists that correlates 
the presence of the TRM cell population in the nasal cavity to long term protection, 
specifically in the nasal cavity of mice 52. Currently, it is suggested that the production of 
IFN-γ and IL-17 are essential to clearance in the nasal cavity, and data have shown the 
production of IFN-γ and IL-17 from TRM and γδ T cells in the nares 8,28,54. However, the 
mechanism of clearance remains to be discovered.  
A closer examination of the nasal cavity, the bacterial burden in the nares can be more 
accurately depicted. The nasal cavity clearance data included in this dissertation, along 
with the work of others, quantify bacteria burden present in nasal lavage fluid 14. This 
method quantifies bacteria that were removed from the upper respiratory system by the 
lavage; however, it is apparent that a significant portion of the bacteria remain 52. In 
moving forward, techniques to more accurately quantify the bacterial burden in the 
nares will be necessary to establish true sterilizing immunity. The importance of 
clearance in the nares is emphasized by our findings that the infection in the lung was 
cleared, but not nasal cavity. The different anatomy and microenvironments of the lung 
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and of the upper respiratory tract may play a role in bacterial adherence and 
colonization 55. Findings by Conover et al. suggest that B. pertussis can potentially form 
biofilms in the mouse nose, while they did not in the mouse lungs; however, this is yet to 
be shown by other groups 56. The authors found that the BPS polysaccharide of B. 
pertussis was responsible for colonization and promoted biofilm formation in the nasal 
cavity; but not in the lungs. Additionally, FHA has also been shown to promote biofilm 
formation and is critical for biofilm formation in the mouse nose and trachea 57. 
Understanding of differences between the lower and upper respiratory system will be 
essential in determining why B. pertussis infection persists in the nasal cavity compared 
to the lower respiratory system. To observe these differences, experiments capable of 
addressing the mechanisms behind the immune responses between the tissues are 
needed. 
In wP immunized and naïve mice we have measured robust recruitment of 
macrophages and neutrophils to the lungs (Chap. 2, Fig. 4, Chap. 3, Fig. 5,6, Chap. 4, 
Fig. 6). In these experiments, we determined the numbers of cells recruited to the 
infection; we did not address their functionality. It is possible that due to the Th1 
response induced in convalescent or wP vaccine-induced protection APCs may more 
efficiently phagocytose bacteria. The experiments performed by Wilk et al. and Solans 
et al. have shown that IL-17 is critical for B. pertussis clearance from the nasal cavity. 
The mechanism; however, is yet to be determined. It would make the most sense to 
start with the roles of neutrophils in the nasal cavity, as IL-17 is known to induce 
recruitment of neutrophils.  
Neutrophils in the nasal cavity, the unsung hero? 
The question we are faced with is what changes between neutrophils in the mucosal 
response of an immune individual and that of a naïve individual? We have already 
discussed the first answer, that neutrophils have only been found to play a role in the 
clearance when bacteria are opsonized. We now know that IgA secreted through the 
mucosa can opsonize B. pertussis, presumingly leading to increased phagocytosis 28. 
Another reason may be the timing of the neutrophil response. In a primary infection, 
there is a slight increase in neutrophils at day 1; however, the neutrophil response does 
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not peak until days 5 and 7 post-infection 58–61. It could be hypothesized that the IL-17 
produced by TRM and γδ T cells present in the nasal cavity, would recruit neutrophils to 
the nasal cavity earlier. Thus, decreasing the ability of B. pertussis toxins to inhibit 
phagocytosis of the bacteria. A third reason could be the neutralization of the toxins 
themselves. Secreted IgA and IgG present in the mucosa of a protected host could be 
inhibiting dysregulation of the innate immune response. The neutralization of PT alone 
has been shown in numerous studies to provide protection 62,63. Neutralizing PT in the 
mucosa would increase neutrophil and macrophage recruitment to the site of infection, 
PT inhibits both macrophage and neutrophil recruitment to the infection 64,65. Lastly, it 
was previously mentioned that B. pertussis biofilm formation could occur in the 
nasopharynx and trachea of a mouse 66. Neutrophils produce NETS that trap bacteria in 
a “web” of DNA and proteins, destroying them through released enzymatic granules and 
proteases 11. Recently Thanabalasuriar et al., demonstrating that NETS were able to 
confine P. aeruginosa biofilms in the ocular biofilms and prevent dissemination 67. 
These mechanisms provide potential roles of neutrophil-mediated clearance in the 
mucosal response to B. pertussis; however, as mentioned above, experiments need to 
be performed on neutrophils of the nasal cavity.  
Neutralizing ACT in the nasal cavity 
In chapter 3, we demonstrated the neutralization of ACT from serum of aP+RTX 
immunized mice (Chap. 3, Fig. 1). ACT can inhibit many of the bactericidal actions of 
macrophages and neutrophils, as discussed in Chapter 1. Determining the effects of 
neutralizing ACT directly in the respiratory tract, could lead to a more complete inhibition 
of the “one-two punch” toxin activity of PT and ACT, thus increasing clearance of B. 
pertussis in the nasal cavity64. In chapter 3, found that the inclusion of RTX into DTaP 
administered through IP injection reduced IL-6 production in the lung. (Chap 3, Fig. 4). 
IL-6 is a pleiotropic pro-inflammatory cytokine known to be increased upon B. pertussis 
infection, as we and others have observed a large increase in IL-6 following challenge 
of a naïve or wP protected mouse 31,68. In our interpretation, a reduction of IL-6 
correlates with DTaP-mediated protection. Interestingly, in chapter 4, we observed the 
lowest levels of IL-6 in the lung when mice were immunized intranasally compared to 
intraperitoneally with IN-aP or IN-caP (Chap. 4, Fig 5.). Suggesting that priming the site 
185 
 
of infection, rather than inducing priming in a distal lymph node and generating a 
systemic response induces a stronger response in the respiratory tract.  
It would then appear that by administering RTX in an intranasal DTaP vaccine, one 
could combine the additive effects of neutralizing RTX, with the enhanced local 
response generated from an intranasal vaccine. One would suspect that these 
protective effects would be the most evident in the bactericidal activity of macrophages 
and neutrophils in the respiratory tract where the cells would encounter active ACT. In 
particular, we would hypothesize enhanced phagocytosis and bacterial killing in 
neutrophils and macrophages due to neutralizing ACT mediated inhibition of oxidative 
burst. Additionally, it is known that ACT can inhibit NET formation due to cAMP levels 11. 
It would be interesting to measure NET production and bacteria mediated killing in the 
lungs and nasal cavity, although these fragile structures will require fine-tuning of 
protocols. Furthermore, there is potential for NET formation to reduce biofilm formation 
in the upper respiratory system. Again, these experiments will need to focus on the 
upper respiratory system, but the results could be pivotal in the generation of future 
pertussis vaccines.  
Potential future adjuvants 
Our work with curdlan adjuvant demonstrated a modest increase in IL-17A in the lungs 
of mice immunized with DTaP and curdlan compared to mice immunized with DTaP 
alone (Chap. 3, Fig. 5). However, we did not observe an increase in macrophages or 
neutrophils recruited to the lungs. This may be due to the fact that all DTaP groups still 
contain aluminum hydroxide, promoting a Th2 response that is masking the effects of 
curdlan. Experiments to further elucidate the effects of β-glucans without aluminum 
hydroxide are ongoing and have yielded positive initial results. Still, it may be that 
optimal adjuvant is still yet to be found. Studies examining TLR 2 and 9 agonists from 
the Kingston Mills group have had success in the mouse model inducing Th1/Th17 
responses and increasing IgG2a antibodies 14,69. The same group has combined a 
TLR2 agonist with c-di-GMP, an agonist for the intracellular receptor stimulator of 
interferon genes (STING). This parenteral vaccine has been shown to promote 
Th1/Th17 responses, and particularly a B. pertussis-specific TRM response in the lungs. 
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Importantly, this protective response was measured up to 10 months after 
immunization. Work isolating outer membrane vesicles (OMV) from B. pertussis has 
proven to be successful. B. pertussis OMVs and DT toxoids were shown to induce 
Th1/Th17 immune responses and increase the IgG2a/IgA ratio compared to a DTaP 
vaccine 70. OMV vaccines are promising because they provide an increased pro-
inflammatory response compared to DTaP; but, less reactogenicity than wP 
immunizations 46,71. Particulate adjuvants are an interesting area of research as the 
particles may increase phagocytosis in the upper respiratory system, as discussed 
above. The combination of DTaP, CpG, and microparticles intranasally administered 
was shown to protect mice similar to levels observed in mice immunized with parenteral 
administered DTaP 72. It is possible that the conjugation of toxoids to the particles could 
increase vaccine effectiveness in future vaccines. Defining an optimal adjuvant is crucial 
to the success of a mucosal pertussis vaccine. The problem arises that boosting the 
immune response with a powerful adjuvant could have adverse effects and ultimately 
might also prevent licensure due to safety concerns.  
Mucosal pertussis booster  
It is because of this balancing act that the commercial producers of pertussis vaccines 
are at an impasse. DTaP/Tdap do prevent a large number of potential cases of 
whooping cough but these vaccines are not as effective as the wP vaccines in regard to 
the durability of protection. The use of the DTaP/Tdap vaccine strategy does protect the 
majority of those who receive the vaccine from clinical pertussis. It is clear that 
shortcomings exist with DTaP/Tdap vaccines, but the question remains, what is the 
alternative? DTaP/Tdap vaccines were originally designed to be safer vaccines capable 
of inducing similar protection to that of their wP predecessors, and they have. After 
completing the 5th dose DTaP protection ranges from 80-90% effectiveness 2. Data from 
adolescents suggest that the problem exists in years following the completion of DTaP 
73. According to ClinicalTrials.gov, there are currently 318 clinical trials either ongoing, 
recently completed or upcoming studying pertussis, of those 62 are focused on booster 
immunizations. However, most of these focus on safety and formulation of currently 
available immunizations. It seems that the vaccine industry is reluctant to replace 
current vaccines due to effectiveness in preventing disease and their safety. However, 
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there is potential for replacement of Tdap with a booster vaccine capable of inducing a 
Th1/Th17 response. The problem, as eluded to in chapter 1, is that vaccine imprinting of 
the Th1 primary response induced from wP in humans promotes the same response 
even after DTaP booster immunizations 74. This dilemma provides the strongest support 
for the development of an intranasal vaccine. The hypothesis being that parenteral 
booster immunizations are recognized by the memory T and B cells generated from the 
parenteral priming immunization. In altering the route of administration to the intranasal 
route, and with a different mucosal adjuvant the vaccine will stimulate the differentiation 
of naive B and T cells and induce a local mucosal immune response.  
The work completed in this dissertation highlights the need to re-evaluate a system 
when the current strategies cannot address the problem. The development of the next 
generation of B. pertussis vaccines must improve upon waning immunity of DTaP/Tdap 
immunizations. It is the consensus of current literature that the most applicable way to 
do so is through mimicking the natural infection. To accomplish this goal researchers 
will need to continue to optimize systems that have reached their potential. To do so will 
require innovative methods, that are outside the realm of previous strategies. In this 
work, we demonstrate the optimization of the mouse model of pertussis to implement 
testing of future B. pertussis antigens and demonstrate the incorporation of a protective 
ACT toxoid into an acellular pertussis vaccine. We then altered the route of 
administration of the DTaP vaccine to a mucosal delivered vaccine and demonstrated 
the additive effects of generating a local mucosal immune response, capable of 
neutralizing B. pertussis toxins at the site of infection. This work establishes a 
foundation for future vaccine development, demonstrating the potential for 
improvements of DTaP/Tdap vaccines through the inclusion of RTX and intranasal 
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